Document:

exv10w19

 

Exhibit 10.19

12 June 2007

LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT

THIS AGREEMENT (“Agreement”), made this 12th day of June, 2007 (“Effective Date”), is
entered into by and between Cook Incorporated, an Indiana corporation having a place of business at
750 Daniels Way, Bloomington, Indiana 47404, USA, and its Affiliates (“Cook”), and Cardica, Inc., a
Delaware corporation having a place of business at 900 Saginaw Drive, Redwood City, CA 94063, and
its Affiliates (“Cardica”).

RECITALS

	A.	 	Cardica is developing a medical device known as the PFO Closure Device for use in patent
foramen ovale (“PFO”) closure procedures, among other applications.
	 
	B.	 	Cook is engaged in the business of developing, manufacturing and selling medical devices.
	 
	C.	 	Cook is amenable to funding certain development work to be performed by Cardica in exchange
for receiving a license under the terms and conditions set forth herein to continue to develop
and to commercialize the PFO Closure Device worldwide for PFO closure procedures, as further
described in this Agreement.

The parties agree as follows:

ARTICLE I

DEFINITIONS

In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings
set forth below:

	1.1	 	“Affiliates” with respect to a party means any entity, existing now or in the future,
domestic or foreign, that directly or indirectly controls, is controlled by or is under common
control with such party; provided that such entity will be considered an Affiliate only for
the time during which such control exists.
	 
	1.2	 	“Approval” means receipt from the applicable regulatory authority in a given country or
countries to market a Product in such country or countries.
	 
	1.3	 	“Cardica Know-How” means Information that (a) is necessary or useful for the research,
development or commercialization of Products, and (b) is Controlled by Cardica. Cardica
Know-How shall exclude Cardica Patents.

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

 1.

 

	1.4	 	“Cardica Patents” means a Patent that (a) claims the Product or any component thereof, or any
other method, apparatus, material or article of manufacture useful in the development,
manufacture, use or sale of Product, and (b) is Controlled by Cardica.
	 
	1.5	 	“Clinical Feasibility Trial” means the initial human clinical trial of the Product, which is
expected to include between 10 and 200 subjects.
	 
	1.6	 	“Control” means, with respect to any Information or intellectual property right, the right
and power of the relevant party to grant the right to make, use, sell, offer to sell, and
import, or to grant a license or a sublicense to, such Information or intellectual property
right as provided for herein and without violating the terms of any agreement or other
arrangement with any Third Party.
	 
	1.7	 	“Cook Know-How” means Information that (a) is necessary or useful for the research,
development or commercialization of Products, and (b) is Controlled by Cook. Cook Know-How
shall exclude Cook Patents.
	 
	1.8	 	“Cook Patents” means a Patent that (a) covers the Product or any component thereof, or any
other method, apparatus, material or article of manufacture useful in the development,
manufacture, use or sale of Product, (b) claiming an invention conceived by employees or
agents or independent contractors of Cook that have access to the Confidential Information of
Cardica related to the Product, and (c) is Controlled by Cook.
	 
	1.9	 	“Field” means use of the Product for closure of a PFO.
	 
	1.10	 	“Invention” means any article, material, process or technology, whether or not patentable,
made or conceived in the course of developing and commercializing Products pursuant to this
Agreement, in whole or in part by a party, its employees, agents or independent contractors,
that have access to the Confidential Information of the other party.
	 
	1.11	 	“Information” means (a) techniques and data relating to the development, manufacture, use or
sale of Products, including, but not limited to, inventions, practices, methods, knowledge,
know-how, skill, experience, test data including pre-clinical and clinical test data,
analytical and quality control data, regulatory submissions, correspondence and
communications, marketing, pricing, distribution, cost, sales, manufacturing, patent and legal
data or descriptions, and (b) compositions of matter, devices, prototypes, articles of
manufacture, assays and biological, chemical or physical materials relating to development,
manufacture, use or sale of Products.
	 
	1.12	 	“Net Sales” means the gross revenue actually received by Cook, its Affiliates or sublicensees
from the commercial sale of the Products during a given period of time, minus, to the extent
billed to the purchaser, the costs of (i) sales, value added and/or use taxes, (ii) duties and
similar governmental assessments paid, (iii) transportation, packing, shipping, and
insurances, (iv) discounts allowed and taken , and (v) amounts allowed or credited due to
rejections and/or returns. If the Products are sold as part of a kit, then royalties due with
respect to Net Sales of Products will be determined using the formula

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended

 2.

 

	 	 	set forth in Sections 5.4(C) and (D). Net Sales shall be determined in accordance with
generally accepted accounting principles, consistently applied.

	1.13	 	“Other Cardica IP” shall mean any intellectual property rights that are necessary or useful
for the research, development or commercialization of Products, and Controlled by Cardica,
other than the Cardica Patents and Cardica Know-How.
	 
	1.14	 	“Other Cook IP” shall mean any intellectual property rights that are necessary or useful for
the research, development or commercialization of Products, and developed by Cook employees
having access to the Confidential Information of Cardica related to the Product and Controlled
by Cook, other than the Cook Patents and Cook Know-How.
	 
	1.15	 	“Patent” means (a) unexpired United States and foreign patents, including without limitation
any substitution, extension, registration, confirmation, reissue, re-examination, renewal of
such patents and (b) pending applications for such patents, including without limitation any
continuation, divisional or continuation-in-part thereof and any provisional applications.
	 
	1.16	 	“Product” means the PFO Closure Device developed under this Agreement and described in the
Device Description and Sequence of Operation as set forth in Attachment A.
	 
	1.17	 	“Sunk Costs” means pro-rated amounts for any work actually performed by Cardica under the
Development Plan up to the effective date of termination and supported by documentation
provided by Cardica to Cook, including [ * ] overhead for such work and all expenditures for
such work and non-cancelable commitments that are consistent with the original budget and
phases set forth in the Development Plan and incurred by Cardica in performing the Development
Plan prior to Cardica’s receipt of Cook’s notice of termination.
	 
	1.18	 	“Territory” means worldwide.
	 
	1.19	 	“Third Party” means any person or entity other than Cardica or Cook, or their respective
Affiliates.
	 
	1.20	 	“Unexpectedly Low Sales” means sales in each of three consecutive quarters of a number of
Products that result in an Earned Royalty less than [ * ] of the Minimum Royalty for each such
quarter.
	 
	1.21	 	“Valid Claim” means an unexpired claim of an issued Patent which has not been found to be
unpatentable, invalid or unenforceable by an unreversed and unappealable decision of a court
or other authority in the subject country and that has not been disclaimed or admitted to be
invalid or unenforceable through reissue, disclaimer or otherwise.

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended

 3.

 

ARTICLE II

DEVELOPMENT AND COMMERCIALIZATION

	2.1	 	Development Committee. Each party will appoint two (2) representatives, each having
decision-making authority, to form a development committee (“Development Committee”). The
Development Committee will be responsible for authorizing completion of specific project
phases, thereby authorizing subsequent phase payments, and making decisions regarding the
changes in strategy for developing the product in accordance with this Agreement. Such
authorizations and decisions will be made by unanimous consent of the Development Committee.
In the event unanimous consent regarding a development issue cannot be reached by the
Development Committee during any meeting of the Development Committee, then a cooling off
period of at least two (2) but no more than seven (7) calendar days will follow such meeting
after which period all of the members of the Development Committee will meet again. In the
event that the Development Committee is unable to achieve unanimous consent after the cooling
off period, a senior executive from each party will meet to resolve the issue. The
Development Committee shall disband upon commencement of full scale production of the Product.

	2.2	 	Product Development and Commercialization Responsibilities.

                 A. Cardica will have following responsibilities within this project:

	 	—	 	Design Control compliance;
	 
	 	—	 	Quality Assurance compliance;
	 
	 	—	 	Develop product criteria and product specifications;
	 
	 	—	 	Develop proof-of-concept breadboards and CAD databases of Product;
	 
	 	—	 	Launch, build and qualify all production tools;
	 
	 	—	 	Design and fabricate all manufacturing equipment;
	 
	 	—	 	Design and fabricate packaging;
	 
	 	—	 	Perform bench testing;
	 
	 	—	 	Develop and file intellectual property;
	 
	 	—	 	Manufacture Product (optional).

             B. Cook will have the following responsibilities within this project:

	 	—	 	Market assessment for PFO closure;

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended

 4.

 

	 	—	 	Preclinical testing of Product prototype and final product;
	 
	 	—	 	Clinical Product evaluation;
	 
	 	—	 	Obtain regulatory approvals worldwide, at Cook’s sole discretion;
	 
	 	—	 	Package sealing and sterilization;
	 
	 	—	 	Product sales and marketing
	 
	 	—	 	Basketwire development

	2.3	 	Product Development. The obligations of Cardica for developing Product are set forth in
Section 2.2 and Attachment A to this Agreement (“Development Plan”), which may be modified
from time to time by unanimous decision of the Development Committee or in accordance with
Section 11.9 (Integration) of this Agreement, and which is hereby incorporated by reference.
Cardica will use commercially reasonable efforts to perform its obligations under the Section
2.2 and the Development Plan. Cardica will provide the deliverables set forth in Attachment A
for no more than the costs set forth in Attachment A, unless the Development Committee
unanimously agrees to an increase in those costs. In the event a conflict arises between this
Agreement and the Development Plan, the terms of this Agreement will control. Without limiting
the foregoing, Cook will use commercially reasonable efforts to apply for a CE Mark and FDA
Approval within a reasonable period of time after Cardica’s completion of Phase 2 of the
Development Plan. It is understood that commercially reasonable efforts to develop a
production version of the Product may be unsuccessful, and that neither party guarantees or
can guarantee that commercially reasonable efforts to implement the Development Plan will
result in a production version of the Product or in a saleable Product.

	2.4	 	Commercialization. Cook will use commercially reasonable efforts to commercialize Products
for use in the Field in each country in the Territory in which it obtains regulatory approval,
at its expense. Selection of particular countries in the Territory for regulatory approval is
at Cook’s sole discretion. Without limiting the foregoing, Cook will be responsible, at its
cost, for promoting, detailing and distributing Products for use in the Field in each country
in the Territory in which it obtains regulatory approval, and will book all resulting Product
sales. Following the Approval of Product, Cook will provide to Cardica on a semi-annual basis
its good faith non-binding quarterly forecast of Product sales in the Field and in the
Territory for the following eighteen (18) month period. Following the Approval of Product, if
the Product is manufactured by Cardica under Section 7.1, Cardica will transfer the Product to
Cook for a price (“Transfer Price”) that will include only the costs of materials, direct
labor, manufacturing overhead, manufacturing yield, cost of manufacturing fixtures as well as
other reusable or disposable materials used in the manufacturing of the Product. An additional
cost of no more than [ * ] manufacturing profit will be included in the final transfer price.
Additional expenses associated with changes approved by Cook to the tooling necessary to make
the components of the Product as a result of tool wear or changes necessary due 

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended

 5.

 

	 	 	to product
iterations or reliability improvement will be covered by Cook to the extent such changes are
not the result of inaccuracy or oversight by Cardica.

	2.5	 	Development Costs. Except as otherwise expressly provided in this Agreement, each party will
make resources available that it reasonably deems necessary to fulfill its obligations under
this Agreement and shall bear its own costs incurred with respect thereto.

	2.6	 	Specifications. The Development Committee will approve the Product criteria for each Product
being developed. The specifications may be updated from time to time by unanimous decision of
the Development Committee as the Product moves through the design control process under
Cardica’s direction.

ARTICLE III

OWNERSHIP OF INTELLECTUAL PROPERTY

	3.1	 	Ownership of Inventions. Ownership by the parties of Inventions will be determined in
accordance with the rules of inventorship and ownership under US law.

	3.2	 	Joint Inventions. With respect to Inventions jointly owned by the parties, each party will
enjoy all of the rights of an owner thereof with no duty to account to the other party
regarding any economic benefit realized and no need to seek approval from the other party for
its disclosure or use of such Invention, except with respect to exclusivity provisions
expressly stated in this Agreement. Each party’s interest in such jointly owned Inventions
and intellectual property rights therein will be included in such party’s intellectual
property rights that are either licensed to the other party or the subject of covenants made
to the other party pursuant to this Agreement.

	3.3	 	Prosecution. The parties will cooperate in good faith to decide whether to seek patent
protection for any Inventions that are owned jointly by the parties. The party solely owning
an Invention will be responsible, but not obligated, for filing and prosecuting patent
applications on such Inventions, and maintaining patents issued thereon, at such party’s sole
expense. If a party responsible for filing patent applications on Inventions solely owned by
such party decides not to proceed with the filing, prosecution or maintenance of patent
applications and patents on such Invention (without first filing a continuation or
continuation in part of any such application), such party shall notify the other party in
writing in advance of relevant deadlines, and the other party shall have the right, but not
the obligation, to assume responsibility for such activities, on behalf of the sole owner but
at the assuming party’s sole expense. The parties will meet to discuss whether or not to
pursue patent protection for Inventions jointly owned by the parties. If the parties agree to
pursue such protection for such Inventions, they shall designate one party to be responsible
for filing and prosecuting patent applications on such Inventions, and for maintaining patents
issuing thereon. Unless otherwise agreed by the parties, the parties will share equally all
expenses of pursuing and maintaining patent protection on jointly owned Inventions that they
agree to pursue under this Section 3.3. Each party will have the right to review and comment
on the other party’s correspondence with any

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended

 6.

 

	 	 	patent office with regard to patent applications
and patents on Inventions that are necessary or useful for the development and
commercialization of Products in the Field.

	3.4	 	Enforcement.

	 	A.	 	Cook has the first right to enforce patents licensed to it by Cardica against
Third Parties that make, use, offer for sale, sell or import products that are covered
by such patents and that are competitive with Products in the Field. If Cook elects
not to undertake such enforcement, then Cardica may request and Cook may, in its sole
discretion, permit Cardica to enforce such patents against such Third Parties, such
permission not to be unreasonably withheld.
	 
	 	B.	 	Each party will cooperate with the other party when asserting patents against
Third Parties in accordance with this Section 3.4. A party enforcing a patent against
a Third Party will give the other party notice prior to bringing any enforcement action
(including, but not limited to, injunctions or restraining orders). The other party
will have the right to participate or not participate in such enforcement, at its sole
discretion. If the other party chooses to participate, it will bear its own expenses
and/or share expenses, as the parties jointly determine to be appropriate. If the other
party chooses not to participate in an enforcement action brought in accordance with
this Section 3.4, it nonetheless agrees to be named in the enforcement action, and upon
request and at the cost of the enforcing party, will make available all relevant
information in its possession or under its control.
	 
	 	C.	 	Any money damages obtained as a result of any enforcement action under this
Section 3.4 shall first be allocated to reimburse the parties’ respective expenses of
such enforcement, and the remainder of such proceeds, if any, shall be allocated [ * ]
percent ([ * ]%) to the party controlling such suit, and [ * ] percent ([ * ]%) to the
other party.
	 
	 	D.	 	Cook may offset against any payment due under Sections 5.4 or 5.5 of this
Agreement up to [ * ] percent ([ * ]%) of any monies expended by Cook in defending
Products against assertions of intellectual property rights by third parties.

	3.5	 	Cardica Patent Prosecution. Cardica will use reasonable efforts to obtain patents included
in the Cardica Patents in [ * ]. Cardica shall transmit to Cook for its review and comment at
least each U.S. patent application thirty (30) days prior to filing. Cardica will notify Cook
of Cardica’s foreign filing decisions with respect to each of the Cardica Patents in writing
in advance of relevant deadlines. Cook will have the right, but not the obligation, to assume
responsibility at Cook’s sole expense for pursuing and/or maintaining patent protection in any
other country, and to assume maintenance of patent protection in any country that Cardica
intends not to continue to maintain patent protection.

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended

 7.

 

ARTICLE IV

LICENSE AND COMMERCIALIZATION

	4.1	 	By Cardica. Subject to the terms and conditions of this Agreement, Cardica hereby grants to
Cook and its Affiliates an exclusive license in the Territory, bearing royalties as set forth
in this Agreement, with the right to grant sublicenses, under the Cardica Patents, Cardica
Know-How and Other Cardica IP, to make, have made, use, sell, offer for sale and import
Products for use solely in the Field and in the Territory. For clarity, Cardica grants the
foregoing exclusive license to the fullest extent possible under the Cardica Patents, Cardica
Know-How and Other Cardica IP in the Field and in the Territory with respect to Products,
retaining only rights to the extent necessary or useful for Cardica to perform its
responsibilities under the Development Plan with respect to Product in the Field and in the
Territory.
	 
	4.2	 	Cardica Representations. Cardica represents and warrants that as of the Effective Date: (a)
Cardica has the right and power to enter into this Agreement and to grant the rights it grants
to Cook under this Agreement; (b) it has not assigned, granted a license under or otherwise
transferred or encumbered any intellectual property licensed to Cook under this Agreement in a
manner inconsistent with this Agreement, other than grants of security interests disclosed
pursuant to a letter agreement of even date herewith; (c) to its knowledge, Cook’s practice of
the license granted to Cook pursuant to this Agreement under the Cardica Know-How, Cardica
Patents and Other Cardica IP will not infringe any Patents owned or controlled by a Third
Party; (d) its performance under this Agreement is not inconsistent with any obligation owed
to a third party; and (e) its employees and/or agents assigned to perform work under a
Development Plan have executed agreements that enable Cardica to grant the rights it grants to
Cook under this Agreement. Additionally, Cardica represents, warrants and covenants that it
has not employed, contracted with or retained, and shall not employ, contract with or retain,
any person or entity in connection with the development or manufacture of Products in the
Field pursuant to this Agreement who has been or is debarred by the FDA under 21 U.S.C. §
335(a) or disqualified as described in 21 C.F.R. §812.119.
	 
	4.3	 	By Cook. Cook agrees not to sue Cardica under any Cook Patents, Cook Know-How or Other Cook
IP solely to the extent necessary or useful for Cardica to perform its responsibilities under
the Development Plan with respect to Product in the Field and in the Territory. Subject to
the terms and conditions of this Agreement, and upon request by Cardica, the parties shall
negotiate in good faith the terms of a non-exclusive, royalty-bearing license for use by
Cardica in developing and commercializing products other than the Products under all Cook
Patents, Cook Know-How and Other Cook IP covering Inventions as defined in Section 1.10, which
license Cook in its sole discretion may elect, but is not obligated, to execute with Cardica.
	 
	4.4	 	Cook Representations. Cook represents and warrants that as of the Effective Date: (a) Cook
has the right and power to enter into this Agreement; (b) its performance under this Agreement
is not inconsistent with any obligation owed to a third party; (c) to its knowledge, Cardica’s
practice of the covenant not to sue granted to Cardica pursuant to

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended

 8.

 

	 	 	Section 4.3 of this Agreement under the Cook Know-How, Cook Patents and Other Cook IP will
not infringe any Patents owned or controlled by a Third Party; and (d) its employees and/or
agents assigned to perform work under a Development Plan have executed agreements that
enable Cook to grant the rights it grants to Cardica under this Agreement. Additionally,
Cook covenants that it shall not employ, contract with or retain any person or entity in
connection with the development, manufacture and commercialization of Products in the Field
pursuant to this Agreement who has been or is debarred by the FDA under 21 U.S.C. § 335(a)
or disqualified as described in 21 C.F.R. §812.119.
	 
	4.5	 	No Implied Licenses. Neither party grants to the other party any licenses or covenants not
to sue under such party’s intellectual property rights except as expressly provided in this
Agreement.

ARTICLE V

CONSIDERATION

	5.1	 	Signing Fee and Phase 1 Payments. Cook will pay Cardica a signing fee payable in two
installments, (1) the first installment in the amount of [ * ], due within ten (10) days after
execution of this Agreement by both parties, and (2) the second installment in the amount of [
* ], due three (3) months after execution of this Agreement by both parties.

	5.2	 	Additional Phase Payments. Development of the Product by Cardica will proceed through
discrete phases set forth in the Development Plan. Cook will pay Cardica the following phase
payments, each due within thirty (30) days following Cardica’s achievement and the Development
Committee’s unanimous approval of the previous phase as set forth below:
	 
	 	 	Phase 2. [ * ] after the Development Committee approves Cardica’s successful completion of
Phase 1 per the Development Plan.
	 
	 	 	Phase 3. [ * ] after the Development Committee approves Cardica’s successful completion of
Phase 2 per the Development Plan.
	 
	 	 	Phase 4. [ * ] after the Development Committee approves Cardica’s successful completion of
Phase 3 per the Development Plan.
	 
	 	 	Phase 5. [ * ] after the Development Committee approves Cardica’s successful completion of
Phase 4 per the Development Plan.
	 
	 	 	Phase 6. Additional funds in an amount to be determined after Cardica’s successful
completion of Phase 5 of the Development Plan may be approved by the Development Committee
to perform Phase 6 of the Development Plan. Phase 6 is an optional phase to complete all
tasks required to support full scale production of the Product.

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended

 9.

 

	 	 	The Development Committee shall document the successful completion of each phase in writing
and sign such writing. If at any point in the development of the Product
significant design enhancements are required to meet the performance requirements, the
Development Committee may increase the phase payment during any given phase and for
subsequent phases to compensate for additional efforts to meet the altered requirements.

	5.3	 	Reimbursement for Products in Other Formats. Cook will reimburse Cardica for additional
reasonable research, development and tooling costs actually incurred by Cardica for the
development of Feasibility Prototypes and the production of variants of the Product, such as
but not limited to Product capable of deploying a differently-sized clip, having additional
clips, having anchoring features, having variations in the actuation mechanism, having changes
to visualization, and including integration with other devices, if requested by Cook and
completed by Cardica in accordance with a research plan and budget approved in advance and in
writing by each member of the Development Committee. Such reimbursements will be calculated
using full time equivalent rates for engineering services and labor and will include Cardica’s
reasonable and actual out of pocket expenses for fabrication of the pre-production tooling,
fixtures and prototypes. Cardica shall add an overhead charge of [ * ] of the amounts to be
so reimbursed, and Cook shall pay such additional amounts, to compensate Cardica for overhead
expenses. The agreed upon research plan and budget will establish the phases and timing to be
met by Cardica in order for such reimbursement payments to be made by Cook to Cardica.

5.4         Earned Royalties.

	A.	 	Cook will pay to Cardica (on a quarterly basis) during the Term of this Agreement a royalty
based on Net Sales by Cook, its Affiliates or sublicensees (“Earned Royalty”) of Product
units, based on the following table:

[ * ]

	 	 	The Earned Royalty is due on Net Sales of Products in any particular country in which
Cook sells Product, irrespective of whether or not Cardica has obtained a Patent in the
particular country. The parties acknowledge that this Earned Royalty includes compensation
to Cardica for its research, development and technology transfer efforts relating to the
Product

	B.	 	In the event that Cook must make payments to one or more Third Parties to obtain a license or
similar right within a particular country, or if Cook must make payments to one or more Third
Parties under a preexisting license within a particular country, in either case in the absence
of which Cook could not legally make, use or sell a Product in that particular country (“Third
Party Royalty”), then upon notice to Cardica, Cook may subtract one half of the Third Party
Royalty percentage from the Earned Royalty percentage due under this Agreement, where the
Third Party Royalty is subtracted only from the Earned Royalty attributable to that particular
country and to the Product subject to the Third Party Royalty, provided that such reduction
shall in no event result in reduction of the Earned Royalty percentage by more than [ * ]. As
an illustration of the

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended

 10.

 

	 	 	foregoing calculation, if Cook must pay a Third Party Royalty equal to
[ * ], then Cook may subtract [ * ] from the Earned Royalty percentage that would have been
due under
Section 5.4(A)(i) (if the Earned Royalty would otherwise have been [ * ], for instance, the
revised Earned Royalty would be [ * ]).
	 
	C.	 	If Cook, its affiliate or sublicensee sells a Product unit as part of a bundle or combination
of products (a “Bundle or Combination”), then the royalty due with respect to the Product
unit sold as part of such bundle or combination will be calculated by multiplying the royalty
rates set forth above by the Net Sales of the Bundle or Combination in such country during the
applicable reporting period, and then by the fraction, A/(A+B), where A is the average sale
price of the Product unit by Cook, its Affiliates or sublicensees when sold separately in
finished form in such country, and B is the average sale price charged by Cook, its Affiliates
or sublicensees of the other product(s) included in the Bundle or Combination when sold
separately in finished form in such country, in each case during the applicable reporting
period.

	D.	 	In the event either the Product unit or the other product(s) included in the Bundle or
Combination are not sold separately in finished form in such country, then the royalty due
with respect to a Product unit sold as part of a Bundle or Combination will be calculated by
multiplying the royalty rates set forth above by the Net Sales of the bundle or combination in
such country, and then by the fraction of F/(F+G) where F is the fair market value of the
Product unit and G is the fair market value of all other product(s) included in the Bundle or
Combination, as reasonably determined in good faith by Cook.

	E.	 	Regardless of the number of Valid Claims included in the Cardica Patents claiming a given
Product, Cook will owe only one royalty with respect to the sale of each unit of such Product,
that royalty being the Earned Royalty set forth above.

	5.5	 	Minimum Royalties.

	 	A.	 	Provided that the Product developed under this Agreement for use in the Field
does not have any identified or known design defect, and that no Product performance
problem (as determined based upon the Product specifications) has arisen that affects
Cook’s ability to sell such Product, Cook will pay to Cardica during the Term of this
Agreement a minimum royalty (“Minimum Royalty”) in an amount equal to the following
one-time payments under this Agreement: (i) [ * ] for the first full calendar year
following the first commercial sale of the first and only the first Product for use in
the Field, (ii) [ * ] for the second full calendar year following the first commercial
sale of the first and only the first Product for use in the Field, (iii) [ * ] for the
third full calendar year following the first commercial sale of the first and only the
first Product in the Field, (iv) [ * ] for the fourth full calendar year following the
first commercial sale of the first and only the first Product for use in the Field, and
(v) in each calendar year of the next ten (10) calendar years following the third
anniversary of the first commercial sale of first and only the first Product for use in
the Field, an amount equal to the sum of the minimum royalty for the previous calendar
year plus [ * ] of the minimum royalty for the previous calendar year. Any amount paid
by Cook in any calendar

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended

 11.

 

	 	 	 	year as Earned Royalty that exceeds the minimum royalty due for
that calendar
year may be applied and accumulated by Cook to satisfy the minimum royalties for any
of the subsequent calendar years provided above.

	 	B.	 	In the event that Product meets the relevant specifications, but Cook has
experienced Unexpectedly Low Sales of Product not by reason of any substantial lack of
diligence by Cook in commercializing Products in accordance with Section 2.4, Cook
shall pay only a portion of the Minimum Royalty (“Interim Period Payment”) for a time
period (“Interim Period”) beginning upon the last day of those [ * ] consecutive
calendar quarters of Unexpectedly Low Sales. During the Interim Period, each Interim
Period Payment shall be spent by Cardica solely on improvements to the Product, with
the amount of each Interim Period Payment to be approved by Cook and not to exceed the
actual amount spent by Cardica in the Interim Period on improvements to the Product
plus [ * ] overhead. One or more Interim Period Payments may exceed the Minimum Royalty
that would have been payable for that period, in the event that the cost of
improvements to the Product plus overhead for that period is greater than the Minimum
Royalty that would have been payable for that period. Cook’s obligation to pay Minimum
Royalties under this Agreement will resume in the first full calendar year after the
cessation of the Interim Period, which occurs at the end of the first quarter in which
there are no longer Unexpectedly Low Sales.
	 
	 	 	 	If sales of Product continue during the Interim Period, then Minimum Royalties shall
not increase under Section 5.5(A) during the Interim Period. For example, if an
Interim Period occurs in the second year of this Agreement, and Product is sold
during the Interim Period, the Minimum Royalties due after cessation of the Interim
Period are the Minimum Royalties due in the second year under Section 5.5A,
regardless of the duration of the Interim Period. Cook is still obligated to pay
Cardica Earned Royalties during the Interim Period based on its sales of Product.
	 
	 	 	 	If no sales of Product are made during the Interim Period, then after the Interim
Period the Minimum Royalties revert to those set forth above in Section 5.5A
calculated based on the date of cessation of the Interim Period. For example, if an
Interim Period occurs in the second year of this Agreement, and Product is not sold
during the Interim Period, and if the first commercial sale of the Product after the
Interim Period then occurs in the third year of the this Agreement, then the Minimum
Royalty due for the first full calendar year after the Interim Period is as set
forth in Section 5.5A(ii). The Minimum Royalty due in the subsequent full calendar
year would be as set forth in Section 5.5A(iii), and so on.
	 
	 	C.	 	In the event Cook pays Cardica more than zero but less than the minimum
royalties set forth above for a period of [ * ], other than during an Interim Period,
then upon Cardica’s written notice to Cook, Cardica may in its sole discretion
terminate this Agreement for breach by Cook pursuant to Section 8.3 of this Agreement.

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended

 12.

 

	5.6	 	Royalty Payments and Reports. Cook shall provide a report to Cardica within twenty (20) days
after the end of each quarter that summarizes the Net Sales during such quarter in a manner
sufficient to enable Cardica to comply with its reporting requirements. Within forty-five
(45) days after the end of each quarter (or, for the last quarter in a year, sixty (60) days
after the end of such quarter), Cook shall make all royalty payments payable to Cardica under
this Agreement with respect to such quarter. Along with such payments, Cook shall also
provide detailed information regarding the calculation of Earned Royalties due to Cardica,
including allowable deductions in the calculation of Net Sales of Product in the Territory.
	 
	5.7	 	Taxes. Cardica shall pay any and all taxes required by law that are levied on account of
royalties or other payments it receives under this Agreement. If laws or regulations require
that taxes be withheld, Cook will (a) deduct those taxes from the remittable royalty or other
payment, (b) pay the taxes to the proper taxing authority, and (c) send to Cardica within
fifteen (15) days following such payment evidence of the obligation together with proof of
payment.
	 
	5.8	 	Sublicenses. In the event Cook or its Affiliate grants licenses or sublicenses to others to
sell Product, Cook shall account for and report to Cardica the sales of Product by the
sublicensee on the same basis as if such sales were Net Sales by Cook, and Cook shall pay to
Cardica Earned Royalties on such sales as if such sales of the sublicensee were Net Sales of
Cook, including but not limited to the exclusions from Net Sales set forth in Section 1.12.
	 
	5.9	 	Non-Monetary Consideration. If Cook, its Affiliate or sublicensee receives any non-monetary
consideration in connection with the commercial sale of Product, Cook’s payment obligation
under Section 5.4 shall be based on the fair market value of such other consideration
	 
	5.10	 	Records and Audit. Cook and its Affiliates shall keep or cause to be kept for a period of
three (3) years such records as are required to determine, in a manner consistent with this
Agreement, amounts due for any calendar year to Cardica pursuant to this Article V. At the
request (and expense) of Cardica, Cook and its Affiliates shall permit an independent
certified public accountant appointed by Cardica and reasonably acceptable to Cook, at
reasonable times and upon reasonable notice, to examine only those records as may be necessary
to determine, with respect to any calendar year ending not more than three (3) years prior to
Cardica’s request, the correctness or completeness of any report or payment made under this
Article V. The foregoing right of review may be exercised only once per year and only once
with respect to each such periodic report and payment. Results of any such examination shall
be (a) limited to information relating to the Product, (b) made available to both parties and
(c) subject to Article IX. Cardica shall bear the full cost of the performance of any such
audit, unless such audit discloses a variance to the detriment of Cardica of more than five
percent (5%) from the amount of the original report, royalty or payment calculation. In such
case, Cook shall bear the full cost of the performance of such audit.

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended

 13.

 

ARTICLE VI

REGULATORY FILINGS AND COMMUNICATIONS

	6.1	 	Regulatory Approvals. Cook will be solely responsible for the preparation and filing of all
documents required in connection with seeking and obtaining regulatory approval of Products in
the Field in each country in the Territory, at its sole expense and discretion, including
without limitation the CE Mark, IDE applications and PMA (or equivalent) approvals, and will
solely own all rights in such documents and approvals.
	 
	6.2	 	Regulatory Information. To enable Cook and Cardica to comply with regulatory requirements,
Cook will provide Cardica with copies of all customer complaints received by Cook that allege
any Product used in the Field is defective and any reports of adverse events experienced in
connection with Products manufactured by Cook. For any such allegedly defective Product that
is returned to Cook or its Affiliate or sublicensee by its customer, Cook will provide Cardica
with copies of all failure analysis or other reports proposed by Cook, its Affiliate or
sublicensee and submitted to the FDA or any other similar regulatory authority. Cook will
provide Cardica with copies of any Inspectional Observations (FDA Form 483) issued by the FDA
in connection with Products that are manufactured by or on behalf of Cook, or its Affiliate or
sublicensee, for use in the Field (or facilities used to manufacture same) and any response
thereto submitted by Cook, its Affiliate or sublicensee. Cook will provide Cardica with copies
of all reports filed by Cook, its Affiliate or sublicensee under FDA Medical Device Reporting
(MDR) regulations in connection with Products for use in the Field. For any Products used in
the Field that are recalled by Cook, its Affiliate or sublicensee, Cook will provide Cardica
with copies of all the applicable documentation that Cook submitted to comply with U.S.,
European and International regulatory laws and requirements, including but not limited to
documentation associated with receiving and administering the recalled Product and
notification of the recall to those persons for whom Cook, its Affiliate or sublicensee
replaced the recalled Product.

ARTICLE VII

SUPPLY

	7.1	 	Technology Transfer. Upon determination by the Development Committee that a Product is ready
for commercialization, Cook will have the option but not the obligation to manufacture such
Product, or to have such Product manufactured by Cardica or a third party designated by Cook
with the consent of Cardica, which consent shall not be unreasonably withheld, conditioned or
delayed.

	 	A.	 	Testing and Development. Cardica will continue to supply to Cook, upon Cook’s
request and at a cost of [ * ] per unit, such additional units of the Product over the
number of units described in Phase 4 of the Development Plan as Cook may reasonably
request for the further testing and development of the Product.

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended

 14.

 

	 	B.	 	Commercialization. Upon Cook’s request, to enable Cook or a third party designated
by Cook to manufacture such Product, Cardica will transfer to Cook or the designated
third party, at no additional cost, all equipment, including all pre-production tooling,
and Cardica Know-How, including but not limited to, all trade secret, manufacturing and
supplier information included therein, related to the Products that is reasonably
necessary for Cook to manufacture such Product. Product manufactured by Cook or its
designated third party is referred to as “Transferred Product”. Upon request from Cook,
Cardica will provide, at no additional cost, reasonable technical assistance to Cook for
the Transferred Product based on the mutual availability of the parties, which assistance
may include: i) training of Cook personnel or personnel of the designated third party in
connection with the manufacture of Transferred Product, ii) advice concerning the
manufacture of Transferred Product, and iii) testing of sample Transferred Product to
verify that such Transferred Product complies with applicable specifications established
by the Development Committee to confirm successful transfer of technology to Cook or the
designated third party hereunder. Additionally, on Cook’s request, the parties will
negotiate the terms under which Cardica may provide engineering services to assist Cook
or the designated third party in the design and modification of Transferred Product to
meet customer and regulatory requirements.

	7.2	 	Production Supply. Except as provided in Section 7.1 above, Cardica will have no obligation
to supply or have supplied any Transferred Product for use in further development and
commercialization of Products in the Field and in the Territory.

ARTICLE VIII

TERM AND TERMINATION

	8.1	 	Term. This Agreement will commence on the Effective Date and continue for a period of twenty
(20) years (“Term”), unless it is earlier terminated in accordance with Section 8.2 below.
This Agreement may be renewed thereafter for additional five (5) year terms by mutual
agreement of the parties.
	 
	8.2	 	Termination. Cook may terminate this Agreement for convenience at any time upon sixty (60)
days prior written notice to Cardica. Either party may terminate this Agreement for material
breach by the other party if such breach remains uncured for thirty (30) days after the
non-breaching party provides a notice to the breaching party specifying such breach in
reasonable detail. Upon termination of this Agreement, all licenses will terminate, except as
otherwise provided in Sections 8.3(C) and 8.4 of this Agreement, and Cook’s obligation to pay
any further royalties or payments of any kind, including but not limited to payment of any
minimum royalties set forth in Section 5.5 above that would have been due after the effective
date of termination, will also terminate, provided that any such termination will not relieve
Cook from any obligation to pay any such royalty or payment that accrued prior to the
effective date of termination.

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended

 15.

 

	8.3	 	Rights upon Termination by Cook for Convenience or Termination by Cardica for Material Breach
by Cook. Upon early termination of this Agreement under Section 8.2 by Cook for convenience,
or by Cardica for material breach by Cook:

	 	A.	 	Cardica will reimburse Cook a pro-rated amount of the current phase payment based
on the amount of the phase payment less the expenses of any work actually performed (plus
a [ * ] overhead factor) by Cardica, consistent with the original budget and phases set
forth in the Development Plan, up to the effective date of termination, to the extent
supported by documentation provided by Cardica to Cook. Such pro-rated payment amount
shall take into account reimbursement for all expenditures and non-cancelable commitments
that are consistent with the original budget and phases set forth in the Development Plan
that are incurred by Cardica in performing the Development Plan prior to the effective
date of termination; provided, however, in no event will such pro-rated payment relate to
any refund other than for the most recent phase payment already made to Cardica under
paragraph 5.2.
	 
	 	B.	 	Cook will transfer to Cardica within thirty (30) days of the effective date of
termination or within a commercially reasonable period, whichever is sooner, all
documentation, and perform any actions and send any necessary notices to government
bodies and other entities (such as notified bodies to the European Union) that are
necessary to allow Cardica both to continue to develop, manufacture and commercialize
Products in the Field and to be the registered sponsor of clinical trials and related
regulatory filings for Products in the Field. Cardica within sixty (60) days of the
effective date of termination will reimburse Cook for its documented expenses relating to
the transfer not to exceed [ * ]. If an IDE or PMA is undertaken by Cook for approval of
the Product, then the filing fees, transfer costs and other costs associated with the IDE
and PMA (such as the costs of clinical studies) to be paid by Cardica will not exceed an
amount to be negotiated in good faith between the parties. Cardica shall pay any
negotiated amount in ten (10) equal installments due semiannually, based on the effective
date of termination. The parties may elect to enter into good faith negotiations with a
view toward executing agreements pursuant to which Cardica may purchase the production
tooling owned by Cook for the Product and/or pursuant to which Cook may distribute
Product manufactured by or for Cardica under terms and conditions agreeable to the
parties.
	 
	 	C.	 	If Cook is then manufacturing or supplying Product under the Agreement and upon
receipt of Cardica’s written request, Cook will continue to manufacture Products for
Cardica for use in the Field for a period not to exceed one (1) year from the effective
date of termination to allow Cardica time to engage an alternate supplier.
	 
	 	D.	 	Cook will not sue Cardica under any Cook Patents, Cook Know-How and Other Cook IP
obtained during the Term of this Agreement on Inventions conceived by Cook employees
working on the project and solely to the extent necessary to allow Cardica to continue
(itself or with or through Third Parties) making, using, selling, offering for sale and
importing Products in the Field and in the Territory. To the extent Product has a been
commercialized under this Agreement incorporating

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended

 16.

 

	 	 	 	Cook Patents, Cook Know-How and/or Other Cook IP Cook will upon Cardica’s written
request negotiate with Cardica in good faith toward a license under reasonable terms
and conditions, which license Cook in its sole discretion may elect, but is not
obligated, to execute with Cardica. In the event that Cook terminates this Agreement
for convenience under Section 8.2 or in the event that Cardica’s termination of this
Agreement based on Cook’s breach under Section 8.2 is determined by a court of
competent jurisdiction to have been proper under this Agreement, then Cook agrees for
a period of five (5) years from the effective date of such termination not to grant to
any competitor of Cardica any right under any Cook Patents, Cook Know-How and Other
Cook IP obtained during the Term of this Agreement on Inventions conceived by Cook
employees working on the project to make, use, sell, offer for sale or import Products
in the Field and in the Territory.

	8.4	 	Rights upon Termination by Cook for Material Breach of Cardica.

	 	A.	 	Upon early termination of this Agreement under Section 8.2 by Cook for a
material breach by Cardica, in the event that such termination occurs after full
payment to Cardica of a phase payment set forth in Sections 5.1 or 5.2 above and before
completion of that phase, Cardica will reimburse Cook the amount of that phase payment,
minus all incurred expenditures, non-cancelable commitments and associated overhead
that are consistent with the original budget and phases set forth in the Development
Plan prior to the effective date of termination. The license granted to Cook under
Section 4.1 will survive, and subject to the payment of any Earned Royalties due to
Cardica under Section 5.4, Cardica will transfer to Cook within thirty (30) days of the
effective date of termination or a commercially reasonable period, whichever is sooner,
all documentation and equipment, including all pre-production tooling, and perform any
actions and send any necessary notices to government bodies and other entities (such as
notified bodies) that are necessary to allow Cook to continue to develop, manufacture
and commercialize Products in the Field.

ARTICLE IX

CONFIDENTIALITY

	9.1	 	Confidential Information. Each party receiving Confidential Information (the “Receiving
Party”) shall maintain in confidence all such Confidential Information disclosed by the other
party pursuant to this Agreement (the “Disclosing Party”), and shall not use, disclose or
grant the use of the Confidential Information for any purpose other than those permitted
hereunder, except on a need-to-know basis to its and its Affiliates’ actual or potential
business partners or sublicensees, directors, officers, employees, agents, consultants,
clinical investigators, contractors, distributors or permitted assignees, to the extent such
disclosure is reasonably necessary in connection with such party’s activities in connection
with its performance under and exercise of rights expressly provided in this Agreement. The
foregoing obligations shall apply for five (5) years after the expiration or termination of
this Agreement. To the extent that disclosure is authorized by this Agreement, prior to
disclosure, a party hereto shall obtain

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended

 17.

 

	 	 	agreement of any such person to hold in confidence and not make use of the Confidential
Information of the other party for any purpose other than those permitted by this Agreement.
For purposes of this Agreement, “Confidential Information” shall mean all information and
materials, received by either party from or on behalf of the other party pursuant to this
Agreement, other than that portion of such information or materials that is publicly
disclosed by the disclosing party, either before or after it becomes known to the Receiving
Party; was known to the Receiving Party, without obligation to keep it confidential, prior
to when it was received from the Disclosing Party, as evidenced by competent written proof;
is subsequently disclosed to the Receiving Party by a Third Party lawfully in possession
thereof without obligation to keep it confidential; has been publicly disclosed other than
by the Disclosing Party and without breach of an obligation of confidentiality with respect
thereto; or has been independently developed by the Receiving Party without the aid,
application or use of Confidential Information, as evidenced by competent written proof.

	9.2	 	Permitted Disclosures. The confidentiality obligations contained in this Article IX shall
not apply to the extent that the Receiving Party is required (a) to disclose information by
law, order or regulation of a governmental agency or a court of competent jurisdiction or to
comply with the rules of a securities exchange, or (b) to disclose information to any
governmental agency for purposes of obtaining approval to test or market a product, provided
in either case that the Receiving Party shall provide written notice thereof to the other
party and reasonable opportunity to object to any such disclosure or to request confidential
treatment thereof, and shall use reasonable efforts to secure confidential treatment of or a
protective order for the information so required to be disclosed. Notwithstanding any other
provision of this Agreement, each Party may disclose Confidential Information of the other
Party as necessary to file or prosecute patent application, prosecute or defend litigation or
otherwise establish rights or enforce obligations under this Agreement, or submit regulatory
filings, but only to the extent that any such disclosure is necessary.

ARTICLE X

INDEMNIFICATION

	10.1	 	By Cook. Cook shall defend, indemnify and hold Cardica harmless from and against any and all
liability, loss, claims, suits, proceedings, expenses, recoveries and damages, including,
without limitation, legal costs and expenses (including reasonable attorney’s fees) resulting
from any claim by Third Parties arising out of Cook’s development, manufacture, use, storage,
transportation, promotion or sale of the Products in the Field and in the Territory under this
Agreement, Cook’s breach of this Agreement or any representations, warranties or covenants it
makes in this Agreement, or Cook’s gross negligence or willful misconduct; except to the
extent that such claim arises from Cardica’s design, manufacture, or use of the Products in
the Field and in the Territory, a breach by Cardica of this Agreement or any of the
representations, warranties or covenants it makes in this Agreement, or Cardica’s gross
negligence or willful misconduct.

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended

 18.

 

	10.2	 	By Cardica. Cardica shall defend, indemnify and hold Cook harmless from and against any and
all liability, loss, claims, suits, proceedings, expenses, recoveries and damages, including,
without limitation, legal costs and expenses (including reasonable attorney’s fees) resulting
from any claim by Third Parties arising out of Cardica’s design, manufacture, or use of the
Products in the Field and in the Territory under this Agreement (liability under the foregoing
sentence to be limited to the amount actually paid by Cook to Cardica under this Agreement),
Cardica’s breach of this Agreement or of any of the representations, warranties or covenants
it makes in this Agreement, or Cardica’s gross negligence or willful misconduct; except to the
extent that such claim arises from a breach by Cook of this Agreement or any of the
representations, warranties or covenants it makes in this Agreement, or Cook’s gross
negligence or willful misconduct.
	 
	10.3	 	Process. If either party is seeking indemnification under Sections 10.1 or 10.2, it shall
inform the indemnifying party of the Third Party claim giving rise to the obligation to
indemnify pursuant to such Section as soon as reasonably practicable after receiving notice of
the claim. The indemnifying party shall have the right to assume the defense of any such
third-party claim for which it is obligated to indemnify the indemnified party under Section
10.1 or 10.2. The indemnified party shall cooperate with the indemnifying party (and its
insurer) as the indemnifying party may reasonably request, and at the indemnifying party’s
sole cost and expense. The indemnified party shall have the right to participate, at its own
expense and with counsel of its choice, in the defense of any claim or suit that has been
assumed by the indemnifying party. Neither party shall have any obligation to indemnify the
other party in connection with any settlement made without the indemnifying party’s written
consent, provided that the indemnifying party does not unreasonably withhold or delay any such
written consent. If the parties cannot agree as to the application of Section 10.1 or 10.2 to
any Third Party claim, the parties may conduct separate defenses of such claims, with each
party retaining the right to claim indemnification from the other in accordance with Section
10.1 or 10.2 upon resolution of the underlying claim.
	 
	10.4	 	Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL,
CONSEQUENTIAL, EXEMPLARY OR INCIDENTAL DAMAGES (INCLUDING LOST OR ANTICIPATED REVENUES OR
PROFITS RELATING TO THE SAME), ARISING FROM ANY CLAIM RELATING TO THIS AGREEMENT, WHETHER SUCH
CLAIM IS BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, EVEN IF AN AUTHORIZED
REPRESENTATIVE OF SUCH PARTY IS ADVISED OF THE POSSIBILITY OR LIKELIHOOD OF THE SAME. NOTHING
IN THIS SECTION 10.4 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS SET FORTH IN
SECTIONS 10.1 AND 10.2.
	 
	10.5	 	No Other Representations. EXCEPT AS EXPRESSLY SET FORTH HEREIN, THE TECHNOLOGY AND
INTELLECTUAL PROPERTY RIGHTS PROVIDED BY EACH PARTY HEREUNDER ARE PROVIDED “AS IS,” AND EACH
PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING,
WITHOUT LIMITATION, THE WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended

 19.

 

	 	 	PURPOSE, NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING
FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES, IN ALL CASES WITH RESPECT THERETO.
Without limiting the generality of the foregoing, neither party makes any warranty of any
kind related to: (i) the success of the research conducted by the parties under the
Agreement; or (ii) the safety or usefulness for any purpose of the technology or other
materials or information it provides hereunder.

ARTICLE XI

MISCELLANEOUS

	11.1	 	All notices relating to this Agreement will be given by fax, first class mail or courier
addressed as follows:

	 	 	 	 	 
	 

	 	If to Cook:
	 	If to Cardica:
	 
	 	 	 	 
	 

	 	Cook Incorporated
	 	Cardica, Inc.
	 

	 	750 Daniels Way
	 	900 Saginaw Drive,
	 

	 	Bloomington, Indiana 47404
	 	Redwood City, CA 9406
	 

	 	Attn: Peter Yonkman
	 	Attn: Robert Newell
	 

	 	General Counsel
	 	Chief Financial Officer
	 

	 	Phone: (812) 339-2235
	 	Phone: (650) 331-7133
	 

	 	Fax: (812) 339-5369
	 	Fax: (650) 364-3134

	 	 	or any other address of which either party notifies the other in writing in accordance with
this Section 11.1. Any notice provided for in this Agreement will be deemed effective on
the date of actual receipt by the party.
	 
	11.2	 	Assignment. Neither party may assign this Agreement without the prior written consent of the
other party, which consent will not be unreasonably withheld. Notwithstanding the forgoing,
either party may, without the prior consent of the other party, assign this Agreement to its
parent or affiliate or to a successor, or to an acquiring entity in connection with a merger
or sale of substantially all of the assets of the business or product line to which this
Agreement relates. This Agreement will inure to the benefit of and be binding upon the parties
hereto and their respective successors and permitted assigns. Any purported assignment not in
accordance with this Section 11.2 shall be void and of no force and effect

	11.3	 	Relationship of the Parties. The parties are independent contractors. Neither party has any
express or implied right or authority to assume or create any obligations on behalf of the
other or to bind the other to any contract, agreement or undertaking with any Third Party.
Nothing in this Agreement is to be construed to create a partnership, joint venture,
employment or agency relationship between Cook and Cardica.

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended

 20.

 

	11.4	 	No Implied Waiver. No express or implied waiver, breach or default of any provision of this
Agreement is to be construed as a continuing waiver, and no waiver will prevent a
party from enforcing or acting upon any other provisions, subsequent breach or default by
the other party.

	11.5	 	Publicity. Nothing in this Agreement is to be construed as granting either party any right
under the trademarks or trade names of the other party. Neither party will make any statement
to the media regarding the relationship of the parties without the prior written approval of
the other party. Each party may, however, without the consent of the other party, describe
the scope and purpose of this Agreement to customers in marketing presentations.

	11.6	 	Force Majeure. Any delay or failure of a party to perform its obligations under this
Agreement will be excused to the extent that the delay or failure is caused by an event or
occurrence beyond the party’s reasonable control, such as, by way of example and not by way of
limitation, acts of God, actions by any governmental authority (whether valid or invalid),
terrorism, fires, floods, windstorms, explosions, riots, natural disasters, wars, sabotage,
labor problems (including lockouts, strikes and slowdowns), inability to obtain power,
material, equipment or transportation or court injunction or order, provided that such party
uses reasonable efforts to overcome such delay or failure.

	11.7	 	Governing Law. This Agreement is to be construed in accordance with the laws of the State of
Delaware, without regard to its conflict of law rules.

	11.8	 	Survival. Articles IX, X (solely to the extent relating to claims arising from activities
conducted during the Term of this Agreement or from Cardica’s practice of the covenant not to
sue granted to it pursuant to Sections 4.3) and XI, and Sections 3.1, 3.2, 3.3, 3.4(B), 3.5
(solely to the extent that the license granted to Cook under Section 4.1 survives termination
of this Agreement under Section 8.4), 4.1 (upon expiration of this Agreement as set forth in
Section 8.4), 5.6 through 5.10, 6.1 (solely to the extent that the license granted to Cook
under Section 4.1 survives termination of this Agreement under Section 8.4 ), 6.2, 8.2, 8.3,
8.4, and 11.1, 11.2, 11.4, 11.7, 11.8 and 11.9 of this Agreement will survive its expiration
or termination. Termination or expiration of this Agreement shall not affect any payment
obligations that accrued prior to the effective date of such termination or expiration.

	11.9	 	Integration. This Agreement, including all attachments hereto, embodies the entire
understanding between the parties relating its subject matter and supercedes all prior written
or oral agreements relating to such subject matter. There are no representations, warranties,
agreements or understandings between the parties related to the subject matter of this
Agreement that are not contained herein. This Agreement may not be amended or modified except
in a writing that is dated and signed by the party against whom enforcement is sought. This
Agreement may be executed and delivered by facsimile and in any number of counterparts, each
such counterpart deemed to be an original, but all of which together constitute one and the
same document.

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended

 21.

 

     Each of the parties has caused this Agreement to be executed by its duly authorized representative.

	 	 	 	 	 	 	 	 	 
	COOK INCORPORATED	 	CARDICA, INC.	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Brian Bates
	 	By:
	 	/s/ Bernard Hausen
	 	 
	 

	 	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Name: Brian Bates	 	Name: Bernard Hausen	 	 
	 
	 	 	 	 	 	 	 	 
	Title: Sr. V.P. Business Development	 	Title: CEO	 	 
	 
	 	 	 	 	 	 	 	 
	Date: 6/14/07	 	Date: 6/15/07	 	 

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended

 22.

 

Attachment A

PFO Closure Device

Research and Development Plan

[ * ]

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended

 23.<PAGE>

                                                                     Exhibit 4.1

                                                                  EXECUTION COPY

================================================================================

                          ASPECT MEDICAL SYSTEMS, INC.

                                     ISSUER

                                   ----------

                         U.S. BANK NATIONAL ASSOCIATION

                                     TRUSTEE

                                   ----------

                                    INDENTURE

                            Dated as of June 20, 2007

                                   ----------

                     2.50% CONVERTIBLE SENIOR NOTES DUE 2014

================================================================================
<PAGE>

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                            PAGE
                                                                            ----
<S>                                                                         <C>

                                    ARTICLE 1
             DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION

Section 1.01.  Definitions...............................................      1
Section 1.02.  Incorporation by Reference of Trust Indenture Act.........     14
Section 1.03.  Notices, Etc. to the Trustee and Company..................     14
Section 1.04.  Effect of Headings and Table of Contents..................     15

                                    ARTICLE 2
                                   NOTE FORMS

Section 2.01.  Form Generally............................................     15
Section 2.02.  Form of Note..............................................     15
Section 2.03.  Form of Notice of Conversion..............................     26
Section 2.04.  Form of Assignment........................................     27
Section 2.05.  Mutilated, Destroyed, Lost or Stolen Notes................     27
Section 2.06.  Execution, Authentication and Delivery of Notes...........     28
Section 2.07.  Exchange and Registration of Transfer of Notes;
               Restrictions on Transfer; Depositary......................     29

                                    ARTICLE 3
                                    THE NOTES

Section 3.01.  Title and Terms...........................................     34
Section 3.02.  Denominations.............................................     35
Section 3.03.  Global Notes; Non-Global Notes; Book-entry Provisions.....     35
Section 3.04.  Payment of Liquidated Damages.............................     36
Section 3.05.  Cancellation of Notes Paid, Etc...........................     37
Section 3.06.  CUSIP Numbers.............................................     37
Section 3.07.  Persons Deemed Owners.....................................     37
Section 3.08.  Special Record Date.......................................     37

                                    ARTICLE 4
                       PARTICULAR COVENANTS OF THE COMPANY

Section 4.01.  Payment of Principal, Interest and Liquidated Damages.....     38
Section 4.02.  Maintenance of Office or Agency...........................     39
Section 4.03.  Appointments to Fill Vacancies in Trustee's Office........     39
Section 4.04.  Provisions as to Paying Agent.............................     40
Section 4.05.  Existence.................................................     41
</TABLE>

                                        i

<PAGE>

<TABLE>
<S>                                                                         <C>
Section 4.06.  Rule 144A Information Requirement and Annual Reports......     41
Section 4.07.  Compliance Certificate; Statements as to Defaults.........     41
Section 4.08.  Further Instruments and Acts..............................     42
Section 4.09.  Liquidated Damages. ......................................     42

                                    ARTICLE 5
                                    REMEDIES

Section 5.01.  Events of Default.........................................     42
Section 5.02.  Acceleration of Maturity; Rescission and Annulment........     44
Section 5.03.  Unconditional Right of Holders to Receive Principal,
               Liquidated Damages and Interest and to Convert............     46
Section 5.04.  Waiver of Past Defaults...................................     46
Section 5.05.  Waiver of Stay, Usury or Extension Laws. .................     46
Section 5.06.  Conditions to Enforcement. ...............................     47
Section 5.07.  Control by Holders. ......................................     47

                                   ARTICLE 6
                            CONCERNING THE TRUSTEE

Section 6.01.  Duties and Responsibilities of Trustee. ..................     47
Section 6.02.  Reliance on Documents, Opinions, Etc. ....................     49
Section 6.03.  No Responsibility for Recitals, Etc. .....................     51
Section 6.04.  Trustee, Paying Agents or Registrar May Own Notes. .......     51
Section 6.05.  Monies to be Held in Trust................................     51
Section 6.06.  Compensation and Expenses of Trustee......................     51
Section 6.07.  Officers' Certificate as Evidence. .......................     52
Section 6.08.  Conflicting Interests of Trustee. ........................     52
Section 6.09.  Eligibility of Trustee....................................     53
Section 6.10.  Resignation or Removal of Trustee.........................     53
Section 6.11.  Acceptance by Successor Trustee...........................     54
Section 6.12.  Succession by Merger, Etc.................................     55
Section 6.13.  Limitation on Rights of Trustee as Creditor...............     55
Section 6.14.  Trustee's Application for Instructions from the Company...     56

                                   ARTICLE 7
                            CONCERNING THE HOLDERS

Section 7.01.  Action By Holders.........................................     56
Section 7.02.  Proof of Execution by Holders.............................     57
Section 7.03.  Revocation of Consents; Future Holders Bound..............     57

                                    ARTICLE 8
                             SUPPLEMENTAL INDENTURES

Section 8.01.  Supplemental Indentures Without Consent of Holders of
               Notes.....................................................     57
</TABLE>

                                       ii

<PAGE>

<TABLE>
<S>                                                                         <C>
Section 8.02.  Supplemental Indentures with Consent of Holders of Notes..     58
Section 8.03.  Effect of Supplemental Indentures.........................     59
Section 8.04.  Notation on Notes. .......................................     60
Section 8.05.  Evidence of Compliance of Supplemental Indenture to be
               Furnished to the Trustee..................................     60

                                    ARTICLE 9
                HOLDERS LISTS AND REPORTS BY TRUSTEE AND COMPANY

Section 9.01.  List of Holders.  ........................................     60
Section 9.02.  Preservation of Information...............................     60

                                  ARTICLE 10
               CONSOLIDATION, MERGER, SALE, CONVEYANCE AND LEASE

Section 10.01. Company May Consolidate, Etc. on Certain Terms............     61
Section 10.02. Successor Corporation to be Substituted. .................     62
Section 10.03. Officers' Certificate and Opinion of Counsel to be Given
               Trustee. .................................................     62

                                   ARTICLE 11
                                HOLDERS' MEETINGS

Section 11.01. Purpose of Meetings. .....................................     63
Section 11.02. Call of Meetings by Trustee. .............................     63
Section 11.03. Call of Meetings by Company or Holders. ..................     63
Section 11.04. Qualifications for Voting. ...............................     64
Section 11.05. Regulations...............................................     64
Section 11.06. Voting....................................................     64
Section 11.07. No Delay of Rights by Meeting.............................     65

                                   ARTICLE 12
                               CONVERSION OF NOTES

Section 12.01. Conversion Privilege and Conversion Rate..................     65
Section 12.02. Exercise of Conversion Privilege..........................     69
Section 12.03. Fractions of Shares.......................................     72
Section 12.04. Adjustment of Conversion Rate.............................     74
Section 12.05. Notice of Adjustments of Conversion Rate..................     85
Section 12.06. Company to Reserve Common Stock...........................     86
Section 12.07. Taxes on Conversions......................................     86
Section 12.08. Certain Covenants.........................................     86
Section 12.09. Cancellation of Converted Notes...........................     87
Section 12.10. Provision in Case of Effect of Reclassification,
               Consolidation, Merger or Sale.............................     87
Section 12.11. Responsibility of Trustee for Conversion Provisions.......     89
Section 12.12. Right to Set-off Withholding Taxes. ......................     89
</TABLE>

                                       iii

<PAGE>

<TABLE>
<S>                                                                         <C>
                                   ARTICLE 13
                                    DISCHARGE

Section 13.01. Discharge of Liability on Notes...........................     90
Section 13.02. Reinstatement.............................................     91
Section 13.03. Officers' Certificate; Opinion of Counsel.................     91

                                  ARTICLE 14
                              REPURCHASE OF NOTES

Section 14.01. Right to Require Repurchase Upon a Fundamental Change.....     91

                                  ARTICLE 15
                           MISCELLANEOUS PROVISIONS

Section 15.01. Provisions Binding on Company's Successors. ..............     96
Section 15.02. Official Acts by Successor Corporation. ..................     96
Section 15.03. Addresses for Notices, Etc................................     96
Section 15.04. Governing Law. ...........................................     96
Section 15.05. Evidence of Compliance with Conditions Precedent;
               Certificates and Opinions of Counsel to Trustee...........     97
Section 15.06. Legal Holidays. ..........................................     97
Section 15.07. No Security Interest Created..............................     97
Section 15.08. Benefits of Indenture. ...................................     97
Section 15.09. Table of Contents, Headings, Etc..........................     97
Section 15.10. Authenticating Agent......................................     98
Section 15.11. Execution in Counterparts.................................     98
Section 15.12. Waiver of Jury Trial......................................     99
Section 15.13. Force Majeure.............................................     99
</TABLE>

                                       iv
<PAGE>

     INDENTURE, dated as of June 20, 2007, between ASPECT MEDICAL SYSTEMS, INC.,
a corporation duly organized and existing under the laws of the State of
Delaware, having its principal office at One Upland Road, Norwood, Massachusetts
02062 (herein called the "COMPANY" as more fully set forth in Section 1.01), and
U.S. BANK NATIONAL ASSOCIATION, a national banking corporation, as Trustee
hereunder (herein called the "TRUSTEE" as more fully set forth in Section 1.01).

                             RECITALS OF THE COMPANY

     WHEREAS, for its lawful corporate purposes, the Company has duly authorized
the issue of its 2.50% Convertible Senior Notes due 2014 (hereinafter sometimes
called the "NOTES"), initially in an aggregate principal amount not to exceed
$125,000,000, and in order to provide the terms and conditions upon which the
Notes are to be authenticated, issued and delivered, the Company has duly
authorized the execution and delivery of this Indenture; and

     WHEREAS, the Notes, the certificate of authentication to be borne by the
Notes, the Form of Assignment, the Form of Fundamental Change Repurchase Notice,
and the Form of Notice of Conversion are to be substantially in the forms
hereinafter provided for; and

     WHEREAS, all acts and things necessary to make the Notes, when executed by
the Company and authenticated and delivered by the Trustee or a duly authorized
authenticating agent, as in this Indenture provided, the valid, binding and
legal obligations of the Company, and to constitute these presents a valid and
legally binding agreement according to its terms, have been done and performed,
and the execution of this Indenture and the issue hereunder of the Notes have in
all respects been duly authorized.

                   NOW, THEREFORE, THIS INDENTURE WITNESSETH:

     For and in consideration of the premises and the purchase of the Notes by
the Holders (as defined below) thereof, it is mutually covenanted and agreed,
for the equal and proportionate benefit of all Holders of the Notes, as follows:

                                    ARTICLE 1
             DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION

     Section 1.01. Definitions.

     For all purposes of this Indenture, except as otherwise expressly provided
or unless the context otherwise requires:

<PAGE>

     (a) the terms defined in this Article 1 have the meanings assigned to them
in this Article 1 and include the plural as well as the singular;

     (b) all accounting terms not otherwise defined herein have the meanings
assigned to them in accordance with generally accepted accounting principles in
the United States, and, except as otherwise herein expressly provided, the term
"generally accepted accounting principles" with respect to any computation
required or permitted hereunder shall mean such accounting principles as are
generally accepted at the date of such computation; and

     (c) all other terms used in this Indenture which are defined in the Trust
Indenture Act or which are by reference therein defined in the Securities Act
(except as herein otherwise expressly provided or unless the context otherwise
requires) shall have the meanings assigned to such terms in the Trust Indenture
Act and in the Securities Act as in force at the date of the execution of this
Indenture. The words "herein," "hereof" and "hereunder" and other words of
similar import refer to this Indenture as a whole and not to any particular
Article, Section or other subdivision.

     "ACT," when used with respect to any Holder of a Note, has the meaning
specified in Section 7.01.

     "ADDITIONAL NOTES" means any Notes (in addition to the Initial Notes)
issued under this Indenture in accordance with Section 3.01, as part of the same
series as the Initial Notes.

     "ADDITIONAL SHARES" has the meaning specified in Section 12.01.

     "ADJUSTMENT DETERMINATION DATE" has the meaning specified in Section 12.04.

     "ADJUSTMENT EVENT" has the meaning specified in Section 12.04.

     "AFFILIATE" of any specified Person means any other Person directly or
indirectly controlling or controlled by or under direct or indirect common
control with such specified Person. For the purposes of this definition,
"CONTROL," when used with respect to any specified Person, means the power to
direct the management and policies of such Person, directly or indirectly,
whether through the ownership of voting securities, by contract or otherwise;
and the terms "CONTROLLING" and "CONTROLLED" have meanings correlative to the
foregoing.

     "AGENT MEMBER" means any member of, or participant in, the Depositary.

     "AMERICAN DEPOSITARY RECEIPTS" means a negotiable United States security
that represents a non-United States company's publicly traded equity.

     "APPLICABLE PROCEDURES" means, with respect to any transfer or transaction
involving a Global Note or beneficial interest therein, the rules and

                                        2

<PAGE>

procedures of DTC or any successor Depositary, in each case to the extent
applicable to such transaction and as in effect from time to time.

     "BOARD OF DIRECTORS" means the Board of Directors of the Company or a
committee of such Board duly authorized to act for it hereunder.

     "BOARD RESOLUTION" means a copy of a resolution certified by the Secretary
or an Assistant Secretary of the Company to have been duly adopted by the Board
of Directors, or duly authorized committee thereof (to the extent permitted by
applicable law), and to be in full force and effect on the date of such
certification, and delivered to the Trustee.

     "BUSINESS DAY" means any day, except a Saturday, Sunday or legal holiday on
which the banking institutions in The City of New York or the city in which the
Corporate Trust Office is located are authorized or obligated by law or
executive order to close.

     "CAPITAL STOCK" means, for any entity, any and all shares, interests,
rights to purchase, warrants, options, participations or other equivalents of or
interests in (however designated) stock issued by that entity.

     "CLOSE OF BUSINESS" means 5:00 p.m. (New York City time).

     "CODE" means the Internal Revenue Code of 1986, as amended.

     "COMMON STOCK" means the Common Stock, par value $0.01 per share, of the
Company authorized at the date of this instrument as originally executed or as
such stock may be constituted from time to time. Subject to the provisions of
Section 12.10, shares issuable upon conversion of Notes shall include only
shares of Common Stock or shares of any class or classes of common stock
resulting from any reclassification or reclassifications thereof; provided,
however, that if at any time there shall be more than one such resulting class,
the shares so issuable on conversion of Notes shall include shares of all such
classes, and the shares of each such class then so issuable shall be
substantially in the proportion which the total number of shares of such class
resulting from all such reclassifications bears to the total number of shares of
all such classes resulting from all such reclassifications.

     "COMMON STOCK" includes any stock of any class of Capital Stock which has
no preference in respect of dividends or of amounts payable in the event of any
voluntary or involuntary liquidation, dissolution or winding up of the issuer
thereof and which is not subject to redemption by the issuer thereof.

     "COMPANY" means Aspect Medical Systems, Inc., a Delaware corporation, and
subject to the provisions of Article 10, shall include its successors and
assigns (including any Successor Company) and, to the extent the obligations
hereunder

                                        3

<PAGE>

shall be obligations of more than one entity pursuant to Section 12.10, shall
include each of such entities.

     "COMPANY ORDER" means a written order of the Company, signed by (a) the
Company's Chief Executive Officer, President, Executive or Senior Vice
President, Managing Director or any Vice President (whether or not designated by
a number or numbers or word or words added before or after the title "Vice
President") and (b) any such other officer designated in clause (a) of this
definition or the Company's Treasurer or Assistant Treasurer or Secretary or any
Assistant Secretary, and delivered to the Trustee.

     "CONTINUING DIRECTORS" means (i) individuals who on the Issue Date
constituted the Board of Directors and (ii) any new directors whose election to
the Board of Directors or whose nomination for election by the Company's
stockholders was approved by at least a majority of the Company's directors then
still in office (or a duly constituted committee thereof), either who were
directors on the Issue Date or whose election or nomination for election was
previously so approved.

     "CONVERSION AGENT" means any Person authorized by the Company to convert
Notes in accordance with Article 12. The Company has initially appointed the
Trustee as its Conversion Agent pursuant to Section 4.02.

     "CONVERSION DATE" has the meaning specified in Section 12.02.

     "CONVERSION OBLIGATION" has the meaning specified in Section 12.01.

     "CONVERSION PRICE" means at any time the amount equal to $1,000 divided by
the then current Conversion Rate.

     "CONVERSION RATE" has the meaning specified in Section 12.01.

     "CORPORATE TRUST OFFICE" means the office of the Trustee at which at any
particular time the trust created by this Indenture shall be principally
administered (which at the date of this Indenture is located at U.S. Bank
National Association, One Federal Street, 3rd Floor, Boston, Massachusetts 02110
Attention: Corporate Trust Services).

     "CORPORATION" means a corporation, company, association, joint-stock
company or business trust.

     "DAILY CONVERSION VALUE" means, for each of the 40 consecutive VWAP Trading
Days during the Observation Period, 1/40th of the product of (a) the applicable
Conversion Rate and (b) the Daily VWAP of the Common Stock (or the Reference
Property pursuant to Section 12.10) on such VWAP Trading Day, as determined by
the Company. Any determination of the Daily Conversion Value by the Company
shall be conclusive absent manifest error.

                                        4

<PAGE>

     "DAILY SETTLEMENT AMOUNT" means, for each of the 40 VWAP Trading Days
during the Observation Period,

          (i) an amount of cash equal to the lesser of (x) $25 and (y) the Daily
     Conversion Value for such VWAP Trading Day; and

          (ii) if such Daily Conversion Value exceeds $25, a number of shares of
     Common Stock equal to (A) the difference between such Daily Conversion
     Value and $25, divided by (B) the Daily VWAP of the Common Stock for such
     VWAP Trading Day.

     "DAILY VWAP" of the Common Stock, or the consideration received by
stockholders in exchange for the Common Stock, means for each of the 40
consecutive VWAP Trading Days during the Observation Period, the per share
volume-weighted average price as displayed under the heading "Bloomberg VWAP" on
Bloomberg page ASPM.Q (equity) AQR (or any equivalent successor page) in respect
of the period from the scheduled open of trading on the principal trading market
for the Common Stock to the scheduled close of trading on such market on such
VWAP Trading Day (without regard to after-hours trading), or if such
volume-weighted average price is unavailable, the market value of one share of
Common Stock (or one unit of Reference Property consisting of marketable equity
securities) on such VWAP Trading Day using a volume-weighted method (or, in the
case of Reference Property consisting of cash, the amount of such cash, or in
the case of Reference Property other than marketable equity securities or cash,
the market value thereof), in each case as determined by a nationally recognized
independent investment banking firm retained by the Board of Directors for this
purpose.

     "DEFAULT" means any event which is, or after notice or lapse of time or
both would become, an Event of Default pursuant to Section 5.01.

     "DEFAULTED INTEREST" has the meaning specified in Section 3.08.

     "DISTRIBUTED PROPERTY" has the meaning specified in Section 12.04.

     "DOLLAR," "U.S. $" or "$" means a dollar or other equivalent unit in such
coin or currency of the United States as at the time shall be legal tender for
the payment of public and private debts.

     "DTC" means The Depository Trust Company, a New York corporation, or any
successor.

     "EFFECTIVE DATE" means the date on which a Make-Whole Fundamental Change
occurs or becomes effective.

     "EVENT OF DEFAULT" has the meaning specified in Section 5.01.

                                        5

<PAGE>

     "EXCHANGE ACT" means the Securities Exchange Act of 1934, as amended, and
the rules and regulations promulgated thereunder.

     "EX-DATE" means, with respect to any issuance or distribution on the Common
Stock or any other equity security, the first date on which the shares of Common
Stock or such other equity security trade on the relevant exchange or in the
relevant market, regular way, without the right to receive such issuance or
distribution.

     "EXTENSION FEE" has the meaning specified in Section 5.02.

     "EXTENSION RIGHT" has the meaning specified in Section 5.02.

     "FUNDAMENTAL CHANGE" will be deemed to have occurred at the time after the
Notes are originally issued that any of the following occurs:

          (1) any Person acquires beneficial ownership directly or indirectly,
     through a purchase, merger or other acquisition transaction or series of
     transactions, of shares of the Company's Capital Stock entitling the Person
     to exercise 50% or more of the total voting power of all shares of the
     Company's Capital Stock entitled to vote generally in elections of
     directors, other than an acquisition by the Company, any of the Company's
     Subsidiaries or any of the Company's employee benefit plans (for purposes
     of this clause (1), whether a Person is a "beneficial owner" shall be
     determined in accordance with Rule 13d-3 under the Exchange Act, and
     "Person" shall include any syndicate or group that would be deemed to be a
     "person" under Section 13(d)(3) of the Exchange Act); or

          (2) the Company (i) merges or consolidates with or into any other
     Person (other than a Subsidiary), another Person merges with or into the
     Company, or the Company conveys, sells, transfers or leases all or
     substantially all of the Company's assets to another Person or (ii) engages
     in any recapitalization, reclassification or other transaction in which all
     or substantially all of the Common Stock is exchanged for or converted into
     cash, securities or other property, in each case other than a merger or
     consolidation:

               (a) that does not result in a reclassification, conversion,
          exchange or cancellation of the Company's outstanding Common Stock;

               (b) which is effected solely to change the Company's jurisdiction
          of incorporation and results in a reclassification, conversion or
          exchange of outstanding shares of the Company's Common Stock solely
          into shares of common stock of the surviving entity; or

                                        6

<PAGE>

               (c) pursuant to which the consideration received by the holders
          of the Company's Common Stock immediately prior to the transaction
          entitles them to exercise, directly or indirectly, 50% or more of the
          voting power of all shares of Capital Stock entitled to vote generally
          in the election of directors of the surviving or resulting corporation
          immediately following such merger or consolidation; or

          (3) the Company's Continuing Directors do not constitute a majority of
     Board of Directors (or, if applicable, a successor Person to the Company);
     or

          (4) the Company is liquidated or dissolved or holders of the Common
     Stock approve any plan or proposal for the Company's liquidation or
     dissolution; or

          (5) shares of Common Stock, or shares of any other Capital Stock or
     American Depositary Receipts in respect of shares of Capital Stock into
     which the Notes are convertible pursuant to the terms of this Indenture,
     are not listed for trading on any of the New York Stock Exchange, the
     American Stock Exchange, the NASDAQ Global Market or the NASDAQ Global
     Select Market (or any of their respective successors).

     "FUNDAMENTAL CHANGE EXPIRATION TIME" has the meaning specified in Section
14.01.

     "FUNDAMENTAL CHANGE REPURCHASE DATE" has the meaning specified in Section
14.01.

     "FUNDAMENTAL CHANGE REPURCHASE NOTICE" has the meaning specified in Section
14.01.

     "FUNDAMENTAL CHANGE REPURCHASE PRICE" has the meaning specified in Section
14.01.

     "FUNDAMENTAL CHANGE REPURCHASE RIGHT NOTICE" has the meaning specified in
Section 14.01.

     "GLOBAL NOTE" means a Note that is registered in the Note Register in the
name of a Depositary or a nominee thereof.

     "HOLDER" means the Person in whose name the Note is registered in the Note
Register.

     "INDENTURE" means this instrument as originally executed or, if amended or
supplemented as herein provided, as so amended or supplemented.

                                        7

<PAGE>

     "INITIAL NOTES" means the first $125,000,000 aggregate principal amount of
the Notes issued under this Indenture on the date hereof.

     "INITIAL PURCHASER" means Goldman, Sachs & Co.

     "INTEREST PAYMENT DATE" means June 15 and December 15 of each year,
beginning December 15, 2007.

     "ISSUE DATE" means June 20, 2007.

     "LAST REPORTED SALE PRICE" means, with respect to the Common Stock or any
other security for which a Last Reported Sale Price must be determined, on any
date, the closing sale price per share of the Common Stock or unit of such other
security (or, if no closing sale price is reported, the average of the last bid
and last ask prices or, if more than one in either case, the average of the
average last bid and the average last ask prices) on such date as reported in
composite transactions for the principal United States national or regional
securities exchange on which it is then traded, if any. If the Common Stock or
such other security is not listed for trading on a United States national or
regional securities exchange on the relevant date, the Last Reported Sale Price
shall be the average of the last quoted bid and ask prices per share of Common
Stock or such other security in the over-the-counter market on the relevant
date, as reported by the National Quotation Bureau or similar organization. In
the absence of such quotation, the Last Reported Sale Price shall be the average
of the mid-point of the last bid and ask prices for the Common Stock or such
other security on the relevant date from each of at least three nationally
recognized independent investment banking firms, which may include the Initial
Purchaser, selected from time to time by the Board of Directors of the Company
for that purpose. The Last Reported Sale Price shall be determined without
reference to extended or after hours trading. Any such determination shall be
made by the Company and shall be conclusive absent manifest error.

     "LIQUIDATED DAMAGES" means Liquidated Damages as defined in the
Registration Rights Agreement.

     "MAKE-WHOLE FUNDAMENTAL CHANGE" means any transaction or event that
constitutes a Fundamental Change pursuant to clauses (1), (2), (4) or (5) under
the definition of Fundamental Change; provided, however, that in the case of
clause (5) under the definition of Fundamental Change, no increase will be made
unless the shares of Common Stock are not listed for trading for a period in
excess of 15 calendar days.

     "MARKET DISRUPTION EVENT" means the occurrence or existence on any
Scheduled Trading Day for the Common Stock of any suspension or limitation
imposed on trading (by reason of movements in price exceeding limits permitted
by the stock exchange or otherwise) in the Common Stock or in any options
contracts or futures contracts relating to the Common Stock, and such suspension

                                        8

<PAGE>

or limitation occurs or exists at any time within the 30 minutes prior to the
closing time of the relevant exchange on such day.

     "MATURITY," when used with respect to any Notes, means the date on which
the principal of such Notes becomes due and payable as therein or herein
provided, whether on the Maturity Date or by declaration of acceleration,
exercise of the repurchase right set forth in Article 14 or otherwise.

     "MATURITY DATE" means June 15, 2014.

     "MEASUREMENT PERIOD" has the meaning specified in Section 12.01.

     "MERGER EVENT" has the meaning specified in Section 12.10.

     "NET SHARE SETTLEMENT ELECTION" has the meaning specified in Section
12.02(b).

     "NOTE REGISTER" shall have the meaning specified in Section 2.07(a).

     "NOTE REGISTRAR" shall have the meaning specified in Section 2.07(a).

     "NOTES" has the meaning ascribed to it in the first paragraph under the
caption "Recitals of the Company." Unless the context otherwise requires, all
references to the Notes shall include the Initial Notes and any Additional
Notes.

     "NOTICE OF CONVERSION" has the meaning specified in Section 12.02.

     "OBSERVATION PERIOD" means, with respect to any Notes:

          (i) with respect to any Conversion Date that occurs on or after the
     45th Scheduled Trading Day prior to the Maturity Date, the 40 consecutive
     VWAP Trading Day period beginning on and including the 42nd Scheduled
     Trading Day prior to the Maturity Date (or if such day is not a VWAP
     Trading Day, the next succeeding VWAP Trading Day); and

          (ii) in all other instances, the 40 consecutive VWAP Trading Day
     period beginning on and including the third VWAP Trading Day after the
     Conversion Date.

     "OFFERING CIRCULAR" means the final offering circular dated June 14, 2007
with respect to the offering and sale of the Notes.

     "OFFICERS' CERTIFICATE" means a certificate signed by (i) the Chairman of
the Board or the Chief Executive Officer, the President or any Vice President
and by (ii) the Chief Financial Officer, Controller, Treasurer, Assistant
Treasurer, Corporate Secretary or Assistant Corporate Secretary and delivered to
the Trustee. One of the Officers signing an Officers' Certificate given pursuant
to Section 4.07 shall be the principal executive, financial or accounting
officer of the Company.

                                        9

<PAGE>

     "OPINION OF COUNSEL" means an opinion in writing signed by legal counsel,
who may be an employee of or counsel to the Company, which is delivered to the
Trustee. Each such opinion shall include the statements in Section 15.05 if and
to the extent required by the provisions of such Section.

     "OUTSTANDING," when used with respect to the Notes, means, as of the date
of determination, all Notes theretofore authenticated and delivered under this
Indenture, except:

          (i) Notes theretofore canceled by the Trustee or delivered to the
     Trustee for cancellation;

          (ii) Notes for the payment of which money in the necessary amount has
     been theretofore deposited with the Trustee or any Paying Agent (other than
     the Company) in trust or set aside and segregated in trust by the Company
     (if the Company shall act as its own Paying Agent) for the Holders of such
     Notes;

          (iii) Notes in lieu of which, or in substitution for which, other
     Notes have been authenticated and delivered pursuant to this Indenture; and

          (iv) Notes converted into Common Stock pursuant to Article 12;

provided, however, that, in determining whether the Holders of the requisite
principal amount of Outstanding Notes are present at a meeting of Holders of
Notes for quorum purposes or have given any request, demand, authorization,
direction, notice, consent or waiver hereunder, Notes owned by the Company or
any other obligor upon the Notes or any Affiliate of the Company or such other
obligor shall be disregarded and deemed not to be Outstanding, except that, in
determining whether the Trustee shall be protected in relying upon any such
determination as to the presence of a quorum or upon any such request, demand,
authorization, direction, notice, consent or waiver, only Notes which a
Responsible Officer of the Trustee has been notified in writing to be so owned
shall be so disregarded. Notes so owned which have been pledged in good faith
may be regarded as Outstanding if the pledgee is not the Company or any other
obligor upon the Notes or any Affiliate of the Company or such other obligor,
and the Trustee shall be protected in relying upon an Officers' Certificate to
such effect.

     "PAYING AGENT" means any Person authorized by the Company to pay the
principal of or interest on any Notes on behalf of the Company and, except as
otherwise specifically set forth herein, such term shall include the Company if
it shall act as its own Paying Agent. The Company has initially appointed the
Trustee as its Paying Agent pursuant to Section 4.02.

                                       10
<PAGE>

     "PERSON" means any individual, corporation, limited liability company,
partnership, joint venture, trust, estate, unincorporated organization or
government or any agency or political subdivision thereof and any syndicate or
group that would be deemed a "person" under Section 13(d)(3) of the Exchange
Act.

     "PLACE OF CONVERSION" has the meaning specified in Section 3.01.

     "PLACE OF PAYMENT" has the meaning specified in Section 3.01.

     "PREDECESSOR NOTE" of any particular Note means every previous Note
evidencing all or a portion of the same debt as that evidenced by such
particular Note; and, for the purposes of this definition, any Note
authenticated and delivered under Section 2.05 of this Indenture in exchange for
or in lieu of a mutilated, destroyed, lost or stolen Note shall be deemed to
evidence the same debt as the mutilated, destroyed, lost or stolen Note.

     "PRESS RELEASE" means any press release issued by the Company and
disseminated to Reuters Business News Services and Bloomberg News Services.

     "PURCHASE AGREEMENT" means that certain Purchase Agreement, dated June 14,
2007, between the Company and the Initial Purchaser.

     "QUALIFIED INSTITUTIONAL BUYER" or "QIB" shall have the meaning specified
in Rule 144A.

     "RECORD DATE" means any Regular Record Date or Special Record Date.

     "RECORD DATE PERIOD" means the period from the close of business on any
Regular Record Date next preceding any Interest Payment Date to 9:00 a.m., New
York City time, on such Interest Payment Date.

     "REFERENCE PROPERTY" has the meaning specified in Section 12.10.

     "REGISTRATION RIGHTS AGREEMENT" means that certain Registration Rights
Agreement, dated as of June 20, 2007, between the Company and Goldman, Sachs &
Co., acting on behalf of itself as the Initial Purchaser, as amended from time
to time.

     "REGULAR RECORD DATE" for interest payable in respect of any Note on any
Interest Payment Date means the close of business on June 1 or December 1
(whether or not a Business Day), as the case may be, next preceding such
Interest Payment Date.

     "RESALE RESTRICTION TERMINATION DATE" shall have the meaning specified in
Section 2.07(b).

                                       11

<PAGE>

     "RESPONSIBLE OFFICER" when used with respect to the Trustee, shall mean an
officer of the Trustee in the Corporate Trust Office, having direct
responsibility for the administration of this Indenture, and also, with respect
to a particular matter, any other officer to whom such matter is referred
because of such officer's knowledge of and familiarity with the particular
subject.

     "RULE 144A" means Rule 144A as promulgated under the Securities Act.

     "SCHEDULED TRADING DAY" means a day that is scheduled to be a Trading Day
on the principal United States national or regional securities exchange or
market on which the Common Stock is listed or admitted for trading or, if the
Common Stock is not listed or admitted for trading on any exchange or market, a
Business Day.

     "SEC" means the Securities and Exchange Commission.

     "SECURITIES ACT" means the Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder.

     "SIGNIFICANT SUBSIDIARY" means, with respect to any Person, a Subsidiary of
such Person that would constitute a "significant subsidiary" as such term is
defined under Rule 1-02 of Regulation S-X under the Securities Act and the
Exchange Act.

     "SPECIAL RECORD DATE" has the meaning specified in Section 3.08.

     "SPIN-OFF" has the meaning specified in Section 12.04.

     "STOCKHOLDER APPROVAL" means the vote of a majority of shares of the Common
Stock voted at a duly called and convened stockholder meeting (or written
consent in lieu of a meeting) to settle conversions of Notes in cash and shares
of the Common Stock in the manner described in Section 12.02(b), all in
accordance with applicable law, the Company's constituent documents and any
applicable exchange or regulatory requirements.

     "STOCK PRICE" means the price paid per share of Common Stock in connection
with a Make-Whole Fundamental Change pursuant to which Additional Shares shall
be added to the Conversion Rate as set forth in Section 12.01(e), which shall be
equal to (i) if holders of Common Stock receive only cash in such Make-Whole
Fundamental Change, the cash amount paid per share of Common Stock and (ii) in
all other cases, the average of the Last Reported Sale Prices of the Common
Stock over the ten consecutive Trading Day period ending on the Trading Day
preceding the date on which such Fundamental Change occurs or becomes effective.

     "STOCK RECORD DATE" has the meaning specified in Section 12.04.

                                       12

<PAGE>

     "SUBSIDIARY" means a corporation more than 50% of the outstanding voting
stock of which is owned, directly or indirectly, by the Company or by one or
more other Subsidiaries, or by the Company and one or more other Subsidiaries.
For the purposes of this definition, "VOTING STOCK" means stock or other similar
interests in the corporation which ordinarily has or have voting power for the
election of directors, or persons performing similar functions, whether at all
times or only so long as no senior class of stock or other interests has or have
such voting power by reason of any contingency.

     "SUCCESSOR COMPANY" has the meaning specified in Section 10.01(a).

     "SUCCESSOR NOTE" of any particular Note means every Note issued after, and
evidencing all or a portion of the same debt as that evidenced by, such
particular Note; and, for the purposes of this definition, any Note
authenticated and delivered under Section 2.05 of this Indenture in exchange for
or in lieu of a mutilated, destroyed, lost or stolen Note shall be deemed to
evidence the same debt as the mutilated, destroyed, lost or stolen Note.

     "TRADING DAY" means a day during which (i) trading in the Common Stock
generally occurs and (ii) there is no Market Disruption Event.

     "TRADING PRICE" with respect to any Notes, on any date of determination,
means the average of the secondary market bid quotations obtained by the Trustee
for $1.0 million principal amount of such Notes at approximately 3:30 p.m., New
York City time, on such determination date from three independent nationally
recognized securities dealers, which may include the Initial Purchaser, selected
by the Company; provided that if three such bids cannot reasonably be obtained
by the Trustee, but two such bids are obtained, then the average of the two bids
shall be used, and if only one such bid can reasonably be obtained by the
Trustee, that one bid shall be used. Any such determination by the Trustee shall
be conclusive absent manifest error.

     "TRADING PRICE CONDITION" has the meaning specified in Section 12.01.

     "TRANSFER" shall have the meaning specified in Section 2.07(b).

     "TRIGGER EVENT" has the meaning specified in Section 12.04.

     "TRUSTEE" means U.S. Bank National Association and its successors and any
corporation resulting from or surviving any consolidation or merger to which it
or its successors may be a party and any successor trustee serving as successor
trustee hereunder.

     "VWAP MARKET DISRUPTION EVENT" means (i) a failure by the principal United
States national or regional securities exchange or market on which the Common
Stock is listed or admitted to trading to open for trading during its regular
trading session or (ii) the occurrence or existence prior to 1:00 p.m. New

                                       13

<PAGE>

York City time on any Scheduled Trading Day for the Common Stock for an
aggregate one half-hour period of any suspension or limitation imposed on
trading (by reason of movements in price exceeding limits permitted by the stock
exchange or otherwise) in the Common Stock or in any options contracts or
futures contracts relating to the Common Stock.

     "VWAP TRADING DAY" means a day during which (i) trading in the Common Stock
generally occurs on the principal United States national or regional securities
exchange or market on which the Common Stock is listed or admitted for trading
and (ii) there is no VWAP Market Disruption Event. For purposes of determining
payment upon conversion of the Notes in accordance with Section 12.02
(including, for the avoidance of doubt, for purposes of the definition of
"Observation Period" in Section 12.02), if the Common Stock is not so listed or
traded, then "VWAP Trading Day" shall mean "Business Day."

     Section 1.02. Incorporation by Reference of Trust Indenture Act.

     This Indenture is subject to the mandatory provisions of the Trust
Indenture Act, which are incorporated by reference in and made a part of this
Indenture. The following Trust Indenture Act terms have the following meanings:

     "INDENTURE SECURITIES" means the Notes.

     "INDENTURE SECURITY HOLDER" means a Holder.

     "INDENTURE TO BE QUALIFIED" means this Indenture.

     "INDENTURE TRUSTEE" or "INSTITUTIONAL TRUSTEE" means the Trustee.

     All other terms in this Indenture that are defined by the Trust Indenture
Act, defined by it by reference to another statute or defined by SEC rule have
the meanings assigned to them by such definitions. If any provision hereof
limits, qualifies or conflicts with another provision hereof which is required
to be included in this Indenture by the Trust Indenture Act, such required
provision shall control.

     Section 1.03. Notices, Etc. to the Trustee and Company.

     Any request, demand, authorization, direction, notice, consent, election,
waiver or other Act of Holders of Notes or other document provided or permitted
by this Indenture to be made upon, given or furnished to, or filed with,

     (a) the Trustee by any Holder of Notes or by the Company shall be
sufficient for every purpose hereunder if made, given, furnished or filed in
writing (which may be via facsimile) to or with a Responsible Officer of the
Trustee and received at its Corporate Trust Office, Attention: Corporate Client
Services (Aspect Medical Systems, Inc.).

                                       14

<PAGE>

     (b) the Company by the Trustee or by any Holder of Notes shall be
sufficient for every purpose hereunder (unless otherwise herein expressly
provided) if in writing, mailed, first-class postage prepaid, or telecopied and
confirmed by mail, first-class postage prepaid, or delivered by hand or
overnight courier, addressed to the Company at One Upland Road, Norwood,
Massachusetts 02062, Attention: Chief Financial Officer, or at any other address
previously furnished in writing to the Trustee by the Company.

     Section 1.04. Effect of Headings and Table of Contents. The Article and
Section headings herein and the Table of Contents are for convenience only and
shall not affect the construction hereof.

                                    ARTICLE 2
                                   NOTE FORMS

     Section 2.01. Form Generally.

     The Notes shall be in substantially the form set forth in this Article 2,
with such appropriate insertions, omissions, substitutions and other variations
as are required or permitted by this Indenture, and may have such letters,
numbers or other marks of identification and such legends or endorsements placed
thereon as may be required to comply with the rules of any securities exchange,
the Code, and regulations thereunder, or as may, consistent herewith, be
determined by the officers executing such Notes, as evidenced by their execution
thereof. The Company shall furnish any such legends and endorsements to the
Trustee in writing. All Notes shall be in fully registered form.

     Notices of Conversion shall be in substantially the form set forth in
Section 2.03.

     The Notes shall be printed, lithographed, typewritten or engraved or
produced by any combination of these methods or may be produced in any other
manner permitted by the rules of any automated quotation system or securities
exchange (including on steel engraved borders if so required by any securities
exchange upon which the Notes may be listed) on which the Notes may be listed
for trading, as the case may be, all as determined by the officers executing
such Notes, as evidenced by their execution thereof.

     Section 2.02. Form of Note.

                             [FORM OF FACE OF NOTE]

THE FOLLOWING LEGEND SHALL APPEAR ON THE FACE OF EACH GLOBAL NOTE:

                                       15

<PAGE>

THIS NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE INDENTURE HEREINAFTER
REFERRED TO AND IS REGISTERED IN THE NAME OF THE DEPOSITARY OR A NOMINEE OF THE
DEPOSITARY, WHICH MAY BE TREATED BY THE COMPANY, THE TRUSTEE AND ANY AGENT
THEREOF AS OWNER AND HOLDER OF THIS NOTE FOR ALL PURPOSES.

UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE
DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION ("DTC"), TO THE COMPANY OR ITS
AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE, OR PAYMENT, AND ANY CERTIFICATE
ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS
REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO
CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED
REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE, OR OTHER USE HEREOF FOR VALUE OR
OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER
HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.

UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR NOTES IN DEFINITIVE
REGISTERED FORM IN THE LIMITED CIRCUMSTANCES REFERRED TO IN THE INDENTURE, THIS
GLOBAL NOTE MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A
NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR
ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A
SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY.

                                       16

<PAGE>

                          ASPECT MEDICAL SYSTEMS, INC.
                     2.50% Convertible Senior Note due 2014

No. ______________                                              $_______________

CUSIP No. ____________

     ASPECT MEDICAL SYSTEMS, INC., a corporation duly organized and existing
under the laws of the State of Delaware (herein called the "COMPANY," which term
includes any successor Person under the Indenture referred to on the reverse
hereof), for value received, hereby promises to pay to _________________, or
registered assigns, the principal sum [of ________ United States Dollars (U.S.
$______ )] [IF THIS NOTE IS A GLOBAL NOTE, THEN INSERT - set forth on the
Principal Schedule Attached to this Note] on June 15, 2014, and to pay interest
thereon, from June 20, 2007, or from the most recent Interest Payment Date (as
defined below) to which interest has been paid or duly provided for,
semi-annually in arrears on June 15 and December 15 in each year (each, an
"INTEREST PAYMENT DATE"), commencing December 15, 2007, at the rate of 2.50% per
annum, until the principal hereof is due, and at the same rate on any overdue
principal and, to the extent permitted by law, on any overdue interest. The
interest so payable, and punctually paid or duly provided for, on any Interest
Payment Date shall, as provided in the Indenture, be paid to the Person in whose
name this Note (or one or more Predecessor Notes) is registered at the close of
business on the Regular Record Date for such interest, which shall be the June 1
or December 1 (whether or not a Business Day), as the case may be, next
preceding such Interest Payment Date. Except as otherwise provided in the
Indenture, any such interest not so punctually paid or duly provided for shall
forthwith cease to be payable to the Holder on such Regular Record Date and may
either be paid to the Person in whose name this Note (or one or more Predecessor
Notes) is registered at the close of business on a Special Record Date for the
payment of such Defaulted Interest to be fixed by the Company, notice whereof
shall be given to Holders of Notes not less than 10 calendar days prior to the
Special Record Date, or be paid at any time in any other lawful manner not
inconsistent with the requirements of any automated quotation system or
securities exchange on which the Notes may be listed for trading, and upon such
notice as may be required by such exchange, all as more fully provided in the
Indenture. Payments of principal shall be made upon the surrender of this Note
at the option of the Holder at the Corporate Trust Office of the Trustee, or at
such other office or agency of the Company as may be designated by it for such
purpose in such lawful monies of the United States of America as at the time of
payment shall be legal tender for the payment of public and private debts, or at
such other offices or agencies as the Company may designate, by United States
Dollar check drawn on, or wire transfer to, a United States Dollar account (such
a transfer to be made only to a Holder of an aggregate principal amount of Notes
in excess of U.S. $5.0 million and only if such Holder shall have furnished wire
instructions in writing to the Trustee no later than 15 calendar days prior to
the relevant payment date). Payment of interest on this Note may be made on an
Interest Payment Date by

                                       17

<PAGE>

United States Dollar check mailed to the address of the Person entitled thereto
as such address shall appear in the Register, or, upon written application by
the Holder to the Registrar setting forth wire instructions not later than the
relevant Record Date, by transfer to a United States Dollar account (such a
transfer to be made only to a Holder of an aggregate principal amount of Notes
in excess of U.S. $5.0 million and only if such Holder shall have furnished wire
instructions in writing to the Trustee no later than 15 calendar days prior to
the relevant payment date).

     Except as specifically provided herein and in the Indenture, the Company
shall not be required to make any payment with respect to any tax, assessment or
other governmental charge imposed by any government or any political subdivision
or taxing authority thereof or therein.

     Reference is hereby made to the further provisions of this Note set forth
on the reverse hereof, which further provisions shall for all purposes have the
same effect as if set forth at this place.

     Unless the certificate of authentication hereon has been executed by the
Trustee referred to on the reverse hereof or an Authenticating Agent by the
manual signature of one of their respective authorized signatories, this Note
shall not be entitled to any benefit under the Indenture or be valid or
obligatory for any purpose.

                  [Remainder of page intentionally left blank]

                                       18

<PAGE>

     IN WITNESS WHEREOF, the Company has caused this Note to be duly executed.

                                        ASPECT MEDICAL SYSTEMS, INC.

                                        By:
                                            ------------------------------------
                                        Name:
                                              ----------------------------------
                                        Title:
                                               ---------------------------------

Attest:

By:
    ---------------------------------
Name:
      -------------------------------
Title:
       ------------------------------

TRUSTEE'S CERTIFICATE OF AUTHENTICATION

This is one of the Notes referred to in the within-mentioned Indenture.

Dated:
       --------------------------

U.S. BANK NATIONAL ASSOCIATION,
as Trustee

By:
    ---------------------------------
    Authorized Signatory

                                       19
<PAGE>

                            [FORM OF REVERSE OF NOTE]

                          ASPECT MEDICAL SYSTEMS, INC.
                     2.50% Convertible Senior Note due 2014

     This Note is one of a duly authorized issue of Notes of the Company
designated as its "2.50% CONVERTIBLE SENIOR NOTES DUE 2014" (herein called the
"NOTES") issued and to be issued under an Indenture dated as of June 20, 2007,
between the Company and U.S. Bank National Association, as Trustee (herein
called the "TRUSTEE," which term includes any successor trustee under the
Indenture referred to herein as the "INDENTURE"), to which the Indenture and all
indentures supplemental thereto reference is hereby made for a statement of the
respective rights, limitations of rights, duties and immunities thereunder of
the Company, the Trustee and the Holders of the Notes and of the terms upon
which the Notes are, and are to be, authenticated and delivered. As provided in
the Indenture and subject to certain limitations therein set forth, the Notes
are exchangeable for a like aggregate principal amount of Notes of any
authorized denominations as requested by the Holder surrendering the same upon
surrender of the Note or Notes to be exchanged, at the Corporate Trust Office of
the Trustee. The Trustee upon such surrender by the Holder shall issue the new
Notes in the requested denominations. Additional Notes may be issued in an
unlimited aggregate principal amount, subject to certain conditions specified in
the Indenture.

     No sinking fund is provided for the Notes and the Notes are not subject to
redemption at the option of the Company.

     In any case where the due date for the payment of the principal of or
interest on any Note or the last day on which a Holder of a Note has a right to
convert his Note shall be, at any Place of Payment or Place of Conversion, as
the case may be, a day on which banking institutions at such Place of Payment or
Place of Conversion are authorized or obligated by law or executive order to
close, then payment of principal, interest or delivery for conversion of such
Note need not be made on or by such date at such place but may be made on or by
the next succeeding day at such place which is not a day on which banking
institutions are authorized or obligated by law or executive order to close,
with the same force and effect as if made on the date for such payment or the
date fixed for redemption or repurchase, or by such last day for conversion, and
no interest shall accrue on the amount so payable for the period after such
date.

     The Indenture contains provisions permitting the Company and the Trustee in
certain circumstances, without the consent of the Holders of the Notes, and in
other circumstances, with the consent of the Holders of not less than a majority
in aggregate principal amount of the Notes at the time outstanding, evidenced as
in the Indenture provided, to execute supplemental indentures adding any
provisions to or changing in any manner or eliminating any of the provisions of
the Indenture or of any supplemental indenture or modifying in any

                                       20

<PAGE>

manner the rights of the Holders of the Notes; provided, however, that no such
supplemental indenture shall make any of the changes set forth in Section
8.02(a)-(i) of the Indenture, without the consent of each Holder of an
outstanding Note affected thereby. It is also provided in the Indenture that,
prior to any declaration accelerating the maturity of the Notes, the Holders of
a majority in aggregate principal amount of the Notes at the time outstanding
may on behalf of the Holders of all of the Notes waive any past Default or Event
of Default under the Indenture and its consequences except as provided in the
Indenture. Any such consent or waiver by the Holder of this Note (unless revoked
as provided in the Indenture) shall be conclusive and binding upon such Holder
and upon all future holders and owners of this Note and any Notes which may be
issued in exchange or substitution hereof, irrespective of whether or not any
notation thereof is made upon this Note or such other Notes.

     No reference herein to the Indenture and no provision of this Note or of
the Indenture shall alter or impair the obligation of the Company, which is
absolute and unconditional, to pay the principal of, and accrued and unpaid
interest on, this Note, at the place, at the respective times, at the rate and
in the lawful money herein prescribed.

     Subject to the provisions of the Indenture, upon the occurrence of a
Fundamental Change, the Holder has the right, at such Holder's option, to
require the Company to repurchase all of such Holder's Notes or any portion
thereof (in principal amounts of $1,000 or integral multiples thereof) on the
Fundamental Change Repurchase Date at a price equal to 100% of the principal
amount of the Notes such Holder elects to require the Company to repurchase,
together with accrued and unpaid interest to but excluding the Fundamental
Change Repurchase Date, unless such Fundamental Change Repurchase Date falls
after a Regular Record Date and on or prior to the corresponding Interest
Payment Date, in which case the Company shall instead pay the full amount of
accrued and unpaid interest payable on such Interest Payment Date to the Holder
of record at the close of business on the corresponding Regular Record Date. The
Company or, at the written request of the Company, the Trustee shall mail to all
Holders of record of the Notes a notice of the occurrence of a Fundamental
Change and of the repurchase right arising as a result thereof after the
occurrence of any Fundamental Change, but on or before the 10th calendar day
following such occurrence.

     Subject to the provisions of the Indenture, the Holder hereof has the
right, at its option, on and after March 15, 2014, or earlier upon the
occurrence of certain conditions specified in the Indenture, and prior to the
close of business on the Scheduled Trading Day immediately preceding the
Maturity Date, to convert any Notes or portion thereof which is $1,000 or an
integral multiple thereof, into shares of Common Stock or Reference Property
(or, if the Company has received Stockholder Approval to make the Net Share
Settlement Election and has irrevocably made the Net Share Settlement Election
pursuant to Section 12.02(b) of the Indenture prior to the Conversion Date, cash
and shares of Common Stock

                                       21

<PAGE>

or Reference Property, if any), in each case at the Conversion Rate specified in
the Indenture, as adjusted from time to time as provided in the Indenture, upon
surrender of this Note, together with a Notice of Conversion, a form of which is
contained under Section 2.03 of the Indenture, as provided in the Indenture and
this Note, to the Company at the office or agency of the Company maintained for
that purpose, or at the option of such Holder, the Corporate Trust Office, and,
unless the shares of Common Stock or Reference Property, as the case may be,
issuable on conversion are to be issued in the same name as this Note, duly
endorsed by, or accompanied by instruments of transfer in form satisfactory to
the Company or its agent duly executed by, the Holder or by his duly authorized
attorney. The initial Conversion Rate shall be 52.4294 shares of Common Stock
for each $1,000 principal amount of Notes. No fractional shares of Common Stock
or Reference Property, as the case may be, shall be issued upon any conversion,
but an adjustment in cash shall be paid to the Holder, as provided in the
Indenture, in respect of any fraction of such share which would otherwise be
issuable upon the surrender of any Note or Notes for conversion. No adjustment
shall be made for dividends on any such shares issued upon conversion of such
Notes except as provided in the Indenture.

     Upon due presentment for registration of transfer of this Note at the
office or agency of the Company, a new Note or Notes of authorized denominations
for an equal aggregate principal amount shall be issued to the transferee in
exchange thereof, subject to the limitations provided in the Indenture, without
charge except for any tax, assessments or other governmental charge imposed in
connection therewith.

     The Company, the Trustee, any Authenticating Agent, any Paying Agent, any
Conversion Agent and any Registrar may deem and treat the registered Holder
hereof as the absolute owner of this Note (whether or not this Note shall be
overdue and notwithstanding any notation of ownership or other writing hereon),
for the purpose of receiving payment hereof, or on account hereof, for the
conversion hereof and for all other purposes, and neither the Company nor the
Trustee nor any authenticating agent nor any Paying Agent nor any Conversion
Agent nor any Registrar shall be affected by any notice to the contrary. All
payments made to or upon the order of such registered Holder shall, to the
extent of the sum or sums paid, satisfy and discharge liability for monies
payable on this Note.

     No recourse for the payment of the principal of, or accrued and unpaid
interest on, this Note, or for any claim based hereon or otherwise in respect
hereof, and no recourse under or upon any obligation, covenant or agreement of
the Company in the Indenture or any indenture supplemental thereto or in any
Note, or because of the creation of any indebtedness represented thereby, shall
be had against any incorporator, stockholder, employee, agent, officer, director
or subsidiary, as such, past, present or future, of the Company or of any
successor corporation, either directly or through the Company or any successor
corporation, whether by virtue of any constitution, statute or rule of law or by
the enforcement

                                       22

<PAGE>

of any assessment or penalty or otherwise, all such liability being, by the
acceptance hereof and as part of the consideration for the issue hereof,
expressly waived and released.

     Terms used in this Note and defined in the Indenture are used herein as
therein defined.

     THE INDENTURE AND THIS NOTE SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.

     Customary abbreviations may be used in the name of a Holder or an assignee,
such as TEN COM (=tenants in common), TENANT (=tenants by the entireties), JT
TEN (joint tenants with right of survivorship and not as tenants in common),
CUST (=custodian), and U/G/M/A (=Uniform gift to Minors Act).

                                       23

<PAGE>

                         [INCLUDE IN GLOBAL NOTES ONLY]

                               PRINCIPAL SCHEDULE

                          ASPECT MEDICAL SYSTEMS, INC.
                     2.50% Convertible Senior Note due 2014

No. _____

The initial principal amount of this Global Note is $________. The following
decreases or increases in this Global Note have been made:

<TABLE>
<CAPTION>
   Date of      Amount of decrease in   Amount of increase in    Principal Amount of this          Signature of
 decrease or       Principal Amount      Principal Amount of    Global Note following such     authorized signatory
   increase      of this Global Note       this Global Note        decrease or increase      of Trustee or Custodian
-------------   ---------------------   ---------------------   --------------------------   -----------------------
<S>             <C>                     <C>                     <C>                          <C>

-------------   ---------------------   ---------------------   --------------------------   -----------------------

-------------   ---------------------   ---------------------   --------------------------   -----------------------

-------------   ---------------------   ---------------------   --------------------------   -----------------------

-------------   ---------------------   ---------------------   --------------------------   -----------------------

-------------   ---------------------   ---------------------   --------------------------   -----------------------

-------------   ---------------------   ---------------------   --------------------------   -----------------------

-------------   ---------------------   ---------------------   --------------------------   -----------------------

-------------   ---------------------   ---------------------   --------------------------   -----------------------

-------------   ---------------------   ---------------------   --------------------------   -----------------------

-------------   ---------------------   ---------------------   --------------------------   -----------------------

-------------   ---------------------   ---------------------   --------------------------   -----------------------

-------------   ---------------------   ---------------------   --------------------------   -----------------------

-------------   ---------------------   ---------------------   --------------------------   -----------------------

-------------   ---------------------   ---------------------   --------------------------   -----------------------

-------------   ---------------------   ---------------------   --------------------------   -----------------------

-------------   ---------------------   ---------------------   --------------------------   -----------------------

-------------   ---------------------   ---------------------   --------------------------   -----------------------

-------------   ---------------------   ---------------------   --------------------------   -----------------------

-------------   ---------------------   ---------------------   --------------------------   -----------------------

-------------   ---------------------   ---------------------   --------------------------   -----------------------

-------------   ---------------------   ---------------------   --------------------------   -----------------------

-------------   ---------------------   ---------------------   --------------------------   -----------------------

-------------   ---------------------   ---------------------   --------------------------   -----------------------

-------------   ---------------------   ---------------------   --------------------------   -----------------------
</TABLE>

                                       24

<PAGE>

                  FORM OF FUNDAMENTAL CHANGE REPURCHASE NOTICE

To: Aspect Medical Systems, Inc.

     The undersigned registered owner of this Note hereby acknowledges receipt
of a notice from Aspect Medical Systems, Inc. (the "COMPANY") as to the
occurrence of a Fundamental Change with respect to the Company and hereby
directs the Company to pay, or cause the Trustee to pay, ______________ an
amount in cash equal to 100% of the entire principal amount, or the portion
thereof (which is $1,000 principal amount or an integral multiple thereof) below
designated, to be repurchased plus interest accrued to, but excluding, the
Fundamental Change Repurchase Date, except as provided in the Indenture.

Dated:
       -----------------------

-------------------------------------

-------------------------------------
Signature(s)

Signature(s) must be guaranteed by an
Eligible Guarantor Institution with
membership in an approved signature
guarantee program pursuant to Rule
17Ad-15 under the Securities Exchange
Act of 1934.

-------------------------------------
Signature Guaranteed

Principal amount to be repurchased
(at least U.S. $1,000 or an integral
multiple of $1,000 in excess
thereof):
          -------------------

Remaining principal amount following
such repurchase (not less than U.S.
$1,000):
         --------------------

                                        By:
                                            ------------------------------------
                                            Authorized Signatory

                                       25
<PAGE>

     Section 2.03. Form of Notice of Conversion.

                              NOTICE OF CONVERSION

     The undersigned Holder of this Note hereby irrevocably exercises the option
to convert this Note, or any portion of the principal amount hereof (which is
U.S. $1,000 or an integral multiple of U.S. $1,000 in excess thereof, provided
that the unconverted portion of such principal amount is U.S. $1,000 or any
integral multiple of U.S. $1,000 in excess thereof) below designated, into
shares of Common Stock or Reference Property, as applicable (or, if the Company
has obtained Stockholder Approval to make the Net Share Settlement Election and
has irrevocably made the Net Share Settlement Election pursuant to Section
12.02(b) of the Indenture prior to the Conversion Date in respect of this
notice, cash and shares of Common Stock or Reference Property, if any) in
accordance with the terms of the Indenture referred to in this Note, and directs
that such shares or such combination of cash and shares, if any, together with a
check in payment for any fractional share and any Notes representing any
unconverted principal amount hereof, be delivered to and be registered in the
name of the undersigned unless a different name has been indicated below. If
shares of Common Stock, Reference Property or Notes are to be registered in the
name of a Person other than the undersigned, (a) the undersigned shall pay all
transfer taxes payable with respect thereto and (b) signature(s) must be
guaranteed by an Eligible Guarantor Institution with membership in an approved
signature guarantee program pursuant to Rule 17Ad-15 under the Securities
Exchange Act of 1934. Any amount required to be paid by the undersigned on
account of interest accompanies this Note.

Dated:
       ------------------------------   ----------------------------------------
                                        Signature(s)

If shares or Notes are to be
registered in the name of a Person
other than the Holder, please print
such Person's name and address:

-------------------------------------
(Name)

-------------------------------------

-------------------------------------
(Address)

-------------------------------------
Social Security or other
Identification Number, if any

                                       26

<PAGE>

-------------------------------------
[Signature Guaranteed]

     If only a portion of the Notes is to be converted, please indicate:

1.   Principal amount to be converted: U.S. $ ___________

2.   Principal amount and denomination of Notes representing unconverted
     principal amount to be issued:

     Amount: U.S. $___________ Denominations: U.S. $____________

(U.S. $1,000 or any integral multiple of U.S. $1,000 in excess thereof, provided
that the unconverted portion of such principal amount is U.S. $1,000 or any
integral multiple of U.S. $1,000 in excess thereof)

     Section 2.04. Form of Assignment.

                                   ASSIGNMENT

     For value received, ________________ hereby sell(s), assign(s) and
transfer(s) unto ________________ (Please insert Social Security or other
identifying number of assignee) the within Note, and hereby irrevocably
constitutes and appoints ____________________ as attorney to transfer the said
Note on the books of the Company, with full power of substitution in the
premises.

Dated:                                  Signature(s)
       ------------------------------                ---------------------------

     Signature(s) must be guaranteed by an Eligible Guarantor Institution with
membership in an approved signature guarantee program pursuant to Rule 17Ad-15
under the Securities Exchange Act of 1934.

                                        ----------------------------------------
                                        Signature Guaranteed

     Section 2.05. Mutilated, Destroyed, Lost or Stolen Notes. In case any Note
shall become mutilated or be destroyed, lost or stolen, the Company in its
discretion may execute, and upon its written request the Trustee or an
authenticating agent appointed by the Trustee shall authenticate and deliver, a
new Note, bearing a number not contemporaneously outstanding, in exchange and
substitution for the mutilated Note, or in lieu of and in substitution for the
Note so destroyed, lost or stolen. In every case the applicant for a substituted
Note shall furnish to the Company, to the Trustee and, if applicable, to such
authenticating agent such security or indemnity as may be required by them to
save each of them harmless from any loss, liability, cost or expense caused by
or connected with

                                       27

<PAGE>

such substitution, and, in every case of destruction, loss or theft, the
applicant shall also (a) furnish to the Company, to the Trustee and, if
applicable, to such authenticating agent evidence to their satisfaction of the
destruction, loss or theft of such Note and of the ownership thereof and (b)
surrender any mutilated Note to the Trustee.

     The Trustee or such authenticating agent may authenticate any such
substituted Note and deliver the same upon the receipt of such security or
indemnity as the Trustee, the Company and, if applicable, such authenticating
agent may require. Upon the issuance of any substituted Note, the Company or the
Trustee may require the payment by the holder of a sum sufficient to cover any
tax, assessment or other governmental charge that may be imposed in relation
thereto and any other expenses connected therewith. In case any Note which has
matured or is about to mature or has been tendered for repurchase upon a
Fundamental Change or is about to be submitted for conversion shall become
mutilated or be destroyed, lost or stolen, the Company may, in its sole
discretion, instead of issuing a substitute Note, pay or authorize the payment
or the conversion of the same (without surrender thereof except in the case of a
mutilated Note), as the case may be, if the applicant for such payment or
conversion shall furnish to the Company, to the Trustee and, if applicable, to
such authenticating agent such security or indemnity as may be required by them
to save each of them harmless for any loss, liability, cost or expense caused by
or connected with such substitution, and, in every case of destruction, loss or
theft, evidence satisfactory to the Company, the Trustee and, if applicable, any
Paying Agent evidence of their satisfaction of the destruction, loss or theft of
such Note and of the ownership thereof.

     Every substitute Note issued pursuant to the provisions of this Section
2.05 by virtue of the fact that any Note is destroyed, lost or stolen shall
constitute an additional contractual obligation of the Company, whether or not
the destroyed, lost or stolen Note shall be found at any time, and shall be
entitled to all the benefits of (but shall be subject to all the limitations set
forth in) this Indenture equally and proportionately with any and all other
Notes duly issued hereunder. To the extent permitted by law, all Notes shall be
held and owned upon the express condition that the foregoing provisions are
exclusive with respect to the replacement or payment or conversion or repurchase
of mutilated, destroyed, lost or stolen Notes and shall preclude any and all
other rights or remedies notwithstanding any law or statute existing or
hereafter enacted to the contrary with respect to the replacement or payment or
conversion of negotiable instruments or other securities without their
surrender.

     Section 2.06. Execution, Authentication and Delivery of Notes.

     The Notes shall be signed in the name and on behalf of the Company by the
manual or facsimile signature of its Chairman or Vice-Chairman of the Board of
Directors, Chief Executive Officer, President, any of its Executive or Senior
Vice Presidents, or any of its Vice Presidents (whether or not designated by a

                                       28

<PAGE>

number or numbers or word or words added before or after the title "Vice
President"). Notes shall be dated the date of their authentication.

     At any time and from time to time after the execution and delivery of this
Indenture, the Company may deliver Notes executed by the Company to the Trustee
for authentication, together with a Company Order for the authentication and
delivery of such Notes, and the Trustee in accordance with such Company Order
shall authenticate and deliver such Notes, without any further action by the
Company hereunder.

     Only such Notes as shall bear thereon a certificate of authentication
substantially in the form set forth on the form of Note set forth in Section
2.02, manually executed by the Trustee (or an authenticating agent appointed by
the Trustee as provided by Section 15.10), shall be entitled to the benefits of
this Indenture or be valid or obligatory for any purpose. Such certificate by
the Trustee (or such an authenticating agent) upon any Note executed by the
Company shall be conclusive evidence that the Note so authenticated has been
duly authenticated and delivered hereunder and that the holder is entitled to
the benefits of this Indenture.

     In case any officer of the Company who shall have signed any of the Notes
shall cease to be such officer before the Notes so signed shall have been
authenticated and delivered by the Trustee, or disposed of by the Company, such
Notes nevertheless may be authenticated and delivered or disposed of as though
the Person who signed such Notes had not ceased to be such officer of the
Company, and any Note may be signed on behalf of the Company by such Persons as,
at the actual date of the execution of such Note, shall be the proper officers
of the Company, although at the date of the execution of this Indenture any such
person was not such an officer.

     Section 2.07. Exchange and Registration of Transfer of Notes; Restrictions
on Transfer; Depositary.

     (a) The Company shall cause to be kept at the Corporate Trust Office a
register (the register maintained in such office and in any other office or
agency of the Company designated pursuant to Section 4.02 being herein sometimes
collectively referred to as the "NOTE REGISTER") in which, subject to such
reasonable regulations as it may prescribe, the Company shall provide for the
registration of Notes and of transfers of Notes. Such register shall be in
written form or in any form capable of being converted into written form within
a reasonable period of time. The Trustee is hereby appointed "Note Registrar"
for the purpose of registering Notes and transfers of Notes as herein provided.
The Company may appoint one or more co-registrars in accordance with Section
4.02.

     Upon surrender for registration of transfer of any Note to the Note
Registrar or any co-registrar, and satisfaction of the requirements for such
transfer set forth in this Section 2.07, the Company shall execute, and the
Trustee shall

                                       29

<PAGE>

authenticate and deliver, in the name of the designated transferee or
transferees, one or more new Notes of any authorized denominations and of a like
aggregate principal amount and bearing such restrictive legends as may be
required by this Indenture.

     Notes may be exchanged for other Notes of any authorized denominations and
of a like aggregate principal amount, upon surrender of the Notes to be
exchanged at any such office or agency maintained by the Company pursuant to
Section 4.02. Whenever any Notes are so surrendered for exchange, the Company
shall execute, and the Trustee shall authenticate and deliver, the Notes which
the Holder making the exchange is entitled to receive, bearing registration
numbers not contemporaneously outstanding.

     All Notes presented or surrendered for registration of transfer or for
exchange, repurchase or conversion shall (if so required by the Company, the
Trustee, the Note Registrar or any co-registrar) be duly endorsed, or be
accompanied by a written instrument or instruments of transfer in form
satisfactory to the Company and duly executed, by the Holder thereof or his
attorney-in-fact duly authorized in writing.

     No service charge shall be charged to the Holder for any exchange or
registration of transfer of Notes, but the Company or the Trustee may require
payment of a sum sufficient to cover any tax, assessments or other governmental
charges that may be imposed in connection therewith.

     None of the Company, the Trustee, the Note Registrar or any co-registrar
shall be required to exchange or register a transfer of any Notes, or a portion
of any Note, surrendered upon a Fundamental Change (and not withdrawn) except in
accordance with Article 14 hereof.

     All Notes issued upon any registration of transfer or exchange of Notes in
accordance with this Indenture shall be the valid obligations of the Company,
evidencing the same debt, and entitled to the same benefits under this Indenture
as the Notes surrendered upon such registration of transfer or exchange.

     (b) Every Note that bears or is required under this Section 2.07(b) to bear
the legend set forth in this Section 2.07(b) (together with any Common Stock
issued upon its conversion and required to bear the legend set forth in Section
2.07(c), collectively, the "RESTRICTED SECURITIES") shall be subject to the
restrictions on transfer set forth in this Section 2.07(b) (including the legend
set forth below), unless such restrictions on transfer shall be waived by
written consent of the Company, and the holder of each such Restricted Security,
by such holder's acceptance thereof, agrees to be bound by all such restrictions
on transfer. As used in this Section 2.07(b) and Section 2.07(c), the term
"TRANSFER" encompasses any sale, pledge, transfer or other disposition
whatsoever of any Restricted Security.

                                       30
<PAGE>

     Until the date (the "RESALE RESTRICTION TERMINATION DATE") that is two
years after the last date of original issuance of the Notes, or such other
period of time as permitted by Rule 144(k) under the Securities Act or any
successor provision thereto, any certificate evidencing such Note (and all
securities issued in exchange therefor or substitution thereof, other than
Common Stock, if any, issued upon conversion thereof which shall bear the legend
set forth in Section 2.07(c), if applicable) shall bear a legend in
substantially the following form (unless such Notes have been transferred
pursuant to a registration statement that has become or been declared effective
under the Securities Act and that continues to be effective at the time of such
transfer, pursuant to the exemption from registration provided by Rule 144 or
any similar provision then in force under the Securities Act, or unless
otherwise agreed by the Company in writing, with notice thereof to the Trustee):

THIS NOTE AND ANY COMMON STOCK ISSUABLE UPON THE CONVERSION OF THIS NOTE HAVE
NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE
"SECURITIES ACT"), AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED IN THE ABSENCE
OF SUCH REGISTRATION OR AN APPLICABLE EXEMPTION THEREFROM. EACH PURCHASER OF
THIS NOTE IS HEREBY NOTIFIED THAT THE SELLER OF THIS NOTE MAY BE RELYING ON THE
EXEMPTION FROM THE PROVISIONS OF SECTION 5 OF THE SECURITIES ACT PROVIDED BY
RULE 144A THEREUNDER.

THIS NOTE AND ANY COMMON STOCK ISSUABLE UPON THE CONVERSION OF THIS NOTE MAY NOT
BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT (A) (1) TO A PERSON
WHO THE TRANSFEROR REASONABLY BELIEVES IS A QUALIFIED INSTITUTIONAL BUYER WITHIN
THE MEANING OF RULE 144A UNDER THE SECURITIES ACT ACQUIRING FOR ITS OWN ACCOUNT
OR FOR THE ACCOUNT OF A QUALIFIED INSTITUTIONAL BUYER IN A TRANSACTION MEETING
THE REQUIREMENTS OF RULE 144A, (2) PURSUANT TO AN EXEMPTION FROM REGISTRATION
UNDER THE SECURITIES ACT PROVIDED BY RULE 144 THEREUNDER (IF AVAILABLE), OR (3)
PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, AND
(B) IN ACCORDANCE WITH ALL APPLICABLE SECURITIES LAWS OF THE STATES OF THE
UNITED STATES AND OTHER JURISDICTIONS.

     THIS NOTE, ANY SHARES OF COMMON STOCK ISSUABLE UPON ITS CONVERSION AND ANY
RELATED DOCUMENTATION MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME TO MODIFY
THE RESTRICTIONS ON RESALES AND OTHER TRANSFERS OF THIS NOTE AND ANY SUCH SHARES
TO REFLECT ANY CHANGE IN APPLICABLE LAW OR REGULATION (OR THE INTERPRETATION
THEREOF) OR IN PRACTICES RELATING TO THE RESALE OR TRANSFER OF RESTRICTED
SECURITIES GENERALLY. THE HOLDER OF THIS NOTE

                                       31

<PAGE>

AND SUCH SHARES SHALL BE DEEMED BY THE ACCEPTANCE OF THIS NOTE AND ANY SUCH
SHARES TO HAVE AGREED TO ANY SUCH AMENDMENT OR SUPPLEMENT.

     Any Note (or security issued in exchange or substitution therefor) as to
which such restrictions on transfer shall have expired in accordance with their
terms may, upon surrender of such Note for exchange to the Note Registrar in
accordance with the provisions of this Section 2.07, be exchanged for a new Note
or Notes, of like tenor and aggregate principal amount, which shall not bear the
restrictive legend required by this Section 2.07(b). The Company shall notify
the Trustee upon the occurrence of the Resale Restriction Termination Date and
promptly after a Registration Statement with respect to the Notes or the Common
Stock has been declared effective under the Securities Act.

     (c) Until the Resale Restriction Termination Date, any stock certificate
representing Common Stock issued upon conversion of a Note shall bear a legend
in substantially the following form (unless the Note or such Common Stock has
been transferred pursuant to a registration statement that has become or been
declared effective under the Securities Act and that continues to be effective
at the time of such transfer or pursuant to the exemption from registration
provided by Rule 144 under the Securities Act or any similar provision then in
force under the Securities Act or unless otherwise agreed by the Company with
written notice thereof to the Trustee and any transfer agent for the Common
Stock):

     THE COMMON STOCK EVIDENCED HEREBY HAS NOT BEEN REGISTERED UNDER THE UNITED
STATES SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND MAY NOT BE
OFFERED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN
APPLICABLE EXEMPTION THEREFROM. EACH PURCHASER OF THIS COMMON STOCK IS HEREBY
NOTIFIED THAT THE SELLER OF THIS COMMON STOCK MAY BE RELYING ON THE EXEMPTION
FROM THE PROVISIONS OF SECTION 5 OF THE SECURITIES ACT PROVIDED BY RULE 144A
THEREUNDER.

     THIS COMMON STOCK MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE
TRANSFERRED EXCEPT (A) (1) TO A PERSON WHO THE TRANSFEROR REASONABLY BELIEVES IS
A QUALIFIED INSTITUTIONAL BUYER WITHIN THE MEANING OF RULE 144A UNDER THE
SECURITIES ACT ACQUIRING FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF A QUALIFIED
INSTITUTIONAL BUYER IN A TRANSACTION MEETING THE REQUIREMENTS OF RULE 144A, (2)
PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT PROVIDED BY
RULE 144 THEREUNDER (IF AVAILABLE), OR (3) PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT WHICH HAS BEEN DECLARED EFFECTIVE UNDER THE SECURITIES ACT, AND (B) IN
ACCORDANCE WITH ALL APPLICABLE

                                       32

<PAGE>

SECURITIES LAWS OF THE STATES OF THE UNITED STATES AND OTHER JURISDICTIONS.

     THIS COMMON STOCK AND ANY RELATED DOCUMENTATION MAY BE AMENDED OR
SUPPLEMENTED FROM TIME TO TIME TO MODIFY THE RESTRICTIONS ON RESALES AND OTHER
TRANSFERS OF THIS COMMON STOCK TO REFLECT ANY CHANGE IN APPLICABLE LAW OR
REGULATION (OR THE INTERPRETATION THEREOF) OR IN PRACTICES RELATING TO THE
RESALE OR TRANSFER OR RESTRICTED SECURITIES GENERALLY. THE HOLDER OF THIS COMMON
STOCK SHALL BE DEEMED BY THE ACCEPTANCE OF THIS COMMON STOCK TO HAVE AGREED TO
ANY SUCH AMENDMENT OR SUPPLEMENT.

     Any such Common Stock as to which such restrictions on transfer shall have
expired in accordance with their terms may, upon surrender of the certificates
representing such shares of Common Stock for exchange in accordance with the
procedures of the transfer agent for the Common Stock, be exchanged for a new
certificate or certificates for a like aggregate number of shares of Common
Stock, which shall not bear the restrictive legend required by this Section
2.07(c).

     (d) Any Note or Common Stock issued upon conversion of a Note that, prior
to the expiration of the holding period applicable to sales thereof under Rule
144(k) under the Securities Act (or any successor provision), is purchased or
owned by the Company or any Affiliate thereof may not be resold by the Company
or such Affiliate unless registered under the Securities Act in a transaction
that results in such Notes or Common Stock, as the case may be, no longer being
"Restricted Securities" (as defined under Rule 144).

     (e) Notwithstanding any provision of Section 2.06 to the contrary, in the
event Rule 144(k) as promulgated under the Securities Act (or any successor
rule) is amended to change the two-year period under Rule 144(k) (or the
corresponding period under any successor rule), from and after receipt by the
Trustee of the Officers' Certificate and Opinion of Counsel provided for in this
Section 2.07(e), (i) each reference in Section 2.07(c) to "two years" and in the
restrictive legend set forth in such paragraph to "TWO YEARS" shall be deemed
for all purposes hereof to be references to such changed period, (ii) each
reference in Section 2.07(c) to "two years" and in the restrictive legend set
forth in such paragraph to "TWO YEARS" shall be deemed for all purposes hereof
to be references to such changed period and (iii) all corresponding references
in the Notes (including the definition of Resale Restriction Termination Date)
and the restrictive legends thereon shall be deemed for all purposes hereof to
be references to such changed period, provided that such changes shall not
become effective if they are otherwise prohibited by, or would otherwise cause a
violation of, the then-applicable federal securities laws. The provisions of
this Section 2.07(e) will not be effective until such time as the Opinion of
Counsel and

                                       33

<PAGE>

Officers' Certificate have been received by the Trustee hereunder. This Section
2.07(e) shall apply to successive amendments to Rule 144(k) (or any successor
rule) changing the holding period thereunder.

                                    ARTICLE 3
                                    THE NOTES

     Section 3.01. Title and Terms.

     The Notes shall be known and designated as the "2.50% Convertible Senior
Notes due 2014" of the Company. Their Maturity Date shall be June 15, 2014, and
they shall bear interest on their principal amount from June 20, 2007, payable
semi-annually in arrears on June 15 and December 15 in each year, commencing
December 15, 2007, at the rate of 2.50% per annum until the principal thereof is
due; provided, however, that payments shall only be made on a Business Day as
provided in Section 15.06. The Company may, without the consent of the Holders
of the Notes, issue Additional Notes from time to time in the future with the
same terms and the same CUSIP number as the Initial Notes in an unlimited
principal amount; provided that such Additional Notes must be part of the same
issue as and fungible with the Initial Notes for United States federal income
tax purposes.

     The Company shall pay interest on overdue principal at the rate borne by
the Notes, and it shall pay interest on overdue installments of interest at the
same rate to the extent lawful.

     The principal of and interest on the Notes shall be payable as provided in
the form of Notes set forth in Section 2.02. The Fundamental Change Repurchase
Price shall be payable at such place as is identified in the Fundamental Change
Repurchase Right Notice given pursuant to Section 14.01(b) (such city in which
the identified Paying Agent is located being herein called a "PLACE OF
PAYMENT").

     The Notes shall be senior unsecured obligations of the Company and shall
rank pari passu with all of the Company's other senior unsecured obligations.

     The Notes may not be redeemed at the option of the Company prior to
Maturity.

     The Notes shall be convertible as provided in Article 12 (any city in which
any Conversion Agent is located being herein called a "PLACE OF CONVERSION").

     The Notes shall be subject to repurchase by the Company at the option of
the Holders as provided in Article 14.

                                       34

<PAGE>

     Section 3.02. Denominations. The Notes shall be issuable only in registered
form, without coupons, in denominations of U.S. $1,000 and integral multiples of
U.S. $1,000 in excess thereof.

     Section 3.03. Global Notes; Non-Global Notes; Book-entry Provisions.

     (a) Global Notes

          (i) Each Global Note authenticated under this Indenture shall be
     registered in the name of the Depositary designated by the Company for such
     Global Note or a nominee thereof and delivered to such Depositary or a
     nominee thereof or custodian therefor, and each such Global Note shall
     constitute a single Note for all purposes of this Indenture. The Company
     hereby appoints DTC as the Depositary.

          (ii) Except for exchanges of Global Notes for definitive, non-Global
     Notes at the sole discretion of the Company, no Global Note may be
     exchanged in whole or in part for Notes registered, and no transfer of a
     Global Note in whole or in part may be registered, in the name of any
     Person other than the Depositary for such Global Note or a nominee thereof
     unless (A) such Depositary (i) has notified the Company that it is
     unwilling or unable to continue as Depositary for such Global Note or (ii)
     has ceased to be a clearing agency registered as such under the Exchange
     Act or announces an intention permanently to cease business or does in fact
     do so or (B) there shall have occurred and be continuing an Event of
     Default with respect to such Global Note. In such event, if a successor
     Depositary for such Global Note is not appointed by the Company within 90
     calendar days after the Company receives such notice or becomes aware of
     such ineligibility, the Company shall execute, and the Trustee, upon
     receipt of an Officers' Certificate directing the authentication and
     delivery of non-Global Notes, shall authenticate and deliver, non-Global
     Notes, in any authorized denominations in an aggregate principal amount
     equal to the principal amount of such Global Note in exchange for such
     Global Note.

          (iii) If any Global Note is to be exchanged for other Notes or
     canceled in whole, it shall be surrendered by or on behalf of the
     Depositary or its nominee to the Trustee, as Registrar, for exchange or
     cancellation, as provided in this Article 3. If any Global Note is to be
     exchanged for other Notes or canceled in part, or if another Note is to be
     exchanged in whole or in part for a beneficial interest in any Global Note,
     in each case, as provided in Article 2 of this Indenture, then either (A)
     such Global Note shall be so surrendered for exchange or cancellation, as
     provided in this Article 3, or (B) the principal amount thereof shall be
     reduced or increased by an amount equal to the portion thereof to be so
     exchanged or canceled, or equal to the principal amount of such other Note
     to be so exchanged for a beneficial interest therein, as the case may

                                       35

<PAGE>

     be, by means of an appropriate adjustment made on the records of the
     Trustee, as Registrar, whereupon the Trustee, in accordance with the
     Applicable Procedures, shall instruct the Depositary or its authorized
     representative to make a corresponding adjustment to its records. Upon any
     such surrender or adjustment of a Global Note, the Trustee shall, subject
     to this Article 3, authenticate and deliver any Notes issuable in exchange
     for such Global Note (or any portion thereof) to or upon the order of, and
     registered in such names as may be directed by, the Depositary or its
     authorized representative. The Trustee shall be entitled to receive from
     the Depositary the names, addresses and tax identification numbers of the
     Persons in whose name the Notes are to be registered prior to such
     authentication and delivery. Upon the request of the Trustee in connection
     with the occurrence of any of the events specified in the preceding
     paragraph, the Company shall promptly make available to the Trustee a
     reasonable supply of Notes that are not in the form of Global Notes. The
     Trustee shall be entitled to rely upon any order, direction or request of
     the Depositary or its authorized representative which is given or made
     pursuant to this Article 3 if such order, direction or request is given or
     made in accordance with the Applicable Procedures (to the extent such
     procedures are applicable to such direction or request).

          (iv) Every Note authenticated and delivered upon registration of
     transfer of, or in exchange for or in lieu of, a Global Note or any portion
     thereof, whether pursuant to this Article 3 or otherwise, shall be
     authenticated and delivered in the form of, and shall be, a registered
     Global Note, unless such Note is registered in the name of a Person other
     than the Depositary for such Global Note or a nominee thereof, in which
     case such Note shall be authenticated and delivered in accordance with
     clause (b) of this Section 3.03.

          (v) The Depositary or its nominee, as registered owner of a Global
     Note, shall be the Holder of such Global Note for all purposes under this
     Indenture and the Notes, and owners of beneficial interests in a Global
     Note shall hold such interests pursuant to the Applicable Procedures.
     Accordingly, any such owner's beneficial interest in a Global Note shall be
     shown only on, and the transfer of such interest shall be effected only
     through, records maintained by the Depositary or its nominee or its Agent
     Members and such owners of beneficial interests in a Global Note shall not
     be considered the owners or holders thereof.

     (b) Non-Global Notes. Notes issued upon the events described in Section
3.03(a)(ii) shall be in definitive, fully registered form, without interest
coupons.

     Section 3.04. Payment of Liquidated Damages. If required by the
Registration Rights Agreement, the Company shall pay Liquidated Damages in the
manner and to the Persons set forth in the Registration Rights Agreement.

                                       36

<PAGE>

Whenever in this Indenture there is mentioned, in any context, the payment of
the principal of, or interest on, or in respect of, any Note, such mention shall
be deemed to include mention of the payment of "Liquidated Damages" provided for
in the Registration Rights Agreement to the extent that, in such context,
Liquidated Damages are, were or would be payable in respect thereof pursuant to
the provisions of the Registration Rights Agreement and express mention of the
payment of Liquidated Damages (if applicable) in any provisions hereof shall not
be construed as excluding Liquidated Damages in those provisions hereof where
such express mention is not made.

     Section 3.05. Cancellation of Notes Paid, Etc.. All Notes surrendered for
the purpose of payment, repurchase, conversion, exchange or registration of
transfer, shall, if surrendered to the Company or any Paying Agent or any Note
Registrar, be surrendered to the Trustee and promptly canceled by it, or, if
surrendered to the Trustee, shall be promptly canceled by it, and no Notes shall
be issued in lieu thereof except as expressly permitted by any of the provisions
of this Indenture. The Trustee shall dispose of canceled Notes in accordance
with its customary procedures and, after such disposal, shall deliver a
certificate of such disposal to the Company, at the Company's written request.
If the Company shall acquire any of the Notes, such acquisition shall not
operate as satisfaction of the debt represented by such Notes unless and until
the same are delivered to the Trustee for cancellation.

     Section 3.06. CUSIP Numbers. The Company in issuing the Notes may use
"CUSIP" numbers (if then generally in use), and, if so, the Trustee shall use
"CUSIP" numbers in all notices to Holders as a convenience to holders of the
Notes; provided, that any such notice may state that no representation is made
as to the correctness of such numbers either as printed on the Notes or on such
notice and that reliance may be placed only on the other identification numbers
printed on the Notes. The Company will promptly notify the Trustee in writing of
any change in the "CUSIP" numbers.

     Section 3.07. Persons Deemed Owners. Prior to due presentment of a Note
for registration of transfer, the Company, the Trustee, any Paying Agent and any
agent of the Company, the Trustee or any Paying Agent may treat the Person in
whose name such Note is registered as the owner of such Note for the purpose of
receiving payment of principal of and interest on such Note and for all other
purposes whatsoever, whether or not such Note be overdue, and neither the
Company, the Trustee, any Paying Agent nor any agent of the Company, the Trustee
or any Paying Agent shall be affected by notice to the contrary.

     Section 3.08. Special Record Date. Any interest on any Note that is
payable but not punctually paid or duly provided for on any Interest Payment
Date ("DEFAULTED INTEREST") shall forthwith cease to be payable to the Holder on
the relevant Regular Record Date by virtue of his, her or its having been such a
Holder, and such Defaulted Interest may be paid by the Company, at its election
in each case, as provided in clause (a) or (b) below:

                                       37

<PAGE>

     (a) The Company may elect to make payment of any Defaulted Interest to
Holders in whose names the Notes are registered at the close of business on a
special record date for the payment of such Defaulted Interest (a "SPECIAL
RECORD DATE"), which shall be fixed in the following manner. The Company shall
notify the Trustee in writing of the Defaulted Interest proposed to be paid on
each Note and the date of the proposed payment, and at the same time the Company
shall deposit with the Trustee an amount of money equal to the aggregate amount
proposed to be paid in respect of such Defaulted Interest or shall make
arrangements satisfactory to the Trustee for such deposit prior to the date of
the proposed payment, such money when deposited to be held in trust for the
benefit of the Holders entitled to such Defaulted Interest as in this clause
provided. Thereupon the Trustee shall fix a Special Record Date for the payment
of such Defaulted Interest which shall be not more than 15 calendar days and not
less than 10 calendar days prior to the date of the proposed payment and not
less than 10 calendar days after the receipt by the Trustee of the notice of the
proposed payment. The Trustee shall promptly notify the Company of such Special
Record Date and, in the name and at the expense of the Company, shall cause
notice of the proposed payment of such Defaulted Interest and the Special Record
Date therefor to be mailed, first-class postage prepaid, to the Holders of the
Notes at their addresses as they appear in the Note Register, not less than 10
calendar days prior to such Special Record Date. Notice of the proposed payment
of such Defaulted Interest and the Special Record Date therefor having been
mailed as aforesaid, such Defaulted Interest shall be paid to the Persons in
whose names the Notes (or their predecessor Notes) are registered at the close
of business on such Special Record Date and shall no longer be payable pursuant
to the following clause (b).

     (b) The Company may make payment of any Defaulted Interest on the Notes in
any other lawful manner not inconsistent with the requirements of any automated
quotation system or securities exchange on which the Notes may be listed, and
upon such notice as may be required by such exchange, if, after notice given by
the Company to the Trustee of the proposed payment pursuant to this clause, such
manner of payment shall be deemed practicable by the Trustee.

                                    ARTICLE 4
                       PARTICULAR COVENANTS OF THE COMPANY

     Section 4.01. Payment of Principal, Interest and Liquidated Damages. The
Company covenants and agrees that it will cause to be paid the principal of, and
accrued and unpaid interest (including Liquidated Damages, if any) on, each of
the Notes at the places, at the respective times and in the manner provided
herein and in the Notes. Each installment of accrued and unpaid interest
(including Liquidated Damages, if any) on the Notes due on any Interest Payment
Date may be paid by mailing checks for the amount payable to or upon the written
order of the Holders entitled thereto as they shall appear on the registry books
of

                                       38

<PAGE>

the Company, provided that, with respect to any Holder with an aggregate
principal amount in excess of $5,000,000, at the application of such holder in
writing to the Note Registrar not later than the relevant record date, accrued
and unpaid interest (including Liquidated Damages, if any) on such holder's
Notes shall be paid by wire transfer in immediately available funds to such
holder's account in the United States supplied by such holder from time to time
to the Trustee and Paying Agent (if different from Trustee); provided further
that payment of accrued and unpaid interest (including Liquidated Damages, if
any) made to the Depositary shall be paid by wire transfer in immediately
available funds in accordance with such wire transfer instructions and other
procedures provided by the Depositary from time to time.

     Section 4.02. Maintenance of Office or Agency. The Company will maintain in
Boston, Massachusetts an office or agency where the Notes may be surrendered for
registration of transfer or exchange or for presentation for payment or
repurchase and where notices and demands to or upon the Company in respect of
the Notes and this Indenture may be served. The Company will give prompt written
notice to the Trustee of the location, and any change in the location, of such
office or agency not designated or appointed by the Trustee. If at any time the
Company shall fail to maintain any such required office or agency or shall fail
to furnish the Trustee with the address thereof, such presentations, surrenders,
notices and demands may be made or served at the Corporate Trust Office or the
office or agency of the Trustee in Boston, Massachusetts.

     The Company may also from time to time designate one or more other offices
or agencies where the Notes may be presented or surrendered for any or all such
purposes and may from time to time rescind such designations; provided that no
such designation or rescission shall in any manner relieve the Company of its
obligation to maintain an office or agency in Boston, Massachusetts for such
purposes. The Company will give prompt written notice to the Trustee of any such
designation or rescission and of any change in the location of any such other
office or agency. The term Paying Agent include any such additional or other
offices or agencies, as applicable.

     The Company hereby initially designates the Trustee as the Paying Agent,
Conversion Agent, Note Registrar and Custodian and the Corporate Trust Office
and the office or agency of the Trustee in Boston, Massachusetts shall be
considered as one such office or agency of the Company for each of the aforesaid
purposes.

     So long as the Trustee is the Note Registrar, the Trustee agrees to mail,
or cause to be mailed, the notices set forth in Section 6.10(a) and the third
paragraph of Section 6.11.

     Section 4.03. Appointments to Fill Vacancies in Trustee's Office. The
Company, whenever necessary to avoid or fill a vacancy in the office of Trustee,

                                       39

<PAGE>

will appoint, in the manner provided in Section 6.10, a Trustee, so that there
shall at all times be a Trustee hereunder.

     Section 4.04. Provisions as to Paying Agent.

     (a) If the Company shall appoint a Paying Agent other than the Trustee or
if the Trustee shall appoint such a Paying Agent, the Company will cause such
Paying Agent to execute and deliver to the Trustee an instrument in which such
agent shall agree with the Trustee, subject to the provisions of this Section
4.04:

          (i) that it will hold all sums held by it as such agent for the
     payment of the principal of, and accrued and unpaid interest (including
     Liquidated Damages, if any) on, the Notes (whether such sums have been paid
     to it by the Company) in trust for the benefit of the holders of the Notes;

          (ii) that it will give the Trustee notice of any failure by the
     Company to make any payment of the principal of, and accrued and unpaid
     interest (including Liquidated Damages, if any) on, the Notes when the same
     shall be due and payable; and

          (iii) that at any time during the continuance of an Event of Default,
     upon request of the Trustee, it will forthwith pay to the Trustee all sums
     so held in trust.

     The Company shall, on or before each due date of the principal of, or
accrued and unpaid interest (including Liquidated Damages, if any) on the Notes,
deposit with the Paying Agent a sum sufficient to pay such principal or accrued
and unpaid interest (including Liquidated Damages, if any) and (unless such
Paying Agent is the Trustee) the Company will promptly notify the Trustee in
writing of any failure to take such action, provided that if such deposit is
made on the due date, such deposit must be received by the Paying Agent by 11:00
a. m., New York City time, on such date.

     (b) If the Company shall act as its own Paying Agent, it will, on or before
each due date of the principal of and accrued and unpaid interest (including
Liquidated Damages, if any) on the Notes, set aside, segregate and hold in trust
for the benefit of the holders of the Notes a sum sufficient to pay such
principal and accrued and unpaid interest (including Liquidated Damages, if any)
so becoming due and will notify the Trustee in writing of any failure to take
such action and of any failure by the Company to make any payment of the
principal of and accrued and unpaid interest (including Liquidated Damages, if
any) on the Notes, when the same shall become due and payable.

     (c) Anything in this Section 4.04 to the contrary notwithstanding, the
Company may, at any time, for the purpose of obtaining a satisfaction and
discharge of this Indenture, or for any other reason, pay or cause to be paid to
the

                                       40

<PAGE>

Trustee all sums held in trust by the Company or any Paying Agent hereunder as
required by this Section 4.04, such sums to be held by the Trustee upon the
trusts herein contained and upon such payment by the Company or any Paying Agent
to the Trustee, the Company or such Paying Agent shall be released from all
further liability with respect to such sums.

     Section 4.05. Existence. The Company shall do or cause to be done all
things necessary to preserve and keep in full force and effect its existence,
or, following any transaction described in Section 10.01, the legal existence of
the resulting, surviving or transferee Person in accordance with Section 10.02.

     Section 4.06. Rule 144A Information Requirement and Annual Reports.

     (a) At any time the Company is not subject to Sections 13 or 15(d) of the
Exchange Act, the Company shall, so long as any of the Notes shall, at such
time, constitute "Restricted Securities" within the meaning of Rule 144(a)(3)
under the Securities Act, promptly provide to the Trustee and shall, upon
written request, provide to any holder, beneficial owner or prospective
purchaser of such Notes, the information required to be delivered pursuant to
Rule 144A(d)(4) under the Securities Act to facilitate the resale of such Notes
pursuant to Rule 144A under the Securities Act. The Company shall take such
further action as any holder or beneficial owner of such Notes may reasonably
request to the extent required from time to time to enable such holder or
beneficial holder to sell such Notes in accordance with Rule 144A under the
Securities Act, as such rule may be amended from time to time.

     (b) The Company will deliver to the Trustee within fifteen (15) days after
the filing of the same with the SEC, copies of the quarterly and annual reports
and of the information, documents and other reports, if any, which the Company
is required to file with the SEC pursuant to Section 13 or 15(d) of the Exchange
Act, and shall otherwise comply with the requirements of Trust Indenture Act
Section 314(a).

     (c) Delivery of such reports, information and documents to the Trustee is
for informational purposes only, and the Trustee's receipt of such shall not
constitute constructive notice of any information contained therein or
determinable from information contained therein, including the Company's
compliance with any of its covenants hereunder (as to which the Trustee is
entitled to conclusively rely exclusively on an Officers' Certificate).

     (d) Documents filed by the Company with the SEC via the EDGAR system will
be deemed filed with the Trustee as of the time such documents are filed via
EDGAR.

     Section 4.07. Compliance Certificate; Statements as to Defaults. The
Company shall deliver to the Trustee within 120 calendar days after the end of
each fiscal year of the Company (beginning with the fiscal year ending on

                                       41

<PAGE>

December 31, 2007) an Officers' Certificate stating whether or not the signer
thereof has knowledge of any failure by the Company to comply with all
conditions and covenants then required to be performed under this Indenture and,
if so, specifying each such failure and the nature thereof.

     In addition, the Company shall deliver to the Trustee, as soon as possible
and in any event within 30 days after the Company becomes aware of the
occurrence of any Event of Default or Default, an Officers' Certificate setting
forth the details of such Event of Default or Default, its status and the action
which the Company proposes to take with respect thereto.

     Any notice required to be given under this Section 4.07 shall be delivered
to the Trustee at its Corporate Trust Office.

     Section 4.08. Further Instruments and Acts. Upon request of the Trustee or
as necessary, the Company will execute and deliver such further instruments and
do such further acts as may be reasonably necessary or proper to carry out more
effectively the purposes of this Indenture.

     Section 4.09. Liquidated Damages. If the Company is required to pay
Liquidated Damages pursuant to the Registration Rights Agreement, the Company
shall deliver to the Trustee an Officers' Certificate to that effect stating (a)
the amount of such Liquidated Damages that is payable and (b) the date on which
such Liquidated Damages are payable. Unless and until a Responsible Officer of
the Trustee receives at the Corporate Trust Office such a certificate, the
Trustee may assume without inquiry that no such Liquidated Damages are payable.
If the Company has paid Liquidated Damages directly to the Persons entitled to
them, the Company shall deliver to the Trustee an Officers' Certificate setting
forth the particulars of such payment.

                                    ARTICLE 5
                                    REMEDIES

     Section 5.01. Events of Default.

     "EVENT OF DEFAULT," wherever used herein, means any one of the following
events with respect to the Notes (whatever the reason for such Event of Default
or whether it shall be voluntary or involuntary or be effected by operation of
law or pursuant to any judgment, decree or order of any court or any order, rule
or regulation of any administrative or governmental body):

     (a) default in any payment of interest or Liquidated Damages on any Note
when due and payable and the default continues for a period of 30 calendar days;
or

                                       42

<PAGE>

     (b) default in the payment of principal of any Note when due and payable at
Maturity, upon required repurchase, upon acceleration or otherwise; or

     (c) failure by the Company to comply with its obligation to convert the
Notes into shares of Common Stock or units of Reference Property or, cash and
shares or units, if any, of Common Stock or Reference Property, as applicable,
upon exercise of a Holder's conversion right, and, in the case of the Company's
failure to convert the Notes into shares of Common Stock or units of Reference
Property, such failure continues for five days; or

     (d) failure by the Company to comply with its obligations under Article 10;
or

     (e) failure by the Company to issue a Fundamental Change Repurchase Right
Notice in accordance with Section 14.01 or comply with its notice requirements
under Sections 12.01(b)-(d) when due; or

     (f) failure by the Company for 90 days after written notice from the
Trustee or the Holders of at least 25% principal amount of the Outstanding Notes
has been received by the Company to comply with any of its other agreements
contained in the Notes or this Indenture; or

     (g) default by the Company or any Subsidiary of the Company with respect to
any mortgage, agreement or other instrument under which there may be
outstanding, or by which there may be secured or evidenced, any debt for money
borrowed in excess of $10.0 million in the aggregate of the Company and/or any
such Subsidiary, whether such debt now exists or shall hereafter be created,
which default results (i) in such debt becoming or being declared due and
payable or (ii) from a failure to pay the principal of any such debt when due
and payable at its stated maturity, upon required repurchase, upon declaration
or otherwise, and in any such case of (i) or (ii), without such debt having been
paid or discharged within a period of 30 days after the occurrence of such debt
becoming or being declared due and payable or the failure to pay, as the case
may be; or

     (h) failure by the Company or any of its Subsidiaries, within 60 calendar
days, to pay, bond or otherwise discharge any judgments or orders for the
payment of money the total uninsured amount of which for the Company or any of
its Subsidiaries exceeds in the aggregate $10.0 million, which are not stayed on
appeal; or

     (i) the Company or any of its Significant Subsidiaries shall commence a
voluntary case or other proceeding seeking liquidation, reorganization or other
relief with respect to itself or its debts under any bankruptcy, insolvency or
other similar law now or hereafter in effect or seeking the appointment of a
trustee, receiver, liquidator, custodian or other similar official of the
Company or any of its Significant Subsidiaries or any substantial part of its
respective property, or shall consent to any such relief or to the appointment
of or taking possession by

                                       43

<PAGE>

any such official in an involuntary case or other proceeding commenced against
it, or shall make a general assignment for the benefit of creditors, or shall
fail generally to pay its debts as they become due; or

     (j) an involuntary case or other proceeding shall be commenced against the
Company or any of its Significant Subsidiaries seeking liquidation,
reorganization or other relief with respect to it or its debts under any
bankruptcy, insolvency or other similar law now or hereafter in effect or
seeking the appointment of a trustee, receiver, liquidator, custodian or other
similar official of the Company or any of its Significant Subsidiaries or any
substantial part of its respective property, and such involuntary case or other
proceeding shall remain undismissed and unstayed for a period of sixty (60)
consecutive calendar days.

     Section 5.02. Acceleration of Maturity; Rescission and Annulment.

     If an Event of Default (other than an Event of Default specified in Section
5.01(i) or Section 5.01(j) with respect to the Company) occurs and is
continuing, then in every such case (except as provided in the immediately
following paragraph) the Trustee or the Holders of not less than 25% in
principal amount of the Outstanding Notes may declare the principal of and
accrued and unpaid interest on all such Notes to be due and payable immediately,
by a notice in writing to the Company (and to the Trustee if given by the
Holders), and upon any such declaration of acceleration, all principal and all
accrued interest (including any Liquidated Damages, if any) on the Notes shall
become immediately due and payable. If an Event of Default specified in Section
5.01(i) or Section 5.01(j) with respect to the Company occurs, the principal of,
and accrued interest (including any Liquidated Damages, if any) on, all of the
Notes shall become immediately due and payable without any declaration or other
Act of the Holders or any act on the part of the Trustee.

     Notwithstanding the foregoing, at the election of the Company, the sole
remedy for an Event of Default specified in Section 5.01(f) relating to the
failure by the Company to comply with its obligations under Section 4.06 and for
any failure by the Company to comply with the requirements of Section 314(a)(1)
of the Trust Indenture Act, shall for the first 90 calendar days after the
occurrence of such an Event of Default consist exclusively of the right (the
"EXTENSION RIGHT") to receive an extension fee on the Notes in an amount equal
to 0.25% of the principal amount of the Notes (the "EXTENSION FEE"). If the
Company so elects, the Extension Fee shall be payable on all Outstanding Notes
on the date on which the Event of Default specified in Section 5.01(f) relating
to a failure to comply with the obligations under Section 4.06 or the failure to
comply with the requirements of Section 314(a)(1) of the Trust Indenture Act
first occurs. If such Event of Default has not been cured or waived pursuant to
Section 5.04 prior to such 91st calendar day, then the Trustee or the Holders of
not less than 25% in principal amount of the Outstanding Notes may declare the
principal of and accrued and unpaid interest (including any Liquidated Damages,
if any) on all such Notes to be due and payable immediately. If the Company
elects to pay the

                                       44

<PAGE>

Extension Fee as the sole remedy for an Event of Default specified in Section
5.01(f) relating to the failure by the Company to comply with its obligations
under Section 4.06 and for any failure by the Company to comply with the
requirements of Section 314(a)(1) of the Trust Indenture Act, the Company shall
notify in writing the Holders, the Paying Agent and the Trustee of such election
at any time on or before the close of business on the first Business Day
following the date on which such Event of Default first occurs. If the Company
fails to give timely notice or pay the Extension Fee, then the Trustee or the
Holders of not less than 25% in principal amount of the outstanding Notes may
declare the principal of and accrued and unpaid interest on all such Notes to be
due and payable immediately. If an Extension Fee is payable under this Section
5.02, the Company shall deliver to the Trustee a certificate to that effect
stating (i) the amount of such Extension Fee that is payable and (ii) the date
on which such Extension Fee is payable. Unless and until a Responsible Officer
of the Trustee receives at the Corporate Trust Office such a certificate, the
Trustee may assume without inquiry that the Extension Fee is not payable. If the
Extension Fee has been paid by the Company directly to the persons entitled to
it, the Company shall deliver to the Trustee a certificate setting forth the
particulars of such payment.

     Notwithstanding the foregoing paragraph, if an Event of Default occurs
under any series of the Company's debt securities (other than the Notes) issued
subsequent to the Issue Date resulting from the Company's failure to comply with
obligations similar to those contained in Section 4.06 or the requirements of
Section 314(a)(1) of the Trust Indenture Act, and such Event of Default is not
subject to extension on terms similar to those set forth in the foregoing
paragraph and results in the principal amount of such debt securities becoming
due and payable, then the Extension Right shall no longer apply and the Notes
shall be subject to acceleration as provided in the first paragraph of this
Section 5.02.

     This Section 5.02, however, is subject to the conditions that if, at any
time after the principal of the Notes shall have been so declared due and
payable, and before any judgment or decree for the payment of the monies due
shall have been obtained or entered as hereinafter provided, the Company shall
pay or shall deposit with the Trustee a sum sufficient to pay installments of
accrued and unpaid interest upon all Notes and the principal of any and all
Notes that shall have become due otherwise than by acceleration (with interest
on overdue installments of accrued and unpaid interest (to the extent that
payment of such interest is enforceable under applicable law) and on such
principal at the rate borne by the Notes during the period of such Default), and
if (1) rescission would not conflict with any judgment or decree of a court of
competent jurisdiction and (2) any and all Events of Default under this
Indenture with respect to such Notes, other than the nonpayment of principal of
and accrued and unpaid interest on such Notes that shall have become due solely
by such acceleration, shall have been cured or waived pursuant to Section 5.04,
then and in every such case the Holders of a majority in aggregate principal
amount of the Outstanding Notes, by written notice to the Company and to the
Trustee, may waive all Defaults or Events of

                                       45

<PAGE>

Default with respect to the Notes and rescind and annul such declaration and its
consequences and such Default shall cease to exist, and any Event of Default
arising therefrom shall be deemed to have been cured for every purpose of this
Indenture; but no such waiver or rescission and annulment shall extend to or
shall affect any subsequent Default or Event of Default, or shall impair any
right consequent thereon. No rescission or annulment referred to above shall
affect any subsequent Default or impair any right consequent thereon.

     Section 5.03. Unconditional Right of Holders to Receive Principal,
Liquidated Damages and Interest and to Convert. Notwithstanding any other
provision in this Indenture, the Holder of any Note shall have the right, which
is absolute and unconditional, to receive payment of the principal of and
interest and Liquidated Damages on such Note on the Maturity Date, and to
convert such Note in accordance with Article 12, and to institute suit for the
enforcement of any such payment and right to convert, and such rights shall not
be impaired without the consent of such Holder.

     Section 5.04. Waiver of Past Defaults. The Holders of not less than a
majority in principal amount of the Outstanding Notes may on behalf of the
Holders of all of the Notes waive any past Default hereunder and its
consequences, except a Default (A) in the uncured payment of the principal of or
interest or Liquidated Damages on any Note or the uncured failure to deliver
shares of Common Stock (or, if the Company has obtained Stockholder Approval to
make the Net Share Settlement Election and the Company has irrevocably made the
Net Share Settlement Election, cash and shares, if any, of Common Stock) due
upon conversion of any Note, or (B) in respect of a covenant or provision hereof
which under Article 8 cannot be modified or amended without the consent of the
Holder of each Outstanding Note affected (which nonetheless may be waived by the
Holders affected thereby).

     Upon any such waiver, such Default shall cease to exist, and any Event of
Default arising therefrom shall be deemed to have been cured, for every purpose
of this Indenture; but no such waiver shall extend to any subsequent or other
Default or impair any right consequent thereon.

     Section 5.05. Waiver of Stay, Usury or Extension Laws. The Company
covenants (to the extent that it may lawfully do so) that it shall not at any
time insist upon, or plead, or in any manner whatsoever claim or take the
benefit or advantage of, any stay, usury or extension law wherever enacted, now
or at any time hereafter in force, that may affect the covenants or the
performance of this Indenture; and the Company (to the extent that it may
lawfully do so) hereby expressly waives all benefit or advantage of any such law
and covenants that it shall not hinder, delay or impede by reason of such law
the execution of any power herein granted to the Trustee, but shall suffer and
permit the execution of every such power as though no such law had been enacted.

                                       46
<PAGE>

     Section 5.06. Conditions to Enforcement. Except to enforce the right to
receive payment of principal, interest and Liquidated Damages when due or to
receive amounts due to it upon conversion, no Holder may pursue any remedy with
respect to this Indenture or the Notes unless:

     (a) such Holder has previously given the Trustee notice that an Event of
Default is continuing;

     (b) Holders of at least 25% principal amount of the Outstanding Notes have
requested the Trustee to pursue the remedy;

     (c) such Holders have offered the Trustee security or indemnity
satisfactory to it against any loss, liability or expense;

     (d) the Trustee has not complied with such request within 60 days after the
receipt of the request and the offer of security or indemnity; and

     (e) the Holders of a majority principal amount of the Outstanding Notes
have not given the Trustee a direction that, in the opinion of the Trustee, is
inconsistent with such request within such 60-day period.

     Section 5.07. Control by Holders. The Holders of a majority in principal
amount of the Outstanding Notes may direct the time, method and place of
conducting any proceeding for any remedy available to the Trustee hereunder, or
of exercising any trust or power hereby conferred upon the Trustee with respect
to the Notes; provided, however, that, subject to the provisions of Section
6.01, the Trustee shall have the right to decline to follow any such direction
if the Trustee being advised by counsel determines that the action so directed
may not lawfully be taken or would be unduly prejudicial to Holders not joining
in such direction or would involve the Trustee in personal liability.

                                    ARTICLE 6
                             CONCERNING THE TRUSTEE

     Section 6.01. Duties and Responsibilities of Trustee. The Trustee, prior
to the occurrence of an Event of Default and after the curing or waiver of all
Events of Default which may have occurred, undertakes to perform such duties and
only such duties as are specifically set forth in this Indenture. In case an
Event of Default has occurred (which has not been cured or waived and is known
to the Trustee) the Trustee shall (a) mail to each Holder notice of the Event of
Default within 90 days after the occurrence of such Event of Default; provided
that the Trustee may withhold notice if and so long as a committee of trust
officers of the Trustee in good faith determines that withholding notice is in
the interests of the Holders, and (b) exercise such of the rights and powers
vested in it by this Indenture, and use the same degree of care and skill in
their exercise, as a prudent person would exercise or use under the
circumstances in the conduct of such

                                       47

<PAGE>

person's own affairs; provided that if an Event of Default occurs and is
continuing, the Trustee will be under no obligation to exercise any of the
rights or powers under this Indenture at the request or direction of any of the
holders unless such holders have offered to the Trustee indemnity or security
reasonably satisfactory to it against loss, liability or expense.

     No provision of this Indenture shall be construed to relieve the Trustee
from liability for its own grossly negligent action, its own grossly negligent
failure to act or its own willful misconduct, except that:

     (a) prior to the occurrence of an Event of Default and after the curing or
waiving of all Events of Default which may have occurred:

          (i) the duties and obligations of the Trustee shall be determined
     solely by the express provisions of this Indenture and, after it has been
     qualified thereunder, the Trust Indenture Act, and the Trustee shall not be
     liable except for the performance of such duties and obligations as are
     specifically set forth in this Indenture and no implied covenants or
     obligations shall be read into this Indenture and the Trust Indenture Act
     against the Trustee; and

          (ii) in the absence of bad faith and willful misconduct on the part of
     the Trustee, the Trustee may conclusively rely, as to the truth of the
     statements and the correctness of the opinions expressed therein, upon any
     certificates or opinions furnished to the Trustee and conforming to the
     requirements of this Indenture; but, in the case of any such certificates
     or opinions which by any provisions hereof are specifically required to be
     furnished to the Trustee, the Trustee shall be under a duty to examine the
     same to determine whether or not they conform to the requirements of this
     Indenture (but need not confirm or investigate the accuracy of mathematical
     calculations or other facts stated therein);

     (b) the Trustee shall not be liable for any error of judgment made in good
faith by a Responsible Officer or Officers of the Trustee, unless it shall be
proved that the Trustee was grossly negligent in ascertaining the pertinent
facts;

     (c) the Trustee shall not be liable with respect to any action taken or
omitted to be taken by it in good faith in accordance with the direction of the
holders of not less than a majority in principal amount of the Outstanding
Notes, or exercising any trust or power conferred upon the Trustee, under this
Indenture;

     (d) whether or not therein provided, every provision of this Indenture
relating to the conduct or affecting the liability of, or affording protection
to, the Trustee shall be subject to the provisions of this Section;

     (e) the Trustee shall not be liable in respect of any payment (as to the
correctness of amount, entitlement to receive or any other matters relating to

                                       48

<PAGE>

payment) or notice effected by the Company or any Paying Agent or any records
maintained by any co-registrar with respect to the Notes;

     (f) if any party fails to deliver a notice relating to an event the fact of
which, pursuant to this Indenture, requires notice to be sent to the Trustee,
the Trustee may conclusively rely on its failure to receive such notice as
reason to act as if no such event occurred, unless such Responsible Officer of
the Trustee had actual knowledge of such event;

     (g) in the absence of written investment direction from the Company, all
cash received by the Trustee shall be placed in a non-interest bearing trust
account. In no event shall the Trustee be liable for the selection of
investments or for investment losses incurred thereon or for losses incurred as
a result of the liquidation of any such investment prior to its stated maturity
or the failure of the party directing such investment to provide timely written
investment direction, and the Trustee shall have no obligation to invest or
reinvest any amounts held hereunder in the absence of such written investment
direction from the Company; and

     (h) in the event that the Trustee is also acting as Custodian, Note
Registrar, Paying Agent or transfer agent hereunder, the rights and protections
afforded to the Trustee pursuant to this Article 6 shall also be afforded to
such Custodian, Note Registrar, Paying Agent or transfer agent.

     None of the provisions contained in this Indenture shall require the
Trustee to expend or risk its own funds or otherwise incur personal financial
liability in the performance of any of its duties or in the exercise of any of
its rights or powers.

     Section 6.02. Reliance on Documents, Opinions, Etc. Except as otherwise
provided in Section 6.01:

     (a) the Trustee may conclusively rely and shall be fully protected in
acting upon any resolution, certificate, statement, instrument, opinion, report,
notice, request, consent, order, bond, note, coupon or other paper or document
believed by it in good faith to be genuine and to have been signed or presented
by the proper party or parties;

     (b) any request, direction, order or demand of the Company mentioned herein
shall be sufficiently evidenced by an Officers' Certificate (unless other
evidence in respect thereof be herein specifically prescribed); and any
resolution of the Board of Directors may be evidenced to the Trustee by a copy
thereof certified by the Secretary or an Assistant Secretary of the Company;

     (c) the Trustee may consult with counsel and require an Opinion of Counsel
and any advice of such counsel or Opinion of Counsel shall be full and complete
authorization and protection in respect of any action taken or omitted by

                                       49

<PAGE>

it hereunder in good faith and in accordance with such advice or Opinion of
Counsel;

     (d) the Trustee shall be under no obligation to exercise any of the rights
or powers vested in it by this Indenture at the request, order or direction of
any of the Holders pursuant to the provisions of this Indenture, unless such
Holders shall have offered to the Trustee security or indemnity satisfactory to
it against the costs, expenses and liabilities which may be incurred therein or
thereby;

     (e) the Trustee shall not be bound to make any investigation into the facts
or matters stated in any resolution, certificate, statement, instrument,
opinion, report, notice, request, direction, consent, order, bond, debenture or
other paper or document, but the Trustee, in its discretion, may make such
further inquiry or investigation into such facts or matters as it may see fit,
and, if the Trustee shall determine to make such further inquiry or
investigation, it shall be entitled to examine the books, records and premises
of the Company, personally or by agent or attorney at the expense of the Company
and shall incur no liability of any kind by reason of such inquiry or
investigation;

     (f) the Trustee may execute any of the trusts or powers hereunder or
perform any duties hereunder either directly or by or through agents,
custodians, nominees or attorneys and the Trustee shall not be responsible for
any misconduct or negligence on the part of any agent, custodian, nominee or
attorney appointed by it with due care hereunder;

     (g) the permissive rights of the Trustee enumerated herein shall not be
construed as duties;

     (h) in the absence of bad faith on its part, the Trustee may conclusively
rely, as to the truth of the statements and the correctness of the opinions
expressed therein, upon Officers' Certificates or Opinions of Counsel furnished
to the Trustee and conforming to the requirements of this Indenture; but in the
case of any such Certificates or Opinions which by any provisions hereof are
specifically required to be furnished to the Trustee, the Trustee shall be under
a duty to examine the same to determine whether or not they conform to the
requirements of this Indenture (but need not confirm or investigate the accuracy
of mathematical calculations or other facts stated therein); and

     (i) the Trustee may request that the Company deliver an Officers'
Certificate setting forth the names of individuals and/or titles of officers'
authorized at such time to take specified actions pursuant to this Indenture,
which Officers' Certificate may be signed by any person authorized to sign
Officers' Certificates, including any person specified as so authorized in any
such certificate previously delivered and not superseded.

     In no event shall the Trustee be liable for any consequential loss or
damage of any kind whatsoever (including but not limited to lost profits), even
if

                                       50

<PAGE>

the Trustee has been advised of the likelihood of such loss or damage and
regardless of the form of action other than through the Trustee's willful
misconduct or gross negligence. The Trustee shall not be charged with knowledge
of any Default or Event of Default with respect to the Notes, unless either (1)
a Responsible Officer shall have actual knowledge of such Default or Event of
Default or (2) written notice of such Default or Event of Default shall have
been given to the Trustee by the Company or by any holder of the Notes at the
Corporate Trust Office of the Trustee, and such notice references the Notes and
this Indenture.

     Section 6.03. No Responsibility for Recitals, Etc. The recitals contained
herein and in the Notes (except in the Trustee's certificate of authentication)
shall be taken as the statements of the Company, and the Trustee assumes no
responsibility for the correctness of the same. The Trustee makes no
representations as to the validity or sufficiency of this Indenture or of the
Notes. The Trustee shall not be accountable for the use or application by the
Company of any Notes or the proceeds of any Notes authenticated and delivered by
the Trustee in conformity with the provisions of this Indenture. The Trustee
shall not be responsible or liable for any loss suffered in connection with any
investment of funds made by it in accordance with this Indenture or at the
direction of the Company. Except for information provided by the Trustee
concerning the Trustee, the Trustee shall have no responsibility for any
information in any offering memorandum, prospectus or other disclosure material
distributed with respect to the Notes.

     Section 6.04. Trustee, Paying Agents or Registrar May Own Notes. The
Trustee, any Paying Agent or Note Registrar, in its individual or any other
capacity, may become the owner or pledgee of Notes with the same rights it would
have if it were not Trustee, Paying Agent or Note Registrar.

     Section 6.05. Monies to be Held in Trust. All monies received by the
Trustee shall, until used or applied as herein provided, be held in trust for
the purposes for which they were received. Money held by the Trustee in trust
hereunder need not be segregated from other funds except to the extent required
by law. The Trustee shall be under no liability for interest on any money
received by it hereunder except as may be agreed from time to time by the
Company and the Trustee.

     Section 6.06. Compensation and Expenses of Trustee. The Company covenants
and agrees to pay to the Trustee from time to time, and the Trustee shall be
entitled to, reasonable compensation for all services rendered by it hereunder
in any capacity (which shall not be limited by any provision of law in regard to
the compensation of a trustee of an express trust) as mutually agreed to in
writing between the Trustee and the Company, and the Company will pay or
reimburse the Trustee upon its request for all reasonable expenses,
disbursements and advances reasonably incurred or made by the Trustee in
accordance with any of the provisions of this Indenture (including the
reasonable compensation and the

                                       51

<PAGE>

expenses and disbursements of its agents and counsel and of all persons not
regularly in its employ) except any such expense, disbursement or advance as may
arise from its gross negligence, willful misconduct or bad faith. The Company
also covenants to indemnify the Trustee in any capacity under this Indenture and
any other document or transaction entered into in connection herewith and its
agents and any authenticating agent for, and to hold them harmless against, any
loss, liability, claim, damage or expense incurred without gross negligence,
willful misconduct or bad faith on the part of the Trustee, its officers,
directors, agents or employees, or such agent or authenticating agent, as the
case may be, and arising out of or in connection with the acceptance or
administration of this trust or in any other capacity hereunder, including the
costs and expenses of defending themselves against any claim of liability in the
premises. The obligations of the Company under this Section 6.06 to compensate
or indemnify the Trustee and to pay or reimburse the Trustee for expenses,
disbursements and advances shall be secured by a lien prior to that of the Notes
upon all property and funds held or collected by the Trustee as such, except
funds held in trust herewith for the benefit of the holders of particular Notes
prior to the date of the accrual of such unpaid compensation or identifiable
claim. The Trustee's right to receive payment of any amounts due under this
Section 6.06 shall not be subordinate to any other liability or debt of the
Company. The obligation of the Company under this Section 6.06 shall survive the
satisfaction and discharge of this Indenture and the earlier resignation or
removal or the Trustee. The Company need not pay for any settlement made without
its consent, which consent shall not be unreasonably withheld. The
indemnification provided in this Section 6.06 shall extend to the officers,
directors, agents and employees of the Trustee.

     When the Trustee and its agents and any authenticating agent incur expenses
or render services after an Event of Default specified in Section 5.01(i) or
Section 5.01(j) with respect to the Company occurs, the expenses and the
compensation for the services are intended to constitute expenses of
administration under any bankruptcy, insolvency or similar laws.

     Section 6.07. Officers' Certificate as Evidence. Except as otherwise
provided in Section 7.01, whenever in the administration of the provisions of
this Indenture the Trustee shall deem it necessary or desirable that a matter be
proved or established prior to taking or omitting any action hereunder, such
matter (unless other evidence in respect thereof be herein specifically
prescribed) may, in the absence of gross negligence, willful misconduct,
recklessness and bad faith on the part of the Trustee, be deemed to be
conclusively proved and established by an Officers' Certificate delivered to the
Trustee, and such Officers' Certificate, in the absence of gross negligence,
willful misconduct, recklessness and bad faith on the part of the Trustee, shall
be full warrant to the Trustee for any action taken or omitted by it under the
provisions of this Indenture upon the faith thereof.

     Section 6.08. Conflicting Interests of Trustee. If the Trustee has or
shall acquire a conflicting interest within the meaning of the Trust Indenture
Act, the

                                       52

<PAGE>

Trustee shall either eliminate such interest or resign, to the extent and in the
manner provided by, and subject to the provisions of, the Trust Indenture Act
and this Indenture.

     Section 6.09. Eligibility of Trustee. There shall at all times be a Trustee
hereunder which shall be a Person that is eligible pursuant to the Trust
Indenture Act to act as such and has a combined capital and surplus of at least
$50,000,000. If such Person publishes reports of condition at least annually,
pursuant to law or to the requirements of any supervising or examining
authority, then for the purposes of this Section, the combined capital and
surplus of such Person shall be deemed to be its combined capital and surplus as
set forth in its most recent report of condition so published. If at any time
the Trustee shall cease to be eligible in accordance with the provisions of this
Section, it shall resign immediately in the manner and with the effect
hereinafter specified in this Article.

     Section 6.10. Resignation or Removal of Trustee.

     (a) The Trustee may at any time resign by giving written notice of such
resignation to the Company and by mailing notice thereof to the Holders at their
addresses as they shall appear on the Note Register. Upon receiving such notice
of resignation, the Company shall promptly appoint a successor trustee by
written instrument, in duplicate, executed by order of the Board of Directors,
one copy of which instrument shall be delivered to the resigning Trustee and one
copy to the successor trustee. If no successor trustee shall have been so
appointed and have accepted appointment sixty (60) days after the mailing of
such notice of resignation to the Holders, the resigning Trustee may petition
any court of competent jurisdiction for the appointment of a successor trustee,
or any Holder who has been a bona fide holder of a Note or Notes for at least
six months may on behalf of itself and all others similarly situated, petition
any such court for the appointment of a successor trustee. Such court may
thereupon, after such notice, if any, as it may deem proper and prescribe,
appoint a successor trustee.

     (b) In case at any time any of the following shall occur:

          (i) the Trustee shall fail to comply with Section 6.08 within a
     reasonable time after written request therefor by the Company or by any
     Holder who has been a bona fide holder of a Note or Notes for at least six
     (6) months, or

          (ii) the Trustee shall cease to be eligible in accordance with the
     provisions of Section 6.09 and shall fail to resign after written request
     therefor by the Company or by any such Holder, or

          (iii) the Trustee shall become incapable of acting, or shall be
     adjudged a bankrupt or insolvent, or a receiver of the Trustee or of its
     property shall be appointed, or any public officer shall take charge or

                                       53

<PAGE>

     control of the Trustee or of its property or affairs for the purpose of
     rehabilitation, conservation or liquidation,

     then, in any such case, the Company may by a Board Resolution remove the
Trustee and appoint a successor trustee by written instrument, in duplicate,
executed by order of the Board of Directors, one copy of which instrument shall
be delivered to the Trustee so removed and one copy to the successor trustee, or
any Holder who has been a bona fide holder of a Note or Notes for at least six
(6) months may, on behalf of itself and all others similarly situated, petition
any court of competent jurisdiction for the removal of the Trustee and the
appointment of a successor trustee. Such court may thereupon, after such notice,
if any, as it may deem proper and prescribe, remove the Trustee and appoint a
successor trustee.

     (c) The holders of a majority in aggregate principal amount of the Notes at
the time Outstanding may at any time remove the Trustee and nominate a successor
trustee which shall be deemed appointed as successor trustee unless within ten
(10) days after notice to the Company of such nomination the Company objects
thereto, in which case the Trustee so removed or any Holder, upon the terms and
conditions and otherwise as in Section 6.10(a) provided, may petition any court
of competent jurisdiction for an appointment of a successor trustee.

     (d) Any resignation or removal of the Trustee and appointment of a
successor trustee pursuant to any of the provisions of this Section 6.10 shall
become effective upon acceptance of appointment by the successor trustee as
provided in Section 6.11.

     Section 6.11. Acceptance by Successor Trustee. Any successor trustee
appointed as provided in Section 6.10 shall execute, acknowledge and deliver to
the Company and to its predecessor trustee an instrument accepting such
appointment hereunder, and thereupon the resignation or removal of the
predecessor trustee shall become effective and such successor trustee, without
any further act, deed or conveyance, shall become vested with all the rights,
powers, duties and obligations of its predecessor hereunder, with like effect as
if originally named as trustee herein; but, nevertheless, on the written request
of the Company or of the successor trustee, the trustee ceasing to act shall,
upon payment of any amounts then due it pursuant to the provisions of Section
6.06, execute and deliver an instrument transferring to such successor trustee
all the rights and powers of the trustee so ceasing to act. Upon request of any
such successor trustee, the Company shall execute any and all instruments in
writing for more fully and certainly vesting in and confirming to such successor
trustee all such rights and powers. Any trustee ceasing to act shall,
nevertheless, retain a lien upon all property and funds held or collected by
such trustee as such, except for funds held in trust for the benefit of holders
of particular Notes, to secure any amounts then due it pursuant to the
provisions of Section 6.06.

                                       54

<PAGE>

     No successor trustee shall accept appointment as provided in this Section
6.11 unless at the time of such acceptance such successor trustee shall be
qualified under the provisions of Section 6.08 and be eligible under the
provisions of Section 6.09.

     Upon acceptance of appointment by a successor trustee as provided in this
Section 6.11, each of the Company and the successor trustee, at the written
direction and at the expense of the Company shall mail or cause to be mailed
notice of the succession of such trustee hereunder to the Holders at their
addresses as they shall appear on the Note Register. If the Company fails to
mail such notice within ten (10) days after acceptance of appointment by the
successor trustee, the successor trustee shall cause such notice to be mailed at
the expense of the Company.

     Section 6.12. Succession by Merger, Etc. Any corporation or other entity
into which the Trustee may be merged or converted or with which it may be
consolidated, or any corporation or other entity resulting from any merger,
conversion or consolidation to which the Trustee shall be a party, or any
corporation or other entity succeeding to all or substantially all of the
corporate trust business of the Trustee (including the administration of this
Indenture), shall be the successor to the Trustee hereunder without the
execution or filing of any paper or any further act on the part of any of the
parties hereto, provided that in the case of any corporation or other entity
succeeding to all or substantially all of the corporate trust business of the
Trustee such corporation or other entity shall be qualified under the provisions
of Section 6.08 and eligible under the provisions of Section 6.09.

     In case at the time such successor to the Trustee shall succeed to the
trusts created by this Indenture, any of the Notes shall have been authenticated
but not delivered, any such successor to the Trustee may adopt the certificate
of authentication of any predecessor trustee or authenticating agent appointed
by such predecessor trustee, and deliver such Notes so authenticated, and in
case at that time any of the Notes shall not have been authenticated, any
successor to the Trustee or an authenticating agent appointed by such successor
trustee may authenticate such Notes either in the name of any predecessor
trustee hereunder or in the name of the successor trustee; and in all such cases
such certificates shall have the full force which it is anywhere in the Notes or
in this Indenture provided that the certificate of the Trustee shall have;
provided, however, that the right to adopt the certificate of authentication of
any predecessor Trustee or to authenticate Notes in the name of any predecessor
Trustee shall apply only to its successor or successors by merger, conversion or
consolidation.

     Section 6.13. Limitation on Rights of Trustee as Creditor. If and when the
Trustee shall be or become a creditor of the Company, the Trustee shall be
subject to the provisions of the Trust Indenture Act regarding the collection of
the claims against the Company.

                                       55

<PAGE>

     Section 6.14. Trustee's Application for Instructions from the Company. Any
application by the Trustee for written instructions from the Company (other than
with regard to any action proposed to be taken or omitted to be taken by the
Trustee that affects the rights of the holders of the Notes under this
Indenture) may, at the option of the Trustee, set forth in writing any action
proposed to be taken or omitted by the Trustee under this Indenture and the date
on and/or after which such action shall be taken or such omission shall be
effective. The Trustee shall not be liable for any action taken by, or omission
of, the Trustee in accordance with a proposal included in such application on or
after the date specified in such application (which date shall not be less than
three (3) Business Days after the date any officer of the Company actually
receives such application, unless any such officer shall have consented in
writing to any earlier date), unless, prior to taking any such action (or the
effective date in the case of any omission), the Trustee shall have received
written instructions from the Company in response to such proposal specifying
the action to be taken or omitted.

                                    ARTICLE 7
                             CONCERNING THE HOLDERS

     Section 7.01. Action By Holders. Whenever in this Indenture it is provided
that the Holders of a specified percentage in aggregate principal amount of the
Notes may take any action (including the making of any demand or request, the
giving of any notice, consent or waiver or the taking of any other action (an
"ACT")), the fact that at the time of taking any Act, the Holders of such
specified percentage have joined therein may be evidenced (a) by any instrument
or any number of instruments of similar tenor executed by Holders in person or
by agent or proxy appointed in writing, or (b) by the record of the Holders
voting in favor thereof at any meeting of Holders duly called and held in
accordance with the provisions of Article 7, or (c) by a combination of such
instrument or instruments and any such record of such a meeting of Holders and,
except as herein otherwise expressly provided, an Act shall become effective
when such instrument or instruments are delivered to the Trustee and, where it
is hereby expressly required, to the Company. Proof of execution of any such
instrument or of a writing appointing any such agent shall be sufficient for any
purpose of this Indenture and conclusive in favor of the Trustee and the
Company, if made in the manner provided in this Section. Whenever the Company or
the Trustee solicits the taking of any Act by the Holders of the Notes, the
Company or the Trustee may fix, but shall not be required to, in advance of such
solicitation, a date as the record date for determining Holders entitled to take
such Act. The record date if one is selected shall be not more than fifteen (15)
days prior to the date of commencement of solicitation of such action. Any
request, demand, authorization, direction, notice consent, waiver or other
action by a Holder of any Note shall bind every future Holder of the same Note,
and the Holder of every Note issued upon the registration of transfer thereof or
in exchange therefor or in lieu thereof in respect of anything done, omitted, or
suffered to be done by the Trustee or the

                                       56

<PAGE>

Company in reliance thereon, whether or not notation of such action is made upon
such Note.

     Section 7.02. Proof of Execution by Holders. Subject to Section 11.05,
proof of the execution of any instrument by a Holder or his agent or proxy shall
be sufficient if made in accordance with such reasonable rules and regulations
as may be prescribed by the Trustee or in such manner as shall be satisfactory
to the Trustee. The holding of Notes shall be proved by the Note Register or by
a certificate of the Note Registrar. The record of any Holders' meeting shall be
proved in the manner provided in Section 11.06.

     Section 7.03. Revocation of Consents; Future Holders Bound. At any time
prior to (but not after) the evidencing to the Trustee, as provided in Section
7.01, of the taking of any action by the holders of the percentage in aggregate
principal amount of the Notes specified in this Indenture in connection with
such action, any holder of a Note that is shown by the evidence to be included
in the Notes the holders of which have consented to such action may, by filing
written notice with the Trustee at its Corporate Trust Office and upon proof of
holding as provided in Section 7.02, revoke such action so far as concerns such
Note.

                                    ARTICLE 8
                             SUPPLEMENTAL INDENTURES

     Section 8.01. Supplemental Indentures Without Consent of Holders of Notes.

     Without the consent of any Holders of Notes, the Company, when authorized
by a Board Resolution, and the Trustee, upon receipt of a Company Request, at
any time and from time to time, may enter into one or more indentures
supplemental hereto for any of the following purposes:

     (a) (x) to cure any ambiguity, manifest error or defect or (y) to cure any
omission or inconsistency; provided that, in the case of clause (y) only if the
rights of the Holders are not adversely affected in any material respect; or

     (b) to evidence the succession of another Person to the Company and the
assumption by any such successor of the covenants and obligations of the Company
herein and in the Notes; or

     (c) to add guarantees with respect to the Notes; or

     (d) to provide for a successor trustee in accordance with the terms of this
Indenture or to otherwise comply with any requirement of this Indenture; or

     (e) to provide for the issuance of Additional Notes, to the extent that the
Company and the Trustee deem such amendment necessary or advisable in

                                       57

<PAGE>

connection with such issuance; provided that no such amendment or supplement may
impair the rights or interests of any holder of the Outstanding Notes; or

     (f) to increase the Conversion Rate; or

     (g) to secure the Notes; or

     (h) to add to the covenants of the Company for the benefit of the Holders
of Notes or to surrender any right or power herein conferred upon the Company;
or

     (i) to provide for the conversion of Notes pursuant to Section 12.10; or

     (j) to make any changes or modifications to this Indenture, provided that
such action pursuant to this clause (j) shall not adversely affect the rights of
the Holders of Notes in any material respect; provided further that any such
action to conform the terms of this Indenture or the Notes to the description of
the Notes contained in the Offering Circular shall not be deemed to be adverse
to the Holders of Notes; or

     (k) to comply with the requirements of the Trust Indenture Act or the rules
and regulations of the SEC thereunder in order to effect or maintain the
qualification of this Indenture under the Trust Indenture Act; or

     (l) to make any changes or modifications necessary in connection with the
registration of the Notes under the Securities Act as contemplated in the
Registration Rights Agreement; provided that such change or modification does
not adversely affect the interests of the Holders of the Notes in any material
respect.

     Upon Company Request, accompanied by a Board Resolution authorizing the
execution of any such supplemental indenture, the Trustee shall join with the
Company in the execution of any supplemental indenture authorized or permitted
by the terms of this Indenture and to make any further appropriate agreements
and stipulations that may be therein contained.

     Section 8.02. Supplemental Indentures with Consent of Holders of Notes.

     With the written consent of the Holders of not less than a majority in
principal amount of the Outstanding Notes (including without limitation,
consents obtained in connection with a purchase of, or tender offer or exchange
offer for Notes), by the Act of said Holders delivered to the Company and the
Trustee, the Company, when authorized by a Board Resolution, and the Trustee may
enter into an indenture or indentures supplemental hereto for the purpose of
adding any provisions to or changing in any manner or eliminating any of the
provisions of this Indenture or of modifying in any manner the rights of the
Holders of Notes under this Indenture; provided, however, that no such
supplemental indenture

                                       58

<PAGE>

shall, without the consent of the Holder of each Outstanding Note affected
thereby:

     (a) reduce the percentage in aggregate principal amount of Notes the
Holders of which must consent to an amendment; or

     (b) reduce the rate or extend the stated time for payment, of interest on
any Note or reduce the amount, or extend the stated time for payment of the
Extension Fee; or

     (c) reduce the principal, or extend the Maturity Date, of any Note; or

     (d) make any change that adversely affects the conversion rights of any
Notes; or

     (e) reduce the Fundamental Change Repurchase Price of any Note or amend or
modify in any manner adverse to the Holders of the Notes the Company's
obligations to make such payments, whether through an amendment or waiver of
provisions in the covenants, definitions or otherwise; or

     (f) change the place or currency of payment of principal, interest or the
Extension Fee in respect of any Note; or

     (g) impair the right of any Holder to receive payment of principal of, and
interest on, such Holder's Notes on or after the due dates therefor or to
institute suit for the enforcement of any payment on or with respect to such
Holder's Note; or

     (h) adversely affect the ranking of the Notes as senior unsecured
indebtedness of the Company; or

     (i) make any change in the provisions of this Article 8 that require each
Holder's consent or in the waiver provisions in Section 5.02 and Section 5.04.

     It shall not be necessary for any Act of Holders of Notes under this
Section 8.02 to approve the particular form of any proposed supplemental
indenture, but it shall be sufficient if such Act shall approve the substance
thereof.

     Section 8.03. Effect of Supplemental Indentures. Any supplemental
indenture executed pursuant to the provisions of this Article 8 shall comply
with the Trust Indenture Act, as then in effect, provided that this Section 8.03
shall not require such supplemental indenture or the Trustee to be qualified
under the Trust Indenture Act prior to the time such qualification is in fact
required under the terms of the Trust Indenture Act, nor shall it constitute any
admission or acknowledgment by any party to such supplemental indenture that any
such qualification is required prior to the time such qualification is in fact
required under the terms of the Trust Indenture Act. Upon the execution of any
supplemental indenture pursuant to the provisions of this Article 8, this
Indenture

                                       59

<PAGE>

shall be and be deemed to be modified and amended in accordance therewith and
the respective rights, limitation of rights, obligations, duties and immunities
under this Indenture of the Trustee, the Company and the Holders shall
thereafter be determined, exercised and enforced hereunder subject in all
respects to such modifications and amendments and all the terms and conditions
of any such supplemental indenture shall be and be deemed to be part of the
terms and conditions of this Indenture for any and all purposes.

     Section 8.04. Notation on Notes. Notes authenticated and delivered after
the execution of any supplemental indenture pursuant to the provisions of this
Article 8 may bear a notation in form approved by the Trustee as to any matter
provided for in such supplemental indenture. If the Company or the Trustee shall
so determine, new Notes so modified as to conform, in the opinion of the Trustee
and the Board of Directors, to any modification of this Indenture contained in
any such supplemental indenture may, at the Company's expense, be prepared and
executed by the Company, authenticated by the Trustee (or an authenticating
agent duly appointed by the Trustee pursuant to Section 15.10) and delivered in
exchange for the Notes then outstanding, upon surrender of such Notes then
outstanding.

     Section 8.05. Evidence of Compliance of Supplemental Indenture to be
Furnished to the Trustee.

     In addition to the documents required by Section 15.05, the Trustee shall
receive an Officers' Certificate and an Opinion of Counsel as conclusive
evidence that any supplemental indenture executed pursuant hereto complies with
the requirements of this Article 8.

                                    ARTICLE 9
                HOLDERS LISTS AND REPORTS BY TRUSTEE AND COMPANY

     Section 9.01. List of Holders. The Company covenants and agrees that it
will furnish or cause to be furnished to the Trustee, semi-annually, not more
than fifteen (15) days after each June 30 and December 31 in each year beginning
with December 31, 2007, and at such other times as the Trustee may request in
writing, within thirty (30) days after receipt by the Company of any such
request (or such lesser time as the Trustee may reasonably request in order to
enable it to timely provide any notice to be provided by it hereunder), a list
in such form as the Trustee may reasonably require of the names and addresses of
the Holders as of a date not more than fifteen (15) days (or such other date as
the Trustee may reasonably request in order to so provide any such notices)
prior to the time such information is furnished, except that no such list need
be furnished so long as the Trustee is acting as Note Registrar.

     Section 9.02. Preservation of Information.

                                       60

<PAGE>

     (a) The Trustee shall preserve, in as current a form as is reasonably
practicable, the names and addresses of Holders contained in the most recent
list furnished to the Trustee and the names and addresses of Holders received by
the Trustee in its capacity as Registrar. The Trustee may destroy any list, if
any, furnished to it upon receipt of a new list so furnished.

     (b) The rights of Holders to communicate with other Holders with respect to
their rights under this Indenture or under the Notes, and the corresponding
rights, and duties of the Trustee, shall be as provided by the Trust Indenture
Act.

     (c) Every Holder of Notes, by receiving and holding the same, agrees with
the Company and the Trustee that neither the Company nor the Trustee nor any
agent of either of them shall be held accountable by reason of any disclosure of
information as to names and addresses of Holders made pursuant to the Trust
Indenture Act.

                                   ARTICLE 10
                CONSOLIDATION, MERGER, SALE, CONVEYANCE AND LEASE

     Section 10.01. Company May Consolidate, Etc. on Certain Terms.

     Subject to the provisions of Section 10.02, the Company shall not
consolidate with, merge with or into, or convey, transfer or lease all or
substantially all of its assets and properties, to another Person, unless:

     (a) the resulting, surviving or transferee Person (the "SUCCESSOR COMPANY")
if not the Company shall be a corporation organized and existing under the laws
of the United States of America, any State thereof or the District of Columbia
and the Successor Company (if not the Company) shall expressly assume, by
supplemental indenture, executed and delivered to the Trustee, in form
satisfactory to the Trustee, all the obligations of the Company under the Notes,
this Indenture and, to the extent that it is otherwise still operative, shall
expressly assume all the obligations of the Company under the Registration
Rights Agreement; and

     (b) immediately after giving effect to such transaction, no Default or
Event of Default shall have occurred and be continuing under this Indenture or
the Registration Rights Agreement.

     Upon any such consolidation, merger, conveyance, transfer or lease the
resulting, surviving or transferee (by conveyance, lease or otherwise) Person
(if not the Company) shall succeed to, and may exercise every right and power
of, the Company under this Indenture and the Registration Rights Agreement.

                                       61
<PAGE>

     Section 10.02. Successor Corporation to be Substituted. In case of any such
consolidation, merger, conveyance, transfer or lease and upon the assumption by
the Successor Company, by supplemental indenture, executed and delivered to the
Trustee and satisfactory in form to the Trustee, of the due and punctual payment
of the principal of and accrued and unpaid interest (including Liquidated
Damages, if any) on all of the Notes, the due and punctual settlement of the
conversion of the Notes and the due and punctual performance of all of the
covenants and conditions of this Indenture to be performed by the Company, such
Successor Company shall succeed to and be substituted for the Company and the
Company shall be released from those obligations, with the same effect as if it
had been named herein as the party of the first part. Such Successor Company
thereupon may cause to be signed, and may issue either in its own name or in the
name of the Company any or all of the Notes issuable hereunder which theretofore
shall not have been signed by the Company and delivered to the Trustee; and,
upon the order of such Successor Company instead of the Company and subject to
all the terms, conditions and limitations in this Indenture prescribed, the
Trustee shall authenticate and shall deliver, or cause to be authenticated and
delivered, any Notes which previously shall have been signed and delivered by
the officers of the Company to the Trustee for authentication, and any Notes
which such Successor Company thereafter shall cause to be signed and delivered
to the Trustee for that purpose. All the Notes so issued shall in all respects
have the same legal rank and benefit under this Indenture as the Notes
theretofore or thereafter issued in accordance with the terms of this Indenture
as though all of such Notes had been issued at the date of the execution hereof.
In the event of any such consolidation, merger, conveyance, transfer or lease,
the Person named as the "COMPANY" in the first paragraph of this Indenture or
any successor which shall thereafter have become such in the manner prescribed
in this Article 10 may be dissolved, wound up and liquidated at any time
thereafter and such Person shall be released from its liabilities as obligor and
maker of the Notes and from its obligations under this Indenture.

     In case of any such consolidation, merger, conveyance, transfer or lease,
such changes in phraseology and form (but not in substance) may be made in the
Notes thereafter to be issued as may be appropriate.

     Section 10.03. Officers' Certificate and Opinion of Counsel to be Given
Trustee. No merger, consolidation, sale transfer or lease shall be effective
unless the Trustee shall receive an Officers' Certificate and an Opinion of
Counsel as conclusive evidence that any such consolidation, merger, conveyance,
transfer or lease and any such assumption complies with the provisions of this
Article 10.

                                       62

<PAGE>

                                   ARTICLE 11
                                HOLDERS' MEETINGS

     Section 11.01. Purpose of Meetings. A meeting of Holders may be called at
any time and from time to time pursuant to the provisions of this Article 11 for
any of the following purposes:

     (a) to give any notice to the Company or to the Trustee or to give any
directions to the Trustee permitted under this Indenture, or to consent to the
waiving of any Default or Event of Default hereunder and its consequences, or to
take any other action authorized to be taken by Holders pursuant to any of the
provisions of Article 5;

     (b) to remove the Trustee and nominate a successor trustee pursuant to the
provisions of Article 6;

     (c) to consent to the execution of an indenture or indentures supplemental
hereto pursuant to the provisions of Article 8; or

     (d) to take any other action authorized to be taken by or on behalf of the
holders of any specified aggregate principal amount of the Notes under any other
provision of this Indenture or under applicable law.

     Section 11.02. Call of Meetings by Trustee. The Trustee may at any time
call a meeting of Holders to take any action specified in Section 11.01, to be
held at such time and at such place as the Trustee shall determine. Notice of
every meeting of the Holders, setting forth the time and the place of such
meeting and in general terms the action proposed to be taken at such meeting and
the establishment of any record date pursuant to Section 7.01, shall be mailed
to holders of such Notes at their addresses as they shall appear on the Note
Register. Such notice shall also be mailed to the Company. Such notices shall be
mailed not less than twenty (20) nor more than ninety (90) days prior to the
date fixed for the meeting.

     Any meeting of Holders shall be valid without notice if the Holders of all
Outstanding Notes are present in person or by proxy or if notice is waived
before or after the meeting by the holders of all Notes outstanding, and if the
Company and the Trustee are either present by duly authorized representatives or
have, before or after the meeting, waived notice.

     Section 11.03. Call of Meetings by Company or Holders. In case at any time
the Company, pursuant to a resolution of its Board of Directors, or the holders
of at least 10% in aggregate principal amount of the Notes then outstanding,
shall have requested the Trustee to call a meeting of Holders, by written
request setting forth in reasonable detail the action proposed to be taken at
the meeting, and the Trustee shall not have mailed the notice of such meeting
within twenty (20) days after receipt of such request, then the Company or such

                                       63

<PAGE>

Holders may determine the time and the place for such meeting and may call such
meeting to take any action authorized in Section 11.01, by mailing notice
thereof as provided in Section 11.02.

     Section 11.04. Qualifications for Voting. To be entitled to vote at any
meeting of Holders a Person shall (a) be a Holder of one or more Notes on the
record date pertaining to such meeting or (b) be a Person appointed by an
instrument in writing as proxy by a Holder of one or more Notes. The only
Persons who shall be entitled to be present or to speak at any meeting of
Holders shall be the Persons entitled to vote at such meeting and their counsel
and any representatives of the Trustee and its counsel and any representatives
of the Company and its counsel.

     Section 11.05. Regulations. Notwithstanding any other provisions of this
Indenture, the Trustee may make such reasonable regulations as it may deem
advisable for any meeting of Holders, in regard to proof of the holding of Notes
and of the appointment of proxies, and in regard to the appointment and duties
of inspectors of votes, the submission and examination of proxies, certificates
and other evidence of the right to vote, and such other matters concerning the
conduct of the meeting as it shall think fit.

     The Trustee shall, by an instrument in writing, appoint a temporary
chairman of the meeting, unless the meeting shall have been called by the
Company or by Holders as provided in Section 11.03, in which case the Company or
the Holders calling the meeting, as the case may be, shall in like manner
appoint a temporary chairman. A permanent chairman and a permanent secretary of
the meeting shall be elected by vote of the holders of a majority in principal
amount of the Notes represented at the meeting and entitled to vote at the
meeting.

     At any meeting of Holders, each Holder or proxyholder shall be entitled to
one vote for each $1,000 principal amount of Notes held or represented by it;
provided, however, that no vote shall be cast or counted at any meeting in
respect of any Note challenged as not outstanding and ruled by the chairman of
the meeting to be not outstanding. The chairman of the meeting shall have no
right to vote other than by virtue of Notes held by it or instruments in writing
as aforesaid duly designating it as the proxy to vote on behalf of other
Holders. Any meeting of Holders duly called pursuant to the provisions of
Section 11.02 or Section 11.03 may be adjourned from time to time by the Holders
of a majority of the aggregate principal amount of Notes represented at the
meeting, whether or not constituting a quorum, and the meeting may be held as so
adjourned without further notice.

     Section 11.06. Voting. The vote upon any resolution submitted to any
meeting of Holders shall be by written ballot on which shall be subscribed the
signatures of the Holders or of their representatives by proxy and the principal
amount of the Notes held or represented by them. The permanent chairman of the
meeting shall appoint two inspectors of votes who shall count all votes cast at
the

                                       64

<PAGE>

meeting for or against any resolution and who shall make and file with the
secretary of the meeting their verified written reports in duplicate of all
votes cast at the meeting. A record in duplicate of the proceedings of each
meeting of Holders shall be prepared by the secretary of the meeting and there
shall be attached to said record the original reports of the inspectors of votes
on any vote by ballot taken thereat and affidavits by one or more Persons having
knowledge of the facts setting forth a copy of the notice of the meeting and
showing that said notice was mailed as provided in Section 11.02. The record
shall show the principal amount of the Notes voting in favor of or against any
resolution. The record shall be signed and verified by the affidavits of the
permanent chairman and secretary of the meeting and one of the duplicates shall
be delivered to the Company and the other to the Trustee to be preserved by the
Trustee, the latter to have attached thereto the ballots voted at the meeting.

     Any record so signed and verified shall be conclusive evidence of the
matters therein stated.

     Section 11.07. No Delay of Rights by Meeting. Nothing contained in this
Section 11 shall be deemed or construed to authorize or permit, by reason of any
call of a meeting of Holders or any rights expressly or impliedly conferred
hereunder to make such call, any hindrance or delay in the exercise of any right
or rights conferred upon or reserved to the Trustee or to the Holders under any
of the provisions of this Indenture or of the Notes.

                                   ARTICLE 12
                               CONVERSION OF NOTES

     Section 12.01. Conversion Privilege and Conversion Rate.

     (a) Solely upon the occurrence of any of the conditions described in clause
(i), (ii), and (iii) below, and upon compliance with the provisions of this
Article 12, a Holder shall have the right, at such Holder's option, to convert
all or any portion (if the portion to be converted is $1,000 principal amount or
an integral multiple thereof) of such Note at any time prior to the close of
business on the Scheduled Trading Day immediately preceding March 15, 2014, at a
rate (the "CONVERSION RATE") of 52.4294 shares of Common Stock (subject to
adjustment by the Company as provided in Section 12.04 and Section 12.01(e)) per
$1,000 principal amount of the Note (the "CONVERSION OBLIGATION") under the
circumstances and during the periods set forth below. On and after March 15,
2014, regardless of the conditions described in clause (i), (ii) and (iii)
below, and upon compliance with the provisions of this Article 12, a Holder
shall have the right, at such Holder's option, to convert all or any portion (if
the portion to be converted is $1,000 principal amount or an integral multiple
thereof) of Notes at the applicable Conversion Rate at any time prior to the
close of business on the Scheduled Trading Day immediately preceding the
Maturity Date.

                                       65

<PAGE>

          (i) The Notes shall be convertible prior to March 15, 2014, during the
     five Business Day period immediately after any five consecutive Trading Day
     period (the "MEASUREMENT PERIOD") in which the Trading Price per $1,000
     principal amount of the Notes for each Trading Day of such Measurement
     Period was less than 97% of the product of the Last Reported Sale Price of
     the Common Stock on such Trading Day and the applicable Conversion Rate in
     effect on such Trading Day (the "TRADING PRICE CONDITION") determined as
     set forth below. If a Holder provides the Company with reasonable evidence
     that the Trading Price of the Notes would be less than 97% of the product
     of (a) the then-applicable Conversion Rate of the Notes and (b) the Last
     Reported Sale Price at such time, then the Company shall instruct the
     Trustee to determine the Trading Price of the Notes beginning on the next
     Trading Day and on each successive Trading Day until the date on which the
     Trading Price per Note is greater than or equal to 97% of the product of
     (a) the then-applicable Conversion Rate of the Notes and (b) the Last
     Reported Sale Price (as provided to the Trustee by the Company on each such
     date). If the Trading Price Condition has been met, the Company shall so
     promptly notify the Holders of the Notes. If, at any time after the Trading
     Price Condition has been met, the Trading Price per $1,000 principal amount
     of the Notes is greater than 97% of the product of (a) the then-applicable
     Conversion Rate of the Notes and (b) the Last Reported Sale Price on such
     date, the Company shall so promptly notify the Holders of the Notes, and
     the Trustee shall have no further obligation to determine the Trading Price
     of the Notes unless requested by the Company to do so again in writing
     pursuant to this Section 12.01(a)(i). Notwithstanding the foregoing, if the
     Trustee cannot reasonably obtain at least one bid for $1.0 million
     principal amount of the Notes from a nationally recognized securities
     dealer selected by the Board of Directors of the Company for the purpose of
     the determining the Trading Price on any Trading Day, then the Trading
     Price per $1,000 principal amount of Notes shall be deemed to be less than
     97% of the product of (a) the then-applicable Conversion Rate of the Notes
     and (b) the Last Reported Sale Price on such date (any such determination
     by the Trustee shall be conclusive absent manifest error). Furthermore, if
     the Company does not, when obligated to do so pursuant to this clause (i),
     instruct the Trustee to determine the Trading Price of the Notes, or if the
     Company so instructs the Trustee, but the Trustee does not make such
     determination, then the Trading Price per $1,000 principal amount of the
     Notes shall be deemed to be less than 97% of the product of (a) the
     then-applicable Conversion Rate of the Notes and (b) the Last Reported Sale
     Price on such date.

          (ii) The Notes shall be convertible prior to March 15, 2014, during
     any calendar quarter after the calendar quarter ending September 30, 2007
     (and only during such calendar quarter), if the Last Reported Sale Price of
     the Common Stock for twenty (20) or more Trading Days in a

                                       66

<PAGE>

     period of thirty (30) consecutive Trading Days ending on the last Trading
     Day of the immediately preceding calendar quarter exceeds 120% of the
     applicable Conversion Price in effect on the last Trading Day of the
     immediately preceding calendar quarter.

          (iii) The Notes shall be convertible prior to March 15, 2014, as
     provided in subsections (b), (c) and (d) of this Section 12.01.

     (b) In the event that the Company elects to:

          (i) distribute to all or substantially all holders of Common Stock any
     rights or warrants entitling them, for a period of not more than 60
     calendar days after the record date for such distribution, to subscribe for
     or purchase Common Stock at a price per share less than the average of the
     Last Reported Sale Prices of the Common Stock for the ten Trading Days
     immediately preceding the declaration date of such distribution; or

          (ii) distribute to all or substantially all holders of Common Stock,
     assets (including cash) or debt securities of the Company or rights to
     purchase the Company's securities, which distribution has a per share value
     (as determined by the Board of Directors) exceeding 10% of the Last
     Reported Sale Price of the Common Stock on the Trading Day immediately
     preceding the date of declaration of such distribution,

then, in either case, Holders may surrender the Notes for conversion at any time
on and after the date that the Company provides the notice to such Holders and
the Trustee referred to in the next sentence until the earlier of 5:00 p.m., New
York City time, on the Business Day immediately preceding the Ex-Date for such
distribution or the date the Company announces that such distribution will not
take place. The Company shall notify Holders and the Trustee of any distribution
referred to in either clause (i) or clause (ii) above and of the resulting
conversion right no later than the 45th Scheduled Trading Day prior to the
Ex-Date for such distribution. A Holder may not exercise this right if such
Holder is permitted to participate (as a result of holding the Notes, and at the
same time as holders of the Common Stock participate) in any distribution
referred to in clause (i) or clause (ii) above as if such Holder held a number
of shares of Common Stock equal to the then-applicable Conversion Rate,
multiplied by the principal amount (expressed in thousands) of Notes held by
such Holder, without having to convert its Notes.

     (c) If the Company is a party to a combination, merger, recapitalization,
reclassification, binding share exchange or other similar transaction or sale or
conveyance of all or substantially all of its properties and assets, in each
case pursuant to which the Common Stock would be converted into cash, securities
and/or other property, then the Holders shall have the right to convert Notes at
any time beginning on the effective date of the transaction and until and
including the date that is 45 Scheduled Trading Days after the date that is the
effective date

                                       67

<PAGE>

of such transaction; provided such transaction does not otherwise constitute a
Fundamental Change to which the provisions of subsections (d) of this Section
shall apply. The Company shall notify Holders and the Trustee and issue a Press
Release on the Effective Date of such transaction. The Board of Directors shall
determine the anticipated effective date of the transaction, and such
determination shall be conclusive and binding on the Holders.

     (d) If a Fundamental Change occurs, the Company shall notify each of the
Holders and the Trustee of the occurrence of any such event or transaction on
the Effective Date of such event or transaction or, if later, within three
Trading Days after the Company has knowledge of such event or transaction. A
Holder may surrender Notes for conversion at any time from and after the
Effective Date of such event or transaction until (i) the Fundamental Change
Repurchase Date for such event or transaction or (ii) if there is no such
Fundamental Change Repurchase Date, 45 Scheduled Trading Days following the
Effective Date of such Fundamental Change.

     (e) If a Holder elects to convert Notes in connection with a Make-Whole
Fundamental Change that occurs prior to the Maturity Date, the Conversion Rate
applicable to each $1,000 principal amount of Notes so converted shall be
increased by an additional number of shares of Common Stock (the "ADDITIONAL
SHARES") as described below; provided, however that no increase shall be made in
the case of a Fundamental Change described in clause (2) of the definition of
Fundamental Change if at least 90% of the consideration paid for the Company's
Common Stock (excluding cash payments for fractional shares and cash payments
made pursuant to dissenters' appraisal rights) in such transaction consists of
shares of Common Stock or American Depositary Receipts in respect of shares of
Common Stock traded on any of the New York Stock Exchange, the American Stock
Exchange, the NASDAQ Global Market or the NASDAQ Global Select Market (or any of
their respective successors) (or that will be so traded immediately following
the transaction) and as a result of such transaction or transactions the Notes
become convertible into such shares of such Common Stock or such American
Depositary Receipts (or, if the Company has made the Net Share Settlement
Election, into cash (in respect of the principal portion of the Notes) and such
shares of such Common Stock or such American Depositary Receipts). For purposes
of this subsection (e), a conversion shall be deemed to be "IN CONNECTION WITH"
a Fundamental Change if such conversion occurs on or after the Effective Date of
a Fundamental Change described in clauses (1), (2), (4) or (5) of such
definition, in each case until the related Fundamental Change Repurchase Date
or, if there is no Fundamental Change Repurchase Date, 45 Scheduled Trading Days
following the Effective Date of such Fundamental Change, as applicable
(regardless of whether the provisions of clause (a)(i), (a)(ii), (b) or (c) of
this Section shall apply to such conversion).

          (i) The number of Additional Shares by which the Conversion Rate will
     be increased shall be determined by the Company by reference to the table
     attached as Schedule A hereto, based on the date on which the

                                       68

<PAGE>

     Make-Whole Fundamental Change occurs or becomes effective and the Stock
     Price at the time of such Make-Whole Fundamental Change; provided that for
     purposes of determining the number of Additional Shares, the date that a
     transaction described in clause (1) or (2) of the definition of Fundamental
     Change occurs or becomes effective shall be the earlier of (x) the date on
     which such transaction occurs or becomes effective and (y) the date of the
     first public announcement of such transaction by the Company or the
     counterparty to the transaction; provided further that if the actual Stock
     Price is between two Stock Price amounts in the table or the Effective Date
     is between two Effective Dates in the table, the number of Additional
     Shares shall be determined by a straight-line interpolation between the
     number of Additional Shares set forth for the next higher and next lower
     Stock Price amounts and the two nearest Effective Dates, as applicable,
     based on a 365-day year; provided further that if (1) the Stock Price is
     greater than $50.00 per share of Common Stock (subject to adjustment in the
     same manner as set forth in Section 12.04), no Additional Shares shall be
     added to the Conversion Rate, and (2) the Stock Price is less than $15.57
     per share (subject to adjustment in the same manner as set forth in Section
     12.04), no Additional Shares shall be added to the Conversion Rate.
     Notwithstanding the foregoing, in no event shall the Conversion Rate exceed
     64.2260 per $1,000 principal amount of Notes (subject to adjustment in the
     same manner as set forth in Section 12.04).

          (ii) The Stock Prices set forth in the first row of the tables in
     Schedule A hereto shall be adjusted by the Company as of any date on which
     the Conversion Rate of the Notes is adjusted. The adjusted Stock Prices
     shall equal the Stock Prices applicable immediately prior to such
     adjustment, multiplied by a fraction, the numerator of which is the
     applicable Conversion Rate in effect immediately prior to the adjustment
     giving rise to the Stock Price adjustment and the denominator of which is
     the Conversion Rate as so adjusted. The number of Additional Shares within
     the table shall be adjusted in the same manner as the Conversion Rate as
     set forth in Section 12.04 (other than by operation of an adjustment to the
     Conversion Rate by adding Additional Shares).

     Section 12.02. Exercise of Conversion Privilege.

     (a) Subject to subsection (b) below, the Company shall satisfy the
Conversion Obligation with respect to each $1,000 principal amount of Notes
tendered for conversion in shares of fully paid Common Stock by delivering on
the third VWAP Trading Day after the relevant Conversion Date a number of shares
of Common Stock equal to (i) (A) the aggregate principal amount of Notes to be
converted, divided by (B) 1,000, multiplied by (ii) the Conversion Rate in
effect on the relevant Conversion Date; provided that the Company will deliver
cash in lieu of fractional shares of Common Stock as provided in Section 12.03.

                                       69

<PAGE>

     (b)(i) If the Company has obtained Stockholder Approval to elect Net Share
Settlement of the Notes and the Company irrevocably elects such settlement
method at any time on or prior to the 45th Scheduled Trading Day prior to the
Maturity Date, the Company shall satisfy the Conversion Obligation with respect
to each $1,000 principal amount of Notes tendered for conversion for which the
Conversion Date occurs after the Company issues the Press Release referred to in
subsection (b)(ii) below by delivering, on the third VWAP Trading Day
immediately following the last VWAP Trading Day of the related Observation
Period, cash and shares of Common Stock, if any, equal to the sum of the Daily
Settlement Amounts during the related Observation Period (the "NET SHARE
SETTLEMENT ELECTION"); provided that the Company shall deliver cash in lieu of
fractional shares of Common Stock as provided in Section 12.03. The Daily
Settlement Amounts shall be determined by the Company promptly following the
last VWAP Trading Day of the Observation Period.

     (ii) If the Company makes the Net Share Settlement Election, the Company
will promptly (x) issue a Press Release (and the Net Share Settlement Election
will become effective on the date when such Press Release is issued) and use its
reasonable efforts to post such information on its website or otherwise publicly
disclose this information and (y) provide written notice to the Holders of Notes
and the Trustee, in accordance with Section 1.03 of this Indenture, including
through the facilities of the Depositary.

     (iii) The Company has no obligation to seek Stockholder Approval, and the
Company will not suffer or incur any penalties under the Notes if it does not
seek, or does not obtain, Stockholder Approval.

     (iv) Notwithstanding anything to the contrary in this Indenture, at any
time before the Company makes the Net Share Settlement Election, the Company may
irrevocably renounce its right to the Net Share Settlement Election in
subsection (b)(i) above at any time prior to the 45th Scheduled Trading Day
preceding the Maturity Date. Upon such renouncement, the Company will no longer
have the right to make the Net Share Settlement Election in respect of its
Conversion Obligation and any such attempt shall have no effect. If the Company
renounces its right to the Net Share Settlement Election, the Company will
promptly (x) issue a Press Release (and the renouncement will become effective
on the date when such Press Release is issued) and use its reasonable efforts to
post such information on its website or otherwise publicly disclose this
information and (y) provide written notice to the Holders of Notes and the
Trustee, in accordance with Section 1.03 of this Indenture, including through
the facilities of the Depositary .

     (c) Before any Holder of a Note shall be entitled to convert the same as
set forth above, such Holder shall (1) in the case of a Global Note, comply with
the procedures of the Depositary in effect at that time and, if required, pay
funds equal to interest payable on the next Interest Payment Date as set forth
in subsection (i) of this Section 12.02 and, if required, pay all taxes or
duties, if any,

                                       70

<PAGE>

and (2) in the case of a Note issued in certificated form, (A) complete and
manually sign and deliver an irrevocable written notice to the Conversion Agent
in the form set forth under Section 2.03 (or a facsimile thereof) (a "NOTICE OF
CONVERSION") at the office of the Conversion Agent and shall state in writing
therein the principal amount of Notes to be converted and the name or names
(with addresses) in which such Holder wishes the certificate or certificates for
any shares of Common Stock, if any, to be delivered upon settlement of the
Conversion Obligation to be registered, (B) surrender such Notes, duly endorsed
to the Company or in blank (and accompanied by appropriate endorsement and
transfer documents), at the office of the Conversion Agent, (C) if required, pay
funds equal to interest payable on the next Interest Payment Date to which such
Holder is not entitled as set forth in subsection (i) of this Section 12.02, and
(D) if required, pay all taxes or duties, if any. A Note shall be deemed to have
been converted immediately prior to the close of business on the date (the
"CONVERSION DATE") that the Holder has complied with the requirements set forth
in this subsection (c).

     No Notice of Conversion with respect to any Notes may be tendered by a
Holder thereof if such Holder has also tendered a Fundamental Change Repurchase
Notice and not validly withdrawn such Fundamental Change Repurchase Notice in
accordance with the applicable provisions of Section 14.01.

     If more than one Note shall be surrendered for conversion at one time by
the same Holder, the Conversion Obligation with respect to such Notes, if any,
that shall be payable upon conversion shall be computed on the basis of the
aggregate principal amount of the Notes (or specified portions thereof to the
extent permitted thereby) so surrendered.

     (d) Delivery of the amounts owing in satisfaction of the Conversion
Obligation shall be made by the Company in no event later than the date
specified in subsections (a) or (b), as applicable, of this Section 12.02. The
Company shall make such delivery by paying the cash amount owed, if any, to the
Holder of the Note surrendered for conversion, or such Holder's nominee or
nominees, and/or by issuing, or causing to be issued, and delivering to such
Holder, or such Holder's nominee or nominees, certificates or a book-entry
transfer through the Depositary for the number of full shares of Common Stock,
if any, to which such Holder shall be entitled as part of such Conversion
Obligation (together with any cash in lieu of fractional shares).

     (e) In case any Note shall be surrendered for partial conversion, the
Company shall execute and the Trustee shall, as provided in a Company Order,
authenticate and deliver to or upon the written order of the Holder of the Note
so surrendered, without charge to such Holder, a new Note or Notes in authorized
denominations in an aggregate principal amount equal to the unconverted portion
of the surrendered Notes.

                                       71

<PAGE>

     (f) If a Holder submits a Note for conversion, the Company shall pay all
stamp and other duties, if any, which may be imposed by the United States or any
political subdivision thereof or taxing authority thereof or therein with
respect to the issuance of shares of Common Stock, if any, upon the conversion.
However, the Holder shall pay any such tax which is due because the Holder
requests any shares of Common Stock to be issued in a name other than the
Holder's name. The Company may refuse to deliver the certificates representing
the shares of Common Stock being issued in a name other than the Holder's name
until the Company receives a sum sufficient to pay any tax which will be due
because the shares are to be issued in a name other than the Holder's name.
Nothing herein shall preclude any tax withholding required by law or
regulations.

     (g) Except as provided in Section 12.04, no adjustment shall be made for
dividends on any shares issued upon the conversion of any Note as provided in
this Article 12.

     (h) Upon the conversion of an interest in a Global Note, the Trustee, or
the Custodian at the direction of the Trustee, shall make a notation on such
Global Note as to the reduction in the principal amount represented thereby. The
Company shall notify the Trustee in writing of any conversion of Notes effected
through any Conversion Agent other than the Trustee.

     (i) Upon conversion, a Holder shall not receive any separate cash payment
for accrued and unpaid interest except as set forth below. The Company's
settlement of the Conversion Obligation as described above shall be deemed to
satisfy its obligation to pay the principal amount of the Note and accrued and
unpaid interest to, but not including, the Conversion Date. As a result, accrued
and unpaid interest to, but not including, the Conversion Date shall be deemed
to be paid in full rather than cancelled, extinguished or forfeited.
Notwithstanding the preceding sentence, if Notes are converted after 5:00 p.m.,
New York City time, on a Record Date, Holders of such Notes as of 5:00 p.m., New
York City time, on the Record Date shall receive the interest payable on such
Notes on the corresponding Interest Payment Date notwithstanding the conversion.
Notes surrendered for conversion during the period from 5:00 p.m., New York City
time, on any Regular Record Date to 9:00 a.m., New York City time, on the
corresponding Interest Payment Date must be accompanied by payment of an amount
equal to the interest payable on the Notes so converted; provided, however, that
no such payment need be made (i) if the Company has specified a Fundamental
Change Purchase Date that is after a Record Date and on or prior to the
corresponding Interest Payment Date; (ii) to the extent of any overdue interest
existing at the time of conversion with respect to such Note; or (iii) with
respect to any Conversion Date that occurs during the period from the close of
business on the Regular Record Date immediately preceding the Maturity Date to
the Maturity Date. Except as described above, no payment or adjustment shall be
made for accrued interest on converted Notes.

     Section 12.03. Fractions of Shares.

                                       72

<PAGE>

     No fractional shares of Common Stock shall be issued upon conversion of any
Note or Notes. If more than one Note shall be surrendered for conversion at one
time by the same Holder, the number of full shares which shall be issuable upon
conversion thereof shall be computed on the basis of the aggregate principal
amount of the Notes (or specified portions thereof) so surrendered. Instead of
any fractional share of Common Stock that would otherwise be issuable upon
conversion of any Note or Notes (or specified portions thereof), the Company
shall calculate and pay a cash adjustment in respect of such fraction
(calculated to the nearest 1/100th of a share) based on the Last Reported Sale
Price of the Common Stock on the Conversion Date (or, if the Company has made
the Net Share Settlement Election, in an amount equal to the same fraction of
the Daily VWAP of the Common Stock on the last VWAP Trading Day of the relevant
Observation Period).

                  [Remainder of page intentionally left blank]

                                       73
<PAGE>

     Section 12.04. Adjustment of Conversion Rate.

     The Conversion Rate shall be adjusted from time to time by the Company as
follows; provided that the Company shall not make any adjustments to the
Conversion Rate if Holders of the Notes participate (as a result of holding the
Notes, and at the same time as holders of the Common Stock participate) in any
the transactions described below as if such Holders held a number of shares of
Common Stock equal to the then-applicable Conversion Rate, multiplied by the
principal amount (expressed in thousands) of Notes held by such Holders, without
having to convert their Notes:

     (a) In case the Company shall issue shares of Common Stock as a dividend or
distribution on shares of the Common Stock, or shall effect a share split or
share combination, the Conversion Rate shall be adjusted based on the following
formula:

                                                 OS'
                             CR' = CR(0) x ---------------
                                                OS(0)

     where,

     CR(0) = the Conversion Rate in effect immediately prior to the Stock Record
     Date for such dividend or distribution or immediately prior to the
     effective date of such share split or combination, as the case may be;

     CR' = the Conversion Rate in effect immediately after the Stock Record Date
     for such dividend or distribution or immediately after the effective date
     of such share split or combination, as the case may be;

     OS(0) = the number of shares of Common Stock outstanding immediately prior
     to the Stock Record Date for such dividend or distribution or immediately
     prior to the effective date of such share split or combination, as the case
     may be; and

     OS' = the number of shares of Common Stock outstanding as of the Stock
     Record Date for such dividend or distribution and immediately after giving
     effect to such dividend or distribution or immediately after the effective
     date of such share split or combination, as the case may be.

     Such adjustment shall become effective immediately after 9:00 a.m., New
York City time, on the Stock Record Date fixed for such dividend or
distribution, or the effective date for such share split or share combination.
If any dividend or distribution of the type described in this Section 12.04(a)
is declared but not so paid or made, or the outstanding shares of Common Stock
are not split or combined, as the case may be, the Conversion Rate shall be
immediately readjusted, effective as of the date the Board of Directors
determines not to pay such dividend or distribution, or split or combine the
outstanding shares of

                                       74

<PAGE>

Common Stock, as the case may be, to the Conversion Rate that would then be in
effect if such dividend, distribution, share split or share combination had not
been declared.

     (b) In case the Company shall distribute to all or substantially all
holders of its outstanding shares of Common Stock any rights or warrants
entitling them (for a period expiring within 60 calendar days after the Stock
Record Date for such distribution) to subscribe for or purchase shares of Common
Stock at a price per share less than the average of Last Reported Sale Prices of
the Common Stock on the ten Trading Days immediately preceding the declaration
date of such distribution, the Conversion Rate shall be adjusted based on the
following formula:

                                              OS(0) + X
                             CR' = CR(0) x ---------------
                                              OS(0) + Y

     where,

     CR(0) = the Conversion Rate in effect immediately prior to the Stock Record
     Date for such distribution;

     CR' = the Conversion Rate in effect immediately after the Stock Record Date
     for such distribution;

     OS(0) = the number of shares of Common Stock outstanding immediately prior
     to the Stock Record Date for such distribution;

     X = the total number of shares of Common Stock issuable pursuant to such
     rights or warrants; and

     Y = the number of shares of Common Stock equal to the aggregate price
     payable to exercise such rights or warrants divided by the average of the
     Last Reported Sale Prices of Common Stock over the 10 consecutive Trading
     Day period ending on the Trading Day immediately preceding the Ex-Date for
     such distribution.

     Such adjustment shall be successively made whenever any such rights or
warrants are distributed and shall become effective immediately after the
opening of business on the Stock Record Date for such distribution. To the
extent that shares of the Common Stock are not delivered after the expiration of
such rights or warrants, the Conversion Rate shall be readjusted to the
Conversion Rate that would then be in effect had the adjustments made upon the
issuance of such rights or warrants been made on the basis of delivery of only
the number of shares of Common Stock actually delivered. If such rights or
warrants are not so issued, the Conversion Rate shall again be adjusted to be
the Conversion Rate that would then be in effect if such Stock Record Date for
such distribution had not been fixed.

                                       75

<PAGE>

     In determining whether any rights or warrants entitle the holders to
subscribe for or purchase shares of Common Stock at less than such Last Reported
Sale Price, and in determining the aggregate offering price of such shares of
Common Stock, there shall be taken into account any consideration received by
the Company for such rights or warrants and any amount payable on exercise or
conversion thereof, the value of such consideration, if other than cash, to be
determined by the Board of Directors.

     (c) In case the Company shall, by dividend or otherwise, distribute to all
or substantially all holders of its Common Stock shares of any class of Capital
Stock of the Company (other than Common Stock as covered by subsection (a) of
this Section), evidences of its indebtedness or other assets or property of the
Company (including securities, but excluding dividends or distributions covered
by subsection (a) or (b) of this Section 12.04, dividends or distributions paid
exclusively in cash referred to in clause (d) below and distributions described
below in this subsection (c) with respect to Spin-Offs) (any of such shares of
Capital Stock, indebtedness, or other asset or property hereinafter in this
subsection (c) called the "DISTRIBUTED PROPERTY"), then, in each such case the
Conversion Rate shall be adjusted based on the following formula:

                                             SP(0)
                          CR' = CR(0) x ---------------
                                          SP(0) - FMV

     where,

     CR(0) = the Conversion Rate in effect immediately prior to the Stock Record
     Date for such distribution;

     CR' = the Conversion Rate in effect immediately after the Stock Record Date
     for such distribution;

     SP(0) = the average of the Last Reported Sale Prices of Common Stock over
     the 10 consecutive Trading Day period ending on the Trading Day immediately
     preceding the Ex-Date for such distribution; and

     FMV = the fair market value on the Ex-Date for such distribution of the
     shares of Capital Stock, evidences of indebtedness, assets or property
     distributed with respect to each outstanding share of Common Stock, as
     determined by the Board of Directors or a committee thereof.

     Such adjustment shall become effective immediately prior to the opening of
business on the Stock Record Date for such distribution; provided that if "FMV"
as set forth above is equal to or greater than "SP0" as set forth above, in lieu
of the foregoing adjustment, adequate provision shall be made so that each
Holder of Notes has the right to receive upon conversion, for each $1,000
principal amount of Notes, the amount of Distributed Property such Holder would
have received had such Holder owned a number of shares of Common Stock

                                       76

<PAGE>

equal to the Conversion Rate on the Stock Record Date for such distribution. If
such distribution is not so paid or made, the Conversion Rate shall again be
adjusted to be the Conversion Rate that would then be in effect if such dividend
or distribution had not been declared, and any provision made by the Company to
provide for receipt of the Distributed Property upon conversion of Notes in lieu
of an adjustment to the Conversion Rate shall no longer be required. If the
Board of Directors determines "FMV" for purposes of this Section 12.04(c) by
reference to the actual or when issued trading market for any securities, it
must in doing so consider the prices in such market over the same period used in
computing the Last Reported Sale Prices of the Common Stock over the ten
consecutive Trading Day period ending on the Trading Day immediately preceding
the Ex-Date for such distribution.

     With respect to an adjustment pursuant to this subsection (c) where there
has been a payment of a dividend or other distribution on the Common Stock or
shares of Capital Stock of any class or series, or similar equity interest, of
or relating to a Subsidiary or other business unit (a "SPIN-OFF"), the
Conversion Rate in effect immediately before 5:00 p.m., New York City time, on
the 10th Trading Day immediately following, and including, the effective date of
the Spin-Off shall be increased based on the following formula:

                                         FMV(0) + MP(0)
                          CR' = CR(0) x ---------------
                                             MP(0)

     where,

     CR(0) = the Conversion Rate in effect immediately prior to the 10th Trading
     Day immediately following the effective date of the Spin-Off;

     CR' = the Conversion Rate in effect immediately after the 10th Trading Day
     immediately following the effective date of the Spin-Off;

     FMV(0) = the average of the Last Reported Sale Prices of the Capital Stock
     or similar equity interest distributed to holders of Common Stock
     applicable to one share of Common Stock over the first 10 consecutive
     Trading Day period immediately following, and including, the effective date
     of the Spin-Off; and

     MP(0) = the average of the Last Reported Sale Prices of the Common Stock
     over the first 10 consecutive Trading Day period immediately following, and
     including, the effective date of the Spin-Off.

     Such adjustment shall occur on the 10th Trading Day from, and including,
the effective date of the Spin-Off; provided that in respect of any conversion
within the 10 Trading Days immediately following, and including, the effective
date of any Spin-Off, references with respect to the Spin-Off to 10 Trading Days
shall be deemed replaced with such lesser number of Trading Days as have

                                       77

<PAGE>

elapsed between the effective date of such Spin-Off and the Conversion Date in
determining the applicable Conversion Rate; provided further that in respect of
any conversion within the first four Trading Days following the effective date
of such Spin-Off (if such Trading Days are also VWAP Trading Days), references
to 10 Trading Days shall be deemed replaced with four (4) Trading Days.

     Rights or warrants distributed by the Company to all holders of Common
Stock, entitling the holders thereof to subscribe for or purchase shares of the
Company's Capital Stock, including Common Stock (either initially or under
certain circumstances), which rights or warrants, until the occurrence of a
specified event or events ("TRIGGER EVENT"): (i) are deemed to be transferred
with such shares of Common Stock; (ii) are not exercisable; and (iii) are also
issued in respect of future issuances of Common Stock, shall be deemed not to
have been distributed for purposes of this Section 12.04 (and no adjustment to
the Conversion Rate under this Section 12.04 shall be required) until the
occurrence of the earliest Trigger Event, whereupon such rights and warrants
shall be deemed to have been distributed and an appropriate adjustment (if any
is required) to the Conversion Rate shall be made under this subsection (c). If
any such rights or warrants are subject to events, upon the occurrence of which
such rights or warrants become exercisable to purchase different securities,
evidences of indebtedness or other assets, then the date of the occurrence of
any and each such event shall be deemed to be the date of distribution and
record date with respect to new rights or warrants with such rights (and a
termination or expiration of the existing rights or warrants without exercise by
any of the holders thereof). In addition, in the event of any distribution (or
deemed distribution) of rights or warrants, or any Trigger Event or other event
(of the type described in the preceding sentence) with respect thereto that was
counted for purposes of calculating a distribution amount for which an
adjustment to the Conversion Rate under this Section 12.04 was made, (1) in the
case of any such rights or warrants that shall all have been redeemed or
repurchased without exercise by any holders thereof, the Conversion Rate shall
be readjusted upon such final redemption or repurchase to give effect to such
distribution or Trigger Event, as the case may be, as though it were a cash
distribution, equal to the per share redemption or repurchase price received by
a holder or holders of Common Stock with respect to such rights or warrants
(assuming such holder had retained such rights or warrants), made to all holders
of Common Stock as of the date of such redemption or repurchase, and (2) in the
case of such rights or warrants that shall have expired or been terminated
without exercise by any holders thereof, the Conversion Rate shall be readjusted
as if such rights and warrants had not been issued.

     For purposes of this subsection (c) and subsections (a) and (b) of this
Section 12.04, any dividend or distribution to which this subsection (c) is
applicable that also includes shares of Common Stock to which subsection (a) of
this Section 12.04 applies or rights or warrants to subscribe for or purchase
shares of Common Stock to which subsection (a) or (b) of this Section 12.04
applies (or

                                       78

<PAGE>

both), shall be deemed instead to be (1) a dividend or distribution of the
evidences of indebtedness, assets or shares of Capital Stock other than such
shares of Common Stock or rights or warrants, to which this subsection (c)
applies (and any Conversion Rate adjustment required by this subsection (c) with
respect to such dividend or distribution shall then be made) immediately
followed by (2) a dividend or distribution of such shares of Common Stock or
such rights or warrants (and any further Conversion Rate adjustment required by
subsections (a) and (b) of this Section 12.04 with respect to such dividend or
distribution shall then be made), except (A) the Stock Record Date of the
dividend or distribution under this subsection (c) shall be substituted as "the
Stock Record Date" within the meaning of subsection (a) and subsection (b) and
(B) any shares of Common Stock included in such dividend or distribution shall
not be deemed "outstanding immediately prior to the Stock Record Date for such
dividend or distribution or immediately prior to the effective date of such
share split or combination, as the case may be" within the meaning of subsection
(a) or "outstanding immediately prior to the Stock Record Date for such
distribution" within the meaning of subsection (b).

     (d) In case the Company shall pay dividends or make distributions
consisting exclusively of cash to all or substantially all holders of its Common
Stock, the Conversion Rate shall be adjusted based on the following formula:

                                             SP(0)
                          CR' = CR(0) x ---------------
                                           SP(0) - C

     where,

     CR(0) = the Conversion Rate in effect immediately prior to the Stock Record
     Date for such distribution;

     CR' = the Conversion Rate in effect immediately after the Stock Record Date
     for such distribution;

     SP(0) = the Last Reported Sale Price of Common Stock on the Trading Day
     immediately preceding the Ex-Date for such distribution;

     C = the amount in cash per share the Company distributes to holders of
     Common Stock in such distribution.

     Such adjustment shall become effective immediately after the opening of
business on the Stock Record Date for such dividend or distribution; provided
that if the portion of the cash so distributed applicable to one share of the
Common Stock is equal to or greater than SP0 as set forth above, in lieu of the
foregoing adjustment, adequate provision shall be made so that each Holder of
Notes shall receive upon conversion, for each $1,000 principal amount of Notes,
the amount of cash such Holder would have received had such Holder owned a
number of shares equal to the Conversion Rate on the Stock Record Date for such

                                       79

<PAGE>

distribution. If such dividend or distribution is not so paid or made, the
Conversion Rate shall again be adjusted to be the Conversion Rate that would
then be in effect if such dividend or distribution had not been declared, and
any provision made by the Company to provide for receipt of the Distributed
Property upon conversion of Notes in lieu of an adjustment to the Conversion
Rate shall no longer be required.

     For the avoidance of doubt, for purposes of this subsection (d), in the
event of any reclassification of the Common Stock, as a result of which the
Notes become convertible into more than one class of Common Stock, if an
adjustment to the Conversion Rate is required pursuant to this subsection (d),
references in this Section 12.04 to one share of Common Stock or Last Reported
Sale Price of one share of Common Stock shall be deemed to refer to a unit or to
the price of a unit consisting of the number of shares of each class of Common
Stock into which the Notes are then convertible equal to the numbers of shares
of such class issued in respect of one share of Common Stock in such
reclassification. The above provisions of this paragraph shall similarly apply
to successive reclassifications.

     (e) In case the Company or any of its Subsidiaries make a payment in
respect of a tender offer or exchange offer for all or any portion of the Common
Stock, to the extent that the cash and value of any other consideration included
in the payment per share of Common Stock exceeds the Last Reported Sale Price of
the Common Stock on the Trading Day next succeeding the last date on which
tenders or exchanges may be made pursuant to such tender or exchange offer (as
it may be amended), the Conversion Rate shall be increased based on the
following formula:

                                       AC + (SP' x OS')
                        CR' = CR(0) x ------------------
                                          OS(0) x SP'

     where,

     CR(0) = the Conversion Rate in effect on the date such tender or exchange
     offer expires;

     CR' = the Conversion Rate in effect on the day next succeeding the date
     such tender or exchange offer expires;

     AC = the aggregate value of all cash and any other consideration as
     determined by the Board of Directors or a committee thereof paid or payable
     for shares purchased in such tender or exchange offer;

     OS(0) = the number of shares of Common Stock outstanding immediately prior
     to the date such tender or exchange offer expires;

                                       80

<PAGE>

     OS' = the number of shares of Common Stock outstanding immediately after
     the date such tender or exchange offer expires (after giving effect to such
     tender offer or exchange offer); and

     SP' = the Last Reported Sale Price of Common Stock on the Trading Day next
     succeeding the date such tender or exchange offer expires.

     Such adjustment shall become effective immediately after close of business
on the Trading Day next succeeding the date such tender or exchange offer
expires. If the Company or its Subsidiary is obligated to purchase shares of
Common Stock pursuant to any such tender or exchange offer, but the Company or
its Subsidiary is permanently prevented by applicable law from effecting all or
any such purchases or all or any portion of such purchases are rescinded, the
Conversion Rate shall again be adjusted to be the Conversion Rate that would
then be in effect if such tender or exchange offer had not been made or had only
been made in respect of the purchases that had been effected.

     (f) If the Company or any of its Subsidiaries make a payment in respect of
a repurchase of the Common Stock, to the extent that the cash and value of any
other consideration included in the payment per share of the Common Stock
exceeds the "CURRENT MARKET PRICE" (as defined below) of the Common Stock (such
excess, the "REPURCHASE PREMIUM"), and such repurchase, together with all other
repurchases of the Common Stock by the Company or one of its Subsidiaries
involving a Repurchase Premium concluded within the preceding 12 months, not
triggering a Conversion Rate adjustment (except for repurchases of the Common
Stock effected by the Company or its agents in conformity with Rule 10b-18 under
the Exchange Act), results in the payment by us of an aggregate consideration
exceeding an amount equal to 10% of our "MARKET CAPITALIZATION" (as defined
below), the Conversion Rate will be increased based on the following formula:

                                              FMV
                        CR' = CR(0) x ------------------
                                         FMV - (RP/OS)

     CR(0) = the Conversion Rate in effect immediately prior to the fifth
     Trading Day immediately following the date of the repurchase triggering the
     adjustment under this clause (f);

     CR' = the Conversion Rate in effect immediately after the scheduled close
     of trading on the fifth Trading Day immediately following the date of the
     repurchase triggering the adjustment under this clause (f);

     FMV = the average of the Last Reported Sale Prices of the Common Stock for
     the five consecutive Trading Days beginning on the Trading Day following
     the date of the repurchase triggering the adjustment under this clause (f)
     (the "FAIR MARKET VALUE");

                                       81

<PAGE>

     RP = the aggregate amount of all of the repurchase premiums paid in
     connection with such repurchases; and

     OS = the number of shares of outstanding Common Stock on the day following
     the date of the repurchase triggering the adjustment under this clause (f),
     as determined by our board of directors.

     "MARKET CAPITALIZATION" means the fair market value of the Common Stock,
multiplied by the number of shares of the Common Stock then outstanding on the
date of the repurchase triggering the adjustment immediately prior to such
repurchase.

     "CURRENT MARKET PRICE" means the average of the Last Reported Closing Sale
Prices of the Common Stock for the ten consecutive Trading Days ending on the
date of the repurchase triggering the adjustment.

     The adjustment to the conversion rate under this clause (f) will occur
immediately after the scheduled close of trading on the fifth Trading Day from,
and including, the date of the repurchase triggering the adjustment; provided
that in respect of any conversion within the five Trading Days immediately
following, and including, the date of the repurchase triggering the adjustment,
references with respect to five Trading Days shall be deemed replaced with such
lesser number of Trading Days as have elapsed between the date of the repurchase
triggering the adjustment and the Conversion Date in determining the applicable
Conversion Rate. If a payment would cause an adjustment to the conversion rate
under both clause (e) and (f), the provisions of clause (f) shall control.

     No adjustment to the Conversion Rate shall be made if the application of
any of the foregoing formulas (other than in connection with a share
combination) would result in a decrease in the Conversion Rate.

     For purposes of this Section 12.04 the term "STOCK RECORD DATE" shall mean,
with respect to any dividend, distribution or other transaction or event in
which the holders of Common Stock have the right to receive any cash, securities
or other property or in which the Common Stock (or other applicable security) is
exchanged for or converted into any combination of cash, securities or other
property, the date fixed for determination of shareholders entitled to receive
such cash, securities or other property (whether such date is fixed by the Board
of Directors or by statute, contract or otherwise).

     Notwithstanding anything to the contrary, if the Company has obtained
Stockholder Approval to make the Net Share Settlement Election and the Company
has irrevocably made the Net Share Settlement Election at any time on or prior
to the 45th Scheduled Trading Day preceding the Maturity Date, then each
reference to "STOCK RECORD DATE" in this Section 12.04 shall be deemed as a
reference to "EX-DATE", effective on the date on which the Net Share Settlement

                                       82

<PAGE>

Election becomes effective pursuant to Section 12.02(b)(i) and Section
12.02(b)(ii).

     (g) In addition to any increases to the Conversion Rate required by
subsections (a), (b), (c), (d), (e) and (f) of this Section 12.04, and to the
extent permitted by applicable law and the rules of the NASDAQ Global Select
Market or any other securities exchange on which the Common Stock is then
listed, the Company from time to time may increase the Conversion Rate by any
amount for a period of at least 20 calendar days if the Board of Directors
determines that such increase would be in the Company's best interest. Whenever
the Conversion Rate is increased pursuant to the preceding sentence, the Company
shall mail to the Holder of each Note at his last address appearing on the
Register provided for in Section 9.01 and the Trustee a notice of the increase
at least 15 calendar days prior to the date the increased Conversion Rate takes
effect, and such notice shall state the increased Conversion Rate and the period
during which it will be in effect. In addition, the Company may also (but is not
required to) increase the Conversion Rate to avoid or diminish any income tax to
holders of Common Stock or rights to purchase Common Stock in connection with
any dividend or distribution of shares (or rights to acquire shares) or similar
event.

     (h) Without limiting the foregoing, no adjustment to the Conversion Rate
will be made:

          (i) upon the issuance of any shares of Common Stock pursuant to any
     present or future plan providing for the reinvestment of dividends or
     interest payable on securities of the Company and the investment of
     additional optional amounts in shares of Common Stock under any plan;

          (ii) upon the issuance of any shares of Common Stock or options or
     rights to purchase shares of Common Stock pursuant to any present or future
     employee, director or consultant benefit plan or program of or assumed by
     the Company or any of its Subsidiaries;

          (iii) upon the issuance of any shares of Common Stock pursuant to any
     option, warrant, right, or exercisable, exchangeable or convertible
     security not described in clause (ii) above and outstanding as of the date
     of this Indenture;

          (iv) upon exercise of the Company's right to repurchase Common Stock
     pursuant to its Termination and Repurchase Agreement dated June 11, 2007
     with Boston Scientific Corporation;

          (v) for a change in the par value of the Common Stock; or

          (vi) for accrued and unpaid Interest.

                                       83

<PAGE>

     (i) All calculations and other determinations under this Article 12 shall
be made by the Company and shall be made to the nearest cent or to the nearest
one-ten thousandth (1/10,000) of a share, as the case may be. If the effective
date of any Adjustment Event occurs during an Observation Period for any Notes,
then the Company will make proportional adjustments to the number of deliverable
shares of Common Stock for each VWAP Trading Day during the portion of the
Observation Period preceding the effective date of such Adjustment Event.

     (j) In any case in which this Section 12.04 provides that an adjustment
shall become effective immediately after (1) the Stock Record Date for an event
or (2) the last date on which tenders or exchanges may be made pursuant to any
tender or exchange offer pursuant to subsection (e) of this Section (each an
"ADJUSTMENT DETERMINATION DATE"), the Company may elect to defer until the
occurrence of the applicable Adjustment Event (as hereinafter defined) (x)
issuing to the Holder of any Note converted after such Adjustment Determination
Date and before the occurrence of such Adjustment Event, the additional shares
of Common Stock or other securities (or, if the Company has obtained Stockholder
Approval to make the Net Share Settlement Election and has irrevocably made the
Net Share Settlement Election, cash and, if applicable, shares of Common Stock
or other securities) issuable upon such conversion by reason of the adjustment
required by such Adjustment Event over and above the amounts deliverable upon
such conversion before giving effect to such adjustment and (y) paying to such
Holder any amount in cash in lieu of any fraction pursuant to Section 12.03. For
purposes of this subsection (i), the term "ADJUSTMENT EVENT" shall mean:

          (i) in any case referred to in clause (1) hereof, the date any
     dividend or distribution of Common Stock, shares of Capital Stock,
     evidences of indebtedness, other assets or property or cash is paid or
     made, the effective date of any share split or combination or the date of
     expiration of any rights or warrants, and

          (ii) in any case referred to in clause (2) hereof, the date a sale or
     exchange of Common Stock pursuant to such tender or exchange offer is
     consummated and becomes irrevocable.

     (k) For purposes of this Section 12.04, the number of shares of Common
Stock at any time outstanding shall not include shares held in the treasury of
the Company but shall include shares issuable in respect of scrip certificates
issued in lieu of fractions of shares of Common Stock.

     (l) For the avoidance of doubt, if a Holder converts Notes prior to the
Effective Date of a Make-Whole Fundamental Change, and the Fundamental Change
does not occur, the Holder shall not be entitled to Additional Shares in
connection with such conversion.

     (m) With respect to a conversion of Notes pursuant to this Article 12, at
and after the close of business on the Conversion Date (or, if the Company has

                                       84

<PAGE>

obtained Stockholder Approval to make the Net Share Settlement Election and has
irrevocably made the Net Share Settlement Election, the last VWAP Trading Day of
the related Observation Period) (each such day the "RELEVANT DATE"), the Person
in whose name any certificate representing any shares of Common Stock issuable
upon such conversion is registered shall be treated as a stockholder of record
of the Company on such Relevant Date; provided, however, that if any such shares
of Common Stock constitute Additional Shares, then the Relevant Date with
respect to such shares that constitute Additional Shares shall instead be deemed
to be the later of (i) the Conversion Date (or, if the Company has made the Net
Share Settlement Election, last VWAP Trading Day of the related Observation
Period) and (ii) the Effective Date of the Fundamental Change resulting in the
Additional Shares. On and after the Conversion Date with respect to a conversion
of Notes pursuant hereto, all rights of the Holders of such Notes shall
terminate, other than the right to receive the consideration deliverable upon
conversion of such Notes as provided herein. A Holder of a Note is not entitled,
as such, to any rights of a holder of Common Stock until, if such Holder
converts such Note and is entitled pursuant hereto to receive shares of Common
Stock in respect of such conversion, the close of business on the Relevant Date
or respective Relevant Dates, as the case may be, with respect to such
conversion.

     (n) Whenever the Company has obtained Stockholder Approval to make the Net
Share Settlement Election and has irrevocably made the Net Share Settlement
Election and any provision of this Article 12 requires a calculation of Last
Reported Sale Prices or Daily VWAP over a span of multiple days, the Company
shall make appropriate adjustments to the Daily Settlement Amount (determined in
good faith by the Board of Directors) to account for any adjustment to the
Conversion Rate that becomes effective, or any event requiring an adjustment to
the Conversion Rate where the Ex-Date of the event occurs, at any time during
the period from which such calculation is to be calculated; provided that such
adjustments shall only be made to the Daily Settlement Amounts relating to days
prior to the date that the adjustment to the Conversion Rate becomes effective.

     (o) For purposes of this Section 12.04, the number of shares of Common
Stock outstanding at any time shall not include shares held in the treasury of
the Company.

     Section 12.05. Notice of Adjustments of Conversion Rate.

     Whenever the Conversion Rate is adjusted as herein provided:

     (a) the Company shall compute the adjusted Conversion Rate in accordance
with Section 12.04 and shall prepare a certificate signed by the Chief Financial
Officer of the Company setting forth the adjusted Conversion Rate and showing in
reasonable detail the facts upon which such adjustment is based, and such
certificate shall promptly be filed with the Trustee and with each Conversion
Agent (if other than the Trustee); and

                                       85

<PAGE>

     (b) upon each such adjustment, a notice stating that the Conversion Rate
has been adjusted and setting forth the adjusted Conversion Rate shall be
required, such notice shall be provided by the Company to all Holders in
accordance with Section 1.03.

     Neither the Trustee nor any Conversion Agent shall be under any duty or
responsibility with respect to any such certificate or the information and
calculations contained therein, except to exhibit the same to any Holder of
Notes desiring inspection thereof at its office during normal business hours.

     Section 12.06. Company to Reserve Common Stock.

     The Company shall at all times reserve and keep available, free from
preemptive rights, out of its authorized but unissued Common Stock, for the
purpose of effecting the conversion of Notes, the full number of shares of
Common Stock then issuable upon the conversion of all Outstanding Notes.

     Section 12.07. Taxes on Conversions.

     Except as provided in the next sentence, the Company shall pay all
documentary, stamp or similar issue or transfer tax due that may be payable in
respect of the issue or delivery of shares of Common Stock on conversion of
Notes pursuant hereto. The Company shall not, however, be required to pay any
tax or duty that may be payable in respect of (i) income of the Holder, or (ii)
any transfer involved in the issue and delivery of shares of Common Stock in a
name other than that of the Holder of the Note or Notes to be converted, and no
such issue or delivery shall be made unless and until the Person requesting such
issue has paid to the Company the amount of any such tax or duty, or has
established to the satisfaction of the Company that such tax or duty has been
paid.

     Section 12.08. Certain Covenants.

     Before taking any action which would cause an adjustment reducing the
Conversion Rate below the then par value, if any, of the shares of Common Stock
issuable upon conversion of the Notes, the Company shall take all corporate
action which it reasonably determines may be necessary in order that the Company
may validly and legally issue shares of such Common Stock at such adjusted
Conversion Rate.

     The Company covenants that all shares of Common Stock issued upon
conversion of Notes shall be fully paid and non-assessable by the Company and
free from all taxes, liens and charges with respect to the issue thereof.

     The Company further covenants that if at any time the Common Stock shall be
listed for trading on any other national securities exchange the Company shall,
if permitted and required by the rules of such exchange, list and keep listed,

                                       86

<PAGE>

so long as the Common Stock shall be so listed on such exchange, all Common
Stock issuable upon conversion of the Notes.

     Section 12.09. Cancellation of Converted Notes.

     All Notes surrendered for the purpose of payment, repurchase, conversion or
registration of transfer, shall, if surrendered to the Company or any Paying
Agent or any Note Registrar, be surrendered to the Trustee and promptly canceled
by it, or, if surrendered to the Trustee, shall be promptly canceled by it, and
no Notes shall be issued in lieu thereof except as expressly permitted by any of
the provisions of this Indenture. The Trustee shall dispose of canceled Notes in
accordance with its customary procedures and, after such disposal, shall deliver
a certificate of such disposal to the Company, at the Company's written request.
If the Company shall acquire any of the Notes, such acquisition shall not
operate as satisfaction of the debt represented by such Notes unless and until
the same are delivered to the Trustee for cancellation.

     Section 12.10. Provision in Case of Effect of Reclassification,
Consolidation, Merger or Sale.

     If any of the following events occur, namely (i) any Fundamental Change
described in clause (2) of the definition of Fundamental Change, (ii) any
reclassification or change of the outstanding shares of Common Stock (other than
a change in par value, or from par value to no par value, or from no par value
to par value, or as a result of a split, subdivision or combination), (iii) any
consolidation, binding share exchange, recapitalization, reclassification,
merger, combination or other similar event of the Company with another Person or
(iv) any sale, transfer or conveyance of all or substantially all of the
property and assets of the Company to any other Person, in each case as a result
of which holders of Common Stock shall be entitled to receive cash, securities
or other property or assets with respect to or in exchange for such Common Stock
(any such event described in clauses (i) through (iv) a "MERGER EVENT"), then:

     (a) the Company or the successor or purchasing Person, as the case may be,
shall execute with the Trustee a supplemental indenture (which shall comply with
the Trust Indenture Act as in force at the date of execution of such
supplemental indenture if such supplemental indenture is then required to so
comply) permitted under Section 8.01(i) providing for the conversion and
settlement of the Notes as set forth in this Indenture. Such supplemental
indenture shall provide for adjustments which shall be as nearly equivalent as
may be practicable to the adjustments provided for in this Article 12 and the
Trustee may conclusively rely on the determination by the Company of the
equivalency of such adjustments. If, in the case of any Merger Event, the
Reference Property includes shares of stock or other securities and assets of a
company other than the successor or purchasing company, as the case may be, in
such change of control, consolidation, binding share exchange, recapitalization,
reclassification, merger, combination, sale, transfer or conveyance or
Fundamental Change described in

                                       87

<PAGE>

clause (2) of the definition of Fundamental Change, then such supplemental
indenture shall also be executed by such other company and shall contain such
additional provisions to protect the interests of the Holders of the Notes as
the Board of Directors shall reasonably consider necessary by reason of the
foregoing, including to the extent required by the Board of Directors and
practicable the provisions providing for the repurchase rights set forth in
Article 14.

     In the event a supplemental indenture is executed pursuant to this Section
12.10, the Company shall promptly file with the Trustee an Officers' Certificate
briefly stating the reasons therefore, the kind or amount of cash, securities or
property or assets that will constitute the Reference Property after any such
Merger Event, any adjustment to be made with respect thereto and that all
conditions precedent have been complied with, and shall promptly mail notice
thereof to all Holders.

     If any securities to be provided for the purpose of conversion of Notes
hereunder require registration with or approval of any governmental authority
under any federal or state law before such securities may be validly issued upon
conversion, each supplemental indenture executed pursuant to this Section shall
provide that the Company or the successor or the purchasing Person, as the case
may be, or if the Reference Property includes shares of stock or other
securities and assets of a company other than the successor or purchasing
company, as the case may be, then such company, shall use all commercially
reasonable efforts, to the extent then permitted by the rules and
interpretations of the SEC (or any successor thereto), to secure such
registration or approval in connection with the conversion of Notes.

     (b) Notwithstanding the provisions of Section 12.02(a) to (b), and subject
to the provisions of Section 12.01, at the effective time of such Merger Event,
the right to convert each $1,000 principal amount of Notes shall be changed to a
right to convert such Notes by reference to the kind and amount of cash,
securities or other property or assets that a holder of a number of shares of
Common Stock equal to the Conversion Rate immediately prior to such transaction
would have owned or been entitled to receive (the "REFERENCE PROPERTY");
provided that if the Company has obtained Stockholder Approval to make the Net
Share Settlement Election and has irrevocably made the Net Share Settlement
Election at any time on or prior to the 45th Scheduled Trading Day preceding the
Maturity Date, a Holder shall be entitled from and after the effective time of
such transaction to convert its Notes into cash and, in lieu of Common Stock, if
any, the same type (and in the same proportions) of Reference Property that a
holder of Common Stock would have received, based on the Daily Settlement
Amounts of Reference Property and the applicable Conversion Rate, as described
under Section 12.02(b) and the definition of "Daily VWAP". For purposes of
determining the constitution of Reference Property, the type and amount of
consideration that a holder of Common Stock would have been entitled to in the
case of changes of control, consolidations, binding share exchanges,
recapitalizations, reclassifications, mergers, combinations, sales or transfers
of

                                       88

<PAGE>

assets or Fundamental Changes described in clause (2) of the definition of
Fundamental Change or other transactions that cause the Common Stock to be
converted into the right to receive more than a single type of consideration
(determined, based in part upon any form of stockholder election) shall be
deemed to be the (i) weighted average of the types and amounts of consideration
received by the holders of Common Stock that affirmatively make such an election
or (ii) if no holders of Common Stock affirmatively make such election, the
types and amounts of consideration actually received by such holders. None of
the foregoing provisions shall affect any right of a Holder of Notes to convert
its Notes in accordance with the provisions of this Article 12 prior to the
effective date.

     (c) The Company shall cause notice of the execution of a supplemental
indenture required by this Section 12.10 to be mailed to each Holder, at his
address appearing on the Register provided for in Section 9.01, within 20
calendar days after execution thereof. Failure to deliver such notice shall not
affect the legality or validity of such supplemental indenture.

     (d) The above provisions of this Section shall similarly apply to
successive Merger Events.

     Section 12.11. Responsibility of Trustee for Conversion Provisions.

     The Trustee and any Conversion Agent shall not at any time be under any
duty or responsibility to any Holder of Notes to determine whether any facts
exist which may require any adjustment of the Conversion Rate, or with respect
to the nature or extent of any such adjustment when made, or with respect to the
method employed, herein or in any supplemental indenture provided to be
employed, in making the same, or whether a supplemental indenture need be
entered into. Neither the Trustee nor any Conversion Agent shall be accountable
with respect to the validity or value (or the kind or amount) of any Common
Stock, or of any other securities or property or cash, which may at any time be
issued or delivered upon the conversion of any Notes; and it or they do not make
any representation with respect thereto. Neither the Trustee nor any Conversion
Agent shall be responsible for any failure of the Company to make or calculate
any cash payment or to issue, transfer or deliver any shares of Common Stock or
share certificates or other securities or property or cash upon the surrender of
any Note for the purpose of conversion; and the Trustee and any Conversion Agent
shall not be responsible for any failure of the Company to comply with any of
the covenants of the Company contained in this Article 12.

     Section 12.12. Right to Set-off Withholding Taxes. The Company may, at its
option, set-off withholding taxes due with respect to Notes against payments of
cash and Common Stock on the Notes. In the case of any such set-off against
Common Stock delivered upon conversion of the Notes, such Common Stock shall be
valued based on the arithmetic average of the Daily VWAP for each VWAP Trading
Day in the relevant Observation Period.

                                       89
<PAGE>

                                   ARTICLE 13
                                    DISCHARGE

     Section 13.01. Discharge of Liability on Notes.

     When (1) the Company shall deliver to the Registrar for cancellation all
Notes theretofore authenticated (other than any Notes which have been mutilated,
destroyed, lost or wrongfully taken and in lieu of or in substitution for which
other Notes shall have been authenticated and delivered) and not theretofore
canceled or (2) all the Notes not theretofore canceled or delivered to the
Registrar for cancellation shall have (a) been deposited for conversion (or, if
the Company has obtained Stockholder Approval to make the Net Share Settlement
Election and has irrevocably made the Net Share Settlement Election, after all
related Observation Periods have elapsed) and the Company shall deliver to the
Holders shares of Common Stock (or, if the Company has obtained Stockholder
Approval to make the Net Share Settlement Election and has irrevocably made the
Net Share Settlement Election, a combination of cash and shares, if any, of
Common Stock), sufficient to pay all amounts owing in respect of all Notes
(other than any Notes which shall have been mutilated, destroyed, lost or
wrongfully taken and in lieu of or in substitution for which other Notes shall
have been authenticated and delivered) not theretofore canceled or delivered to
the Registrar for cancellation or (b) become due and payable on the Maturity
Date, Fundamental Change Repurchase Date or otherwise, and the Company shall
deposit with the Trustee cash sufficient to pay all amounts owing in respect of
all Notes (other than any Notes which shall have been mutilated, destroyed, lost
or wrongfully taken and in lieu of or in substitution for which other Notes
shall have been authenticated and delivered) not theretofore canceled or
delivered to the Registrar for cancellation, including the principal amount and
interest accrued and unpaid to the Maturity Date, Fundamental Change Repurchase
Date or other such date, and if in either case (1) or (2) the Company shall also
pay or cause to be paid all other sums payable hereunder by the Company, then
this Indenture with respect to the Notes shall cease to be of further effect
(except as to (i) remaining rights of registration of transfer, substitution and
conversion of Notes, (ii) rights hereunder of Holders to receive from the
Trustee payments of the amounts then due, including interest with respect to the
Notes and the other rights, duties and obligations of Holders, as beneficiaries
hereof solely with respect to the amounts, if any, so deposited with the Trustee
and (iii) the rights, obligations and immunities of the Trustee, Authenticating
Agent, Paying Agent, Conversion Agent and Registrar under this Indenture with
respect to the Notes, including, without limitation, its rights under Section
6.06), and the Trustee, on demand of the Company accompanied by an Officers'
Certificate and an Opinion of Counsel as required by Section 13.03 and at the
cost and expense of the Company, shall execute proper instruments acknowledging
satisfaction of and discharging this Indenture with respect to the Notes;
provided however, the Company hereby agrees to reimburse the Trustee,
Authenticating Agent, Paying Agent, Conversion Agent and Registrar for any costs
or expenses thereafter reasonably and properly incurred by the Trustee,

                                       90

<PAGE>

Authenticating Agent, Paying Agent, Conversion Agent and Registrar and to
compensate the Trustee, Authenticating Agent, Paying Agent, Conversion Agent and
Registrar for any services thereafter reasonably and properly rendered by the
Trustee, Authenticating Agent, Paying Agent, Conversion Agent and Registrar in
connection with this Indenture with respect to the Notes.

     Section 13.02. Reinstatement.

     If the Trustee or the Paying Agent is unable to apply any money to the
Holders entitled thereto by reason of any order or judgment of any court of
governmental authority enjoining, restraining or otherwise prohibiting such
application, the Company's obligations under this Indenture with respect to the
Notes shall be revived and reinstated as though no deposit had occurred pursuant
to Section 13.01 until such time as the Trustee or the Paying Agent is permitted
to apply all such money in accordance with this Indenture and the Notes to the
Holders entitled thereto; provided, however, that if the Company makes any
payment of principal amount of or interest on any Note following the
reinstatement of its obligations, the Company shall be subrogated to the rights
of the Holders of such Notes to receive such payment from the money held by the
Trustee or Paying Agent.

     Section 13.03. Officers' Certificate; Opinion of Counsel.

     Upon any application or demand by the Company to the Trustee to take any
action under Section 13.01, the Company shall furnish to the Trustee an
Officers' Certificate or Opinion of Counsel stating that all conditions
precedent, if any, provided for in this Indenture relating to the proposed
action have been complied with.

                                   ARTICLE 14
                               REPURCHASE OF NOTES

     Section 14.01. Right to Require Repurchase Upon a Fundamental Change.

     (a) If a Fundamental Change occurs at any time, then each Holder shall have
the right, at such Holder's option, to require the Company to repurchase all of
such Holder's Notes or any portion thereof that is a multiple of $1,000
principal amount, for cash on the date (the "FUNDAMENTAL CHANGE REPURCHASE
DATE") specified by the Company that is not less than 20 calendar days and not
more than 35 calendar days after the date of the Fundamental Change Repurchase
Right Notice at a repurchase price equal to 100% of the principal amount
thereof, together with accrued and unpaid interest thereon to, but excluding,
the Fundamental Change Repurchase Date, unless such Fundamental Change
Repurchase Date falls after a Regular Record Date and on or prior to the
corresponding Interest Payment Date, in which case the Company shall instead pay
the full amount of accrued and unpaid interest payable on such Interest

                                       91

<PAGE>

Payment Date to the Holder of record at the close of business on the
corresponding Regular Record Date (the "FUNDAMENTAL CHANGE REPURCHASE PRICE").

     However, notwithstanding the foregoing, Holders shall not have the right to
require the Company to repurchase any Notes (and the Company shall not be
required to deliver the Fundamental Change Repurchase Right Notice incidental
thereto) if a Fundamental Change under clauses (1), (2) or (3) of the definition
of Fundamental Change occurs and at least 90% of the consideration paid for the
Company's Common Stock (excluding cash payments for fractional shares and, cash
payments made pursuant to dissenters' appraisal rights and cash dividends) in
the case of a Fundamental Change under clause (2) of the definition of
Fundamental Change consists of shares of Capital Stock or American Depositary
Receipts in respect of shares of Capital Stock traded on any of the New York
Stock Exchange, the American Stock Exchange, the NASDAQ Global Select Market or
the NASDAQ Global Market (or any of their respective successors) (or will be so
traded immediately following the completion of the merger or consolidation or
such other transaction) and, as a result of such transaction or transactions,
the Notes become convertible into such shares of Capital Stock or such American
Depositary Receipts (or subject to the Company's right to elect to satisfy its
conversion obligation in cash and such shares of Capital Stock or such American
Depositary Receipts pursuant to Section 12.02 hereof).

     Repurchases of Notes under this Section 14.01 shall be made, at the option
of the Holder thereof, upon:

          (i) if the Notes are held in certificated form, delivery to the
     Trustee (or other Paying Agent appointed by the Company) by a Holder of a
     duly completed notice (the "FUNDAMENTAL CHANGE REPURCHASE NOTICE") in the
     form set forth on the reverse of the Note or, if the Notes are held in
     global form, a notice that complies with the Applicable Procedures, prior
     to the close of business on the Business Day immediately preceding the
     Fundamental Change Repurchase Date; and

          (ii) delivery or book-entry transfer of the Notes to the Trustee (or
     other Paying Agent appointed by the Company) at any time after delivery of
     the Fundamental Change Repurchase Notice (together with all necessary
     endorsements) at the Corporate Trust Office of the Trustee (or other Paying
     Agent appointed by the Company), such delivery being a condition to receipt
     by the Holder of the Fundamental Change Repurchase Price therefor; provided
     that such Fundamental Change Repurchase Price shall be so paid pursuant to
     this Section 14.01 only if the Note so delivered to the Trustee (or other
     Paying Agent appointed by the Company) shall conform in all respects to the
     description thereof in the related Fundamental Change Repurchase Notice.

     The Fundamental Change Repurchase Notice shall state:

                                       92

<PAGE>

               (A) if certificated, the certificate numbers of Notes to be
          delivered for repurchase;

               (B) the portion of the principal amount of Notes to be
          repurchased, which must be $1,000 or an integral multiple thereof; and

               (C) that the Notes are to be repurchased by the Company pursuant
          to the applicable provisions of the Notes and this Indenture.

     Any purchase by the Company contemplated pursuant to the provisions of this
Section 14.01 shall be consummated by the delivery of the consideration to be
received by the Holder promptly following the later of the Fundamental Change
Repurchase Date and the time of the book-entry transfer or delivery of the Note.

     The Trustee (or other Paying Agent appointed by the Company) shall promptly
notify the Company of the receipt by it of any Fundamental Change Repurchase
Notice or written notice of withdrawal thereof in accordance with the provisions
of subsection (c) of this Section 14.01.

     Any Note that is to be repurchased only in part shall be surrendered to the
Trustee (with, if the Company or the Trustee so requires, due endorsement by, or
a written instrument of transfer in form satisfactory to the Company and the
Trustee duly executed by the Holder thereof or his attorney duly authorized in
writing), and the Company shall execute, and the Trustee shall authenticate and
make available for delivery to the Holder of such Note without service charge, a
new Note or Notes, containing identical terms and conditions, each in an
authorized denomination in aggregate principal amount equal to and in exchange
for the unrepurchased portion of the principal of the Note so surrendered.

     (b) After the occurrence of a Fundamental Change, but on or before the 10th
calendar day after the Effective Date of such Fundamental Change, the Company
shall provide to all Holders of record of the Notes and the Trustee and Paying
Agent a notice (the "FUNDAMENTAL CHANGE REPURCHASE RIGHT NOTICE") of the
occurrence of such Fundamental Change and of the repurchase right, if any, at
the option of the Holders arising as a result thereof. Such mailing shall be by
first class mail. Simultaneously with providing such Fundamental Change
Repurchase Right Notice, the Company shall publish a notice containing the
information included therein in a newspaper of general circulation in the City
of New York or on the Company's website or through such other public medium as
the Company may use at such time.

     Each Fundamental Change Repurchase Right Notice shall specify (if
applicable):

          (i) the events causing the Fundamental Change;

                                       93

<PAGE>

          (ii) the date of the Fundamental Change;

          (iii) the Fundamental Change Repurchase Date and the last date on
     which a Holder may exercise the repurchase right;

          (iv) the Fundamental Change Repurchase Price;

          (v) the name and address of the Paying Agent and the Conversion Agent,
     if applicable;

          (vi) the applicable Conversion Rate and any adjustments to the
     applicable Conversion Rate;

          (vii) that the Notes with respect to which a Fundamental Change
     Repurchase Notice has been delivered by a Holder may be converted only if
     the Holder withdraws the Fundamental Change Repurchase Notice in accordance
     with the terms of this Indenture;

          (viii) that the Holder must exercise the repurchase right on or prior
     to the close of business on the third Business Day immediately preceding
     the Fundamental Change Repurchase Date (the "FUNDAMENTAL CHANGE EXPIRATION
     TIME");

          (ix) that the Holder shall have the right to withdraw any Notes
     surrendered for repurchase prior to the Fundamental Change Expiration Time;
     and

          (x) the procedures that Holders must follow to require the Company to
     repurchase their Notes.

     No failure of the Company to give the foregoing notices and no defect
therein shall limit the Holders' repurchase rights or affect the validity of the
proceedings for the repurchase of the Notes pursuant to this Section 14.01.

     (c) A Fundamental Change Repurchase Notice may be withdrawn by means of a
written notice of withdrawal delivered to the Paying Agent in accordance with
the Fundamental Change Repurchase Right Notice at any time prior to the close of
business on the Business Day prior to the Fundamental Change Repurchase Date,
specifying:

          (i) if certificated Notes have been issued, the certificate numbers of
     the withdrawn Notes,

          (ii) the principal amount of the Note with respect to which such
     notice of withdrawal is being submitted, and

          (iii) the principal amount, if any, of such Note that remains subject
     to the original Fundamental Change Repurchase Notice, which

                                       94

<PAGE>

     portion must be in principal amounts of $1,000 or an integral multiple of
     $1,000;

provided, however, that if the Notes are not in certificated form, the notice
must comply with the Applicable Procedures.

     (d) On or prior to 11:00 a.m., New York City time, on the Business Day on
the Fundamental Change Repurchase Date, the Company shall deposit with the
Trustee (or other Paying Agent appointed by the Company or if the Company is
acting as its own Paying Agent, set aside, segregate and hold in trust as
provided in Section 10.03) an amount of money sufficient to repurchase on the
Fundamental Change Repurchase Date all of the Notes to be repurchased on such
date at the Fundamental Change Repurchase Price. Subject to receipt of funds
and/or Notes by the Trustee (or other Paying Agent appointed by the Company),
payment for Notes surrendered for repurchase (and not withdrawn) prior to the
Fundamental Change Expiration Time shall be made promptly after the later of (x)
the Fundamental Change Repurchase Date with respect to such Note (provided the
Holder has satisfied the conditions to the payment of the Fundamental Change
Repurchase Price in this Section 14.01), and (y) the time of book-entry transfer
or the delivery of such Note to the Trustee (or other Paying Agent appointed by
the Company) by the Holder thereof in the manner required by this Section 14.01
by mailing checks for the amount payable to the Holders of such Notes entitled
thereto as they shall appear in the Register; provided, however, that all
payments shall be subject to Section 14.01(a) and payments to the Depositary
shall be made by wire transfer of immediately available funds to the account of
the Depositary or its nominee. The Trustee shall, promptly after such payment
and upon written demand by the Company, return to the Company any funds in
excess of the Fundamental Change Repurchase Price.

     (e) If the Trustee (or other Paying Agent appointed by the Company) holds
money sufficient to repurchase on the Fundamental Change Repurchase Date all the
Notes or portions thereof that are to be purchased as of the Business Day
following the Fundamental Change Repurchase Date, then on and after the
Fundamental Change Repurchase Date (i) such Notes shall cease to be outstanding,
(ii) interest shall cease to accrue on such Notes, and (iii) all other rights of
the Holders of such Notes shall terminate, whether or not book-entry transfer of
the Notes has been made or the Notes have been delivered to the Trustee or
Paying Agent, other than the right to receive the Fundamental Change Repurchase
Price upon delivery or transfer of the Notes.

     (f) No Notes may be repurchased at the option of Holders upon a Fundamental
Change if the principal amount of the Notes has been accelerated, and such
acceleration has not been rescinded on or prior to such date.

                                       95

<PAGE>

                                   ARTICLE 15
                            MISCELLANEOUS PROVISIONS

     Section 15.01. Provisions Binding on Company's Successors. All the
covenants, stipulations, promises and agreements of the Company contained in
this Indenture shall bind its successors and assigns whether so expressed or
not.

     Section 15.02. Official Acts by Successor Corporation. Any act or
proceeding by any provision of this Indenture authorized or required to be done
or performed by any board, committee or officer of the Company shall and may be
done and performed with like force and effect by the like board, committee or
officer of any corporation that shall at the time be the lawful sole successor
of the Company.

     Section 15.03. Addresses for Notices, Etc. Any notice or demand which by
any provision of this Indenture is required or permitted to be given or served
by the Trustee or by the Holders on the Company shall be deemed to have been
sufficiently given or made, for all purposes if given or served by being
deposited postage prepaid by registered or certified mail in a post office
letter box addressed (until another address is filed by the Company with the
Trustee) to Aspect Medical Systems, Inc., One Upland Road, Norwood,
Massachusetts 02062, Attention: General Counsel. Any notice, direction, request
or demand hereunder to or upon the Trustee shall be deemed to have been
sufficiently given or made, for all purposes, if given or served by being
deposited postage prepaid by registered or certified mail in a post office
letter box addressed to the Corporate Trust Office.

     The Trustee, by notice to the Company, may designate additional or
different addresses for subsequent notices or communications.

     Any notice or communication mailed to a Holder shall be mailed to it by
first class mail, postage prepaid, at his address as it appears on the Note
Register and shall be sufficiently given to it if so mailed within the time
prescribed.

     Failure to mail a notice or communication to a Holder or any defect in it
shall not affect its sufficiency with respect to other Holders. If a notice or
communication is mailed in the manner provided above, it is duly given, whether
or not the addressee receives it.

     Section 15.04. Governing Law. THIS INDENTURE AND EACH NOTE SHALL BE DEEMED
TO BE A CONTRACT MADE UNDER THE LAWS OF THE STATE OF NEW YORK, AND FOR ALL
PURPOSES SHALL BE CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK
APPLICABLE TO CONTRACTS ENTERED INTO AND TO BE PERFORMED THEREIN (WITHOUT REGARD
TO THE CONFLICTS OF LAWS PROVISIONS THEREOF).

                                       96

<PAGE>

     Section 15.05. Evidence of Compliance with Conditions Precedent;
Certificates and Opinions of Counsel to Trustee. Upon any application or demand
by the Company to the Trustee to take any action under any of the provisions of
this Indenture, the Company shall furnish to the Trustee an Officers'
Certificate stating that all conditions precedent, if any, provided for in this
Indenture relating to the proposed action have been complied with, and an
Opinion of Counsel stating that, in the opinion of such counsel, all such
conditions precedent have been complied with.

     Each certificate or opinion provided for by or on behalf of the Company in
this Indenture and delivered to the Trustee with respect to compliance with a
condition or covenant provided for in this Indenture shall include (1) a
statement that the Person making such certificate or opinion has read such
covenant or condition; (2) a brief statement as to the nature and scope of the
examination or investigation upon which the statement or opinion contained in
such certificate or opinion is based; (3) a statement that, in the opinion of
such Person, he has made such examination or investigation as is necessary to
enable it to express an informed opinion as to whether or not such covenant or
condition has been complied with; and (4) a statement as to whether or not, in
the opinion of such Person, such condition or covenant has been complied with.

     Section 15.06. Legal Holidays. In any case where any Interest Payment
Date, Fundamental Change Repurchase Date, or Maturity Date will not be a
Business Day (or in the case of Maturity Date, Scheduled Trading Day), then any
action to be taken on such date need not be taken on such date, but may be taken
on the next succeeding Business Day (or, in the case of Maturity Date, the next
succeeding Scheduled Trading Day) with the same force and effect as if taken on
such date, and no interest shall accrue for the period from and after such date
to the next succeeding Business Day (or, in the case of Maturity Date, the next
succeeding Scheduled Trading Day).

     Section 15.07. No Security Interest Created. Nothing in this Indenture or
in the Notes, expressed or implied, shall be construed to constitute a security
interest under the Uniform Commercial Code or similar legislation, as now or
hereafter enacted and in effect, in any jurisdiction.

     Section 15.08. Benefits of Indenture. Nothing in this Indenture or in the
Notes, expressed or implied, shall give to any Person, other than the parties
hereto, any Paying Agent, any authenticating agent, any Note Registrar and their
successors hereunder, and the Holders, any benefit or any legal or equitable
right, remedy or claim under this Indenture.

     Section 15.09. Table of Contents, Headings, Etc. The table of contents and
the titles and headings of the articles and sections of this Indenture have been
inserted for convenience of reference only, are not to be considered a part
hereof, and shall in no way modify or restrict any of the terms or provisions
hereof.

                                       97

<PAGE>

     Section 15.10. Authenticating Agent. The Trustee may appoint an
authenticating agent which shall be authorized to act on its behalf and subject
to its direction in the authentication and delivery of Notes in connection with
the original issuance thereof and transfers and conversions of Notes hereunder,
including under Section 2.05, Section 2.06, and Section 2.07, as fully to all
intents and purposes as though the authenticating agent had been expressly
authorized by this Indenture and those Sections to authenticate and deliver
Notes. For all purposes of this Indenture, the authentication and delivery of
Notes by the authenticating agent shall be deemed to be authentication and
delivery of such Notes "BY THE TRUSTEE" and a certificate of authentication
executed on behalf of the Trustee by an authenticating agent shall be deemed to
satisfy any requirement hereunder or in the Notes for the Trustee's certificate
of authentication. Such authenticating agent shall at all times be a Person
eligible to serve as trustee hereunder pursuant to Section 6.09.

     Any corporation into which any authenticating agent may be merged or
converted or with which it may be consolidated, or any corporation resulting
from any merger, consolidation or conversion to which any authenticating agent
shall be a party, or any corporation succeeding to the corporate trust business
of any authenticating agent, shall be the successor of the authenticating agent
hereunder, if such successor corporation is otherwise eligible under this
Section, without the execution or filing of any paper or any further act on the
part of the parties hereto or the authenticating agent or such successor
corporation.

     Any authenticating agent may at any time resign by giving written notice of
resignation to the Trustee and to the Company. The Trustee may at any time
terminate the agency of any authenticating agent by giving written notice of
termination to such authenticating agent and to the Company. Upon receiving such
a notice of resignation or upon such a termination, or in case at any time any
authenticating agent shall cease to be eligible under this Section, the Trustee
shall promptly appoint a successor authenticating agent (which may be the
Trustee), shall give written notice of such appointment to the Company and shall
mail notice of such appointment to all Holders as the names and addresses of
such holders appear on the Note Register.

     The Company agrees to pay to the authenticating agent from time to time
reasonable compensation for its services although the Company may terminate the
authenticating agent, if it determines such agent's fees to be unreasonable.

     The provisions of Section 6.02, Section 6.03, Section 6.04, Section 3.07
and this Section 15.10 shall be applicable to any authenticating agent.

     Section 15.11. Execution in Counterparts. This Indenture may be executed
in any number of counterparts, each of which shall be an original, but such
counterparts shall together constitute but one and the same instrument.

                                       98

<PAGE>

     Section 15.12. Waiver of Jury Trial. Each of the Company and the Trustee
hereby irrevocably waives, to the fullest extent permitted by applicable law,
any and all right to trial by jury in any legal proceeding arising out of or
relating to this Indenture, the Notes or the transaction contemplated hereby.

     Section 15.13. Force Majeure. In no event shall the Trustee be responsible
or liable for any failure or delay in the performance of its obligations
hereunder arising out of or caused by, directly or indirectly, forces beyond its
control, including, without limitation, strikes, work stoppages, accidents, acts
of war or terrorism, civil or military disturbances, nuclear or natural
catastrophes or acts of God, and interruptions, loss or malfunctions of
utilities, communications or computer (software and hardware) services; it being
understood that the Trustee shall use reasonable efforts which are consistent
with accepted practices in the banking industry to resume performance as soon as
practicable under the circumstances.

     This instrument may be executed in any number of counterparts, each of
which so executed shall be deemed to be an original, but all such counterparts
shall together constitute but one and the same instrument.

                                       99

<PAGE>

     IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be
duly executed all as of the day and year first above written.

                                        ASPECT MEDICAL SYSTEMS, INC.

                                        By: /s/ Nassib G. Chamoun
                                            ------------------------------------
                                        Name: Nassib G. Chamoun
                                        Title: President and Chief Executive
                                               Officer

                                        U.S. BANK NATIONAL ASSOCIATION,
                                        as Trustee

                                        By: /s/ James P. Freeman
                                            ------------------------------------
                                        Name: James P. Freeman
                                        Title: Vice President

<PAGE>

                                   SCHEDULE A

     The following table sets forth the adjustments to the Conversion Rate,
expressed as a number of Additional Shares to be received per $1,000 in
principal amount of the Notes, in the event of a Make-Whole Fundamental Change:

                                 Effective Date

<TABLE>
<CAPTION>
 STOCK   JUNE 20,   JUNE 15,   JUNE 15,   JUNE 15,   JUNE 15,   JUNE 15,   JUNE 15,   JUNE 15,
PRICE      2007       2008       2009       2010       2011       2012       2013       2014
------   --------   --------   --------   --------   --------   --------   --------   --------
<S>      <C>        <C>        <C>        <C>        <C>        <C>        <C>        <C>
$15.57    11.7966    11.7966    11.7966    11.7966    11.7966    11.7966    11.5489    11.7845
$16.00    11.1452    11.2547    11.3214    11.3556    11.2246    10.9306    10.4233    10.0556
$17.00     9.7960     9.8417     9.8295     9.7637     9.5072     9.0354     8.1983     6.3911
$18.00     8.6492     8.6464     8.5751     8.4355     8.0894     7.4955     6.4386     3.1300
$19.00     7.6673     7.6280     7.5131     7.3203     6.9128     6.2405     5.0544     0.4897
$20.00     6.8211     6.7547     6.6083     6.3782     5.9313     5.2148     3.9706     0.0000
$22.50     5.1587     5.0535     4.8652     4.5907     4.1103     3.3832     2.1959     0.0000
$25.00     3.9590     3.8407     3.6428     3.3659     2.9059     2.2453     1.2511     0.0000
$27.50     3.0703     2.9526     2.7620     2.5037     2.0879     1.5215     0.7442     0.0000
$30.00     2.3980     2.2880     2.1127     1.8822     1.5186     1.0491     0.4644     0.0000
$35.00     1.4764     1.3899     1.2523     1.0828     0.8198     0.5143     0.2019     0.0000
$40.00     0.9036     0.8415     0.7392     0.6230     0.4413     0.2493     0.0889     0.0000
$45.00     0.5368     0.4957     0.4222     0.3470     0.2264     0.1067     0.0279     0.0000
$50.00     0.2988     0.2746     0.2232     0.1772     0.1013     0.0274     0.0000     0.0000
</TABLE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}]]